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ABSTRACT
Skeletal muscle glucose metabolism can affect whole body glucose homeostasis
significantly. Vitamin A (VA) plays a role in a number of physiological functions including
glucose metabolism. However, its role in skeletal muscle glucose metabolism has not been well
established. Insulin controls glucose metabolism in the skeletal muscle via the regulations of
glucose uptake, glycogenesis, and glycolysis. We hypothesize that insulin and VA signaling
pathways may converge to regulate glucose metabolism in skeletal muscle. Here, the effects of
retinoic acid (RA) alone and in combination with insulin on glucose utilization in rat L6 muscle
cells were studied. L6 cells were treated with 1 M [micromole] RA and 10 nM [nanomole]
insulin for a period of 6 days. Compared to control, cells treated with RA utilized significantly
more glucose at days 4 and 6. RA synergized with insulin to increase glucose usage at 4 and 6
days after treatment. RA and insulin synergistically increased the protein expression levels of
glycogen synthase and glycogen synthase kinase-3 phosphorylation, while decreasing glycogen
synthase phosphorylation. Similar results were seen in VA deficient (VAD) and sufficient (VAS)
rats with the VAS rats who received insulin injections having decreased levels of glycogen
synthase phosphorylation and increased levels of glycogen synthase. To determine possible
nuclear receptors responsible for the RA effect, L6 cells were treated with specific agonists for
retinoic acid receptor, retinoid-X-receptor, or liver-X-receptor. Only the retinoic acid receptor
specific agonist mimics the effects of RA to increase glucose usage and protein expression level
of glycogen synthase in the presence of insulin. In addition, glycogen content was significantly
increased in L6 cells treated with RA + insulin and TTNPB + insulin. Interestingly, this
increased glucose usage in L6 cells was associated with a reduction of glucose transporter
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(GLUT) 1 and GLUT4 expression, and induction of GLUT3 and GLUT6 expression, a novel
observation that has not been reported. We conclude that RA and insulin signaling pathways
work cooperatively to enhance muscle cell glucose utilization through the induction of
expression level of glycogen synthase, increase of glycogenesis, and alteration of expression
profile of GLUTs in L6 cells.
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CHAPTER I. REVIEW OF LITERATURE ON
VITAMIN A, INSULIN SIGNALING, METABOLIC
DISORDERS, MUSCLE METABOLISM, AND
GLYCOGEN REGULATION

1

1. Vitamin A
1.1 Discovery of VA
A nutrient is known to be essential if it is required for normal physiological function.
With the progression of modern nutritional science, the roles of nutrients and other dietary
components in the prevention, and treatment of various diseases have been gradually revealed.
However, the role of nutrients in the development of chronic metabolic disorders such as obesity,
diabetes, and metabolic syndrome are still not fully understood. It was originally shown in
studies investigating the feeding patterns of experimental animals that researchers discovered
that macronutrients were not the only dietary components essential to life1. The first lipid-soluble
micronutrient to be described was termed fat-soluble factor A which eventually became known
as vitamin A (VA, retinol) in 19202-4. It was shown that when rats were fed a VA-deficient
(VAD) diet, their growth ceased, but growth resumed once VA was added back to the diet3. For
over 100 years now, research on VA has shown its importance on prevention and treatment of
diseases as well as its role in immunity5-7. Clinically, a VA deficiency will manifest in symptoms
related to neurological disorders as well as vision impairment8,9. Likewise, VA toxicity resulting
from either dietary intake, supplementation, or topical administration has been associated with
bone abnormalities as well as alterations in lipid profiles10-13.

1.2 VA Sources
VA is an essential micronutrient since mammals cannot synthesize this fat-soluble
vitamin, therefore, it is required that we obtain molecules with VA activity through dietary
sources. They exist as either preformed VA which is classified as retinol (ROL) or retinyl esters
(RE) and provitamin A which is also termed carotenoids (Figure 1.1)14,15. Preformed VA is
2

derived from animal sources primarily in the form of RE whereas provitamin A is derived from
plant sources. Provitamin A is found in a variety of colored fruits and vegetables that are
enriched with the various carotenoids. The characterization of carotene revealed three isomers
termed -carotene, -carotene, and -carotene, all of which are found in a variety of plants. Of
these three isomers, -carotene is the most abundant and exhibits the most biological activity16.
Another provitamin A molecule called cryptoxanthins can be found along with carotenes in
orange and yellow plants. Similar to - and -carotene, cryptoxanthins possess about only half of
the biological activity that -carotene exhibits16.

1.3 Nomenclature and Properties of VA and VA Derivatives
VA activity refers to any retinoid exhibiting the biological activity of all-trans-retinol
(commonly referred to as retinol, ROL)17. ROL is typically considered the parent retinoid
compound that encompasses both preformed and provitamin A compounds18. Retinoids are
compounds that share structural components such as a -ionone ring, an isoprenoid side chain,
and a functional group at the acyclic terminus (Figure 1.1). The isoprenoid side chain contains
five carbon-carbon double bonds that allows for the structures to exist in cis- or trans- isomers.
Isomerization of these compounds is common in nature as 11-cis-RAL is readily converted into
all-trans-RAL in the rod and cone cells of the eye. Likewise, all-trans-ROL will go through a
process requiring esterification, oxidation, and isomerization to form 11-cis-RAL during the
vision cycle, which due to the polar end of the molecule it will bind to opsin via a Schiff base19.
It is important to note that due to the spatial arrangement of chemical groups in the cis- and
trans- isomers, these compounds will exhibit different biological activity with the transconfiguration often exhibiting more activity compared to its cis- counterpart20,21.
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Due to the presence of the -ionone ring and isoprenoid side chain, retinoids display
hydrophobicity which contributes to the “fat-soluble vitamin” title. VA molecules share
amphipathic characteristics such as micelle formation when in aqueous environments, but in vivo
experiments have shown that ROL and its derivatives will bind to proteins to prevent micelle
formation22. The presence of double bonds in retinoids allows for oxidation reactions to produce
compounds such as retrovitamin A, isoanhydravitamin A, and anhydrovitamin A23.

1.4 VA Absorption, Transport, and Storage
1.4a Preformed VA: REs released from the digestion of animal products will be
enzymatically hydrolyzed to yield ROL and free fatty acids (FFA) within the small intestine
lumen (Figure 1.2). This action is thought to be mediated by a combination of enzymes including
intestinal phospholipases, pancreatic lipases, and esterases with the products, ROL and FFA,
being transferred to the enterocytes for further processing24. Within the enterocytes, two enzymes
termed lecithin-retinol acyltransferase (LRAT) and acyl-CoA: retinol-acyltransferase (ARAT)
will reesterify a portion of the newly arrived ROL back to RE. The reesterified REs are then
packed into chylomicrons for delivery throughout the body via lymph circulation while a portion
of ROL is transported throughout the body via portal circulation25. Once REs arrive to the liver
and are taken up by hepatocytes they are hydrolyzed once again to yield ROL and FFAs. This
ROL can either be reesterified again at its hydroxyl group to produce RE to be stored in stellate
cells in the liver or ROL can be released from the hepatocytes and enter into the circulation or it
can be further processed to yield RAL (also referred to as retinaldehyde), RA, and other
metabolites26. This storage of REs in stellate cells serves as a reserve for periods of starvation or
insufficient VA intake, since the REs can be released into the hepatocytes again for further
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Figure 1.1 Chemical structure of molecules that exert VA activity. See sections 1.2 and 1.3
for details. (A) Chemical structures of Provitamin A and (B) Preformed vitamin A molecules.
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processing. ROL will proceed through two oxidation steps to be converted to RAL and then
RA27. The conversion of ROL to RAL is a reversible process whereas the conversion of RAL to
RA is irreversible28. The process of converting ROL to RAL requires two families of enzymes
termed alcohol dehydrogenases (ADHs) and retinol dehydrogenases (RDHs). RAL will then be
irreversibly oxidized into RA by retinaldehyde dehydrogenases (RALDHs)29. A specific subset
of RALDHs encompassing RALDHs 1-4, are thought to be the primary dehydrogenases
responsible for all-trans- and 9-cis-RA production in a number of tissues29-32. RA synthesis
seems to be primary regulated by the actions of RALDH1 as this enzyme is downregulated when
elevated levels of RA are detected33,34. RA formation has also been postulated to occur in
reactions not involving RALDHs including the oxidation of RAL by cytochrome p450 as well as
by the cleavage of -carotene to produce RA directly, bypassing the typical retinoid
intermediates35. It has been shown that cytochrome p450 26A1 (CYP26A1) does produce
hydrophilic products from RA in hepatocytes and the expression of CYP26A1 is induced by RA
treatment. For these reasons, CYP26A1 is commonly used as an indicator of RA production36-39.
1.4b Provitamin A: Ingested provitamin A carotenoids can be converted to RAL then to
ROL in enterocytes and hepatocytes (Figure 1.2). This process is mediated by two pathways
using the cleavage enzymes ,-carotene-15,15’-dioxygenase (central cleavage) or ,-carotene9’,10’-dioxygenase (eccentric cleavage)25,26. Once RAL is formed it can be reduced to form
ROL. ROL can bind to retinol-binding proteins (RBPs) to form a complex referred to as holoRBPs. This complex is released into the blood circulation and once in the plasma it can interact
with transthyretin (TTR) which will bind to thyroxine (T4). This complex will now transport
both ROL and T4 to tissues expressing RBP receptors. Hepatocytes express the receptor RBP4
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receptor-2 (RBPR2) and peripheral tissues express STRA6 to mediate the uptake of ROL from
the plasma40,41.

1.5 VA Assessment, Recommendations, Deficiency, and Toxicity
1.5a VA Assessment: To determine VA status in humans, both circulating levels of
plasma ROL as well as RE reserves in the liver are analyzed, with the latter considered the best
indicator of VA status. Of course, there are challenges in determining the “universal” levels of
VA in humans such as variations in diets due to culture and geographic region42. With the
advancements in biomedical technology, tools such as high performance liquid chromatography
(HPLC) and mass spectrometry (MS) has become more readily available in clinical settings for
the analysis of plasma ROL in individuals. VA sufficiency has been defined as a plasma ROL
level > 1.05 mol/L while deficiency is set at < 0.7 mol/L43. Serum RBP4 has also been used to
determine VA status, but to a lesser degree compared to serum ROL due to evidence showing
that RBP4 levels decrease during periods of infection44. A newer method termed the relative
dose response (RDR) test has been developed to determine VA levels within the liver. In this
test, the serum ROL concentration of a subject is measured and then the subject is given a dose
of ROL, retinyl palmitate, or a ROL derivative. After 4-6 hours, serum ROL concentrations are
measured once again to compare to baseline with a value greater than 20% considered a
suboptimal VA level45. This method is capitalizing on the concept that the liver will store
exogenous VA under a fed state or VA sufficient state, but these compounds will be released into
the circulation during a fasting or VA deficient state44.

7

Figure 1.2 Schematic graph of the digestion, transport, absorption, and storage of
molecules with VA activity. See section 1.4 for description. Abbreviations: BB-REH, brushborder retinyl ester hydrolase; LRAT, lecithin:retinol acyltransferase; ARAT, acyl-CoA:retinol
acyltransferase; CRBP, cellular retinol binding protein; CRABP, cellular retinoic acid binding
protein; CRALBP, cellular retinaldehye binding protein; RA, retinoic acid; RAL, retinal;
RALDH, retinaldehyde dehydrogenase; RBP, retinol binding protein; RDH, retinol
dehydrogenase; REH, retinyl ester hydrolase; ROL, retinol; STRA6, stimulated by retinoic acid
6; TTR, transthyretin.
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1.5b VA Recommendations: For decades, VA recommendations were expressed in
international units (IU), but it was the Institute of Medicine in 2001 that introduced retinol
activity equivalent (RAE) to replace IU. One RAE is approximately equal to 1 g ROL or 2 g
of supplemental -carotene and 12 g of dietary -carotene. One RAE is also equal to 24 g of
both - and -carotene. The Institute of Medicine (IOM) has set the estimated average
requirement (EAR) for VA at 627 g RAE/day for adult men and 503 g RAE/day for adult
women. The recommended dietary allowance (RDA) for VA is set at 900 g RAE/day for adult
men and 700 g RAE/day for adult women.
1.5c VA Deficiency: VA is known an essential micronutrient which is evidenced by the
clinical symptoms of VA deficiency such as a decrease in growth, impaired immunity,
retinopathies including night blindness, and anemia46. Collectively, these conditions and others
are referred to as vitamin A deficiency disorders (VADD), which is proposed to affect 140-200
million individuals worldwide46. It is in developing countries that VADD continues to be of
utmost concern, particularly in infants and children, resulting in health issues that last a
lifetime47. VA deficiency is a chronic process, as the deficiency continues the clinical symptoms
will become more apparent and severe. Clinically, VA deficiency is diagnosed with a plasma
ROL level below 0.7 µmol/L and/or a RDR value above 20%43,45. Large doses of VA is given to
those who are confirmed to be deficient, usually in a combination of foods rich in VA as well as
in the form of VA supplements. This form of medical nutrition therapy will continue until the
liver VA reserve is established and plasma levels remain within normal range48.
1.5d VA Toxicity: Like a diet deficient in VA, having excessive VA intake, either from
acute or chronic VA overdose, can lead to adverse health effects. Acute toxicity results from
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intakes ≥ 40,000 IU daily or roughly 150,000 g within 1-2 weeks49. Typical symptoms include
headache, nausea, vertigo, blurred vision, muscle aches, alopecia, increased cerebral spinal fluid
pressure, and lack of coordination. Chronic hypervitaminosis A usually becomes apparent 3
months to years after starting moderate high levels (~30,000 g/day) of VA
consumption/supplementation49.

1.6 Retinoid Signaling
1.6a Retinoid Signaling Overview: It is known that VA exerts its physiological
functions by modulating gene expression in cells mainly in the form of RA50. As previously
mentioned, ROL becomes reversibly oxidized to RAL by RDHs, and then, RAL is irreversible
oxidized to RA by RALDHs (Figure 1.3). The reaction of converting ROL to RAL has a low
Vmax value, making this reaction the rate limiting step in the production of RA51. It has been
shown that RDH is anchored within the endoplasmic reticulum (ER) of the cell and cellular
retinol binding protein I (CRBP I) facilitates the transfer of ROL to RDHs by functioning as a
chaperone protein52-54. The RALDHs that catalyze the formation of RA from RAL are expressed
and regulated in a tissue specific manner. RALDH1 is an enzyme that is expressed in all tissues
and has been suggested to be a key regulator of adipogenesis in rodents55. RALDH1 has been
shown not to be required for rodent embryonic development, whereas it is lethal for mice to be
RALDH2 deficient56,57. The cytochrome p450 family of enzymes can contribute to the alteration
of RA by using NADPH and oxygen to form various end products including, but not limited to
4-hydroxy-RA and 18-hydroxy-RA58. CYP26A1 is the most investigated cytochrome p450
enzyme in regards to VA homeostasis due to its immense induction by RA59.
RA molecules will interact with transcription factors once they move into the nucleus and
play a role in regulating gene transcription (Figure 1.3). Metazoans contain a class of ligand10

activated transcription factors termed nuclear receptors that play a role in key physiological
processes such as development, reproduction, differentiation, and metabolism60. Retinoid acid
receptors (RARs) and retinoid-X-receptors (RXRs) are two members of the nuclear receptor
family that are believed to play a key role in the RA-induced effects on gene expression50. RAR
and RXR share a common ligand in 9-cis-RA whereas all-trans-RA only binds to RAR61. While
9-cis-RA binds to both RAR and RXR, this ligand seems to be only produced endogenously and
there is no proof that all-trans-RA goes through isomerization to form 9-cis-RA62. 9-cis-RA has
been shown to be the preferred substrate for RALDH4, but all-trans-RA is typically referred to
as the naturally occurring form of RA that is vital for physiological actions63. Once a ligand
binds to its respective nuclear receptor a conformational change occurs that allows the receptor
to interact with a number of transcriptional cofactors that can alter the regulation of their target
genes64. Within the promoter regions of RA responsive genes, there are short consensus DNA
sequences, which are termed retinoic acid response elements (RAREs) that are typically
recognized by RAR/RXR heterodimer or RXR/RXR homodimer65. But, it has been shown that
depending on the specific gene RXRs can bind to RARE in a heterodimer with other nuclear
receptors such as thyroid hormone receptors (TRs), liver-X-receptors (LXRs), vitamin D3
receptors (VDRs), and chicken ovalbumin up-stream transcription factor II (COUP-TFII)66,67.
1.6b Nuclear Receptors: With the advances in cloning and bioinformatics, it has been
shown that humans encode 48 nuclear receptor family members while mice encode 4968-70. With
the discovery of the full length sequences of the two founding members of the nuclear receptor
family, the human glucocorticoid receptor (GR) and estrogen receptor  (ER), it was shown
that most nuclear receptors share a common structural configuration: a variable N-terminal
region, a central conserved DNA binding domain (DBD), a non-conserved hinge domain, and a
11

Figure 1.3 Schematic depiction of the retinoid signaling pathway within target cells. See
section 1.6 for description. Abbreviations: CRBP, cellular retinol binding protein; CRABP,
cellular retinoic acid binding protein; CYP26, cytochrome p450, family 26; NR, nuclear
receptor; RARE, retinoic acid response element; RAR, retinoic acid receptor; RXR, retinoid-Xreceptor; RA, retinoic acid; RAL, retinal; RALDH, retinaldehyde dehydrogenase; RDH, retinol
dehydrogenase; ROL, retinol; STRA6, stimulated by retinoic acid 6.
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C-terminal region that serves as a ligand binding domain (LBD) (Figure 1.4)60. The DBD
contains two highly conserved zinc finger motifs that allows the receptors to bind to specific
DNA sequences termed hormone response elements (HRE). The non-conserved hinge domain
allows for structural flexibility in the receptor which results in the receptor being able to interact
with multiple HRE sequences. The LBD functions not only for binding of ligands, but also leads
to receptor dimerization. The receptors will bind to a variety of ligands including FAs, RA,
steroid hormones, and thyroid hormones71. A number of nuclear receptors that have been
recognized as to having no identified natural ligand, thus these receptors are termed nuclear
orphan receptors. When not bound to a ligand, the receptors will be found either in the nucleus
bound to a HRE resulting in a repressive complex with a corepressor or in the cytoplasm bound
to heat shock and chaperone proteins72,73.
A characteristic shared by both RAR and RXR is that they both contain three members of
their respective family: , , and . Each of these subtypes of nuclear receptors have been found
to be encoded by separate genes in the human and rodent genomes with each subtype susceptible
to alternate isoforms due to alternative splicing74. Both of these classes of nuclear receptors will
bind to a RARE that is located in the promoter of various genes (Figure 1.3). The RARE
sequence consists of two consensus half sites (AGGTGA) that are separated by nucleotides that
arrange the site as either palindromic, inverted palindromic, or direct repeats75. The regulation of
gene expression depends on a variety of factors including the receptor specificity for the
promoter region, the cofactors that bind with the receptors, and the arrangements of the RARE
sequences75-77. Cofactors that can promote or suppress transcription typically interact with RARs
and RXRs through their LBD domains. Once a cofactor binds to the LBD it can induce a
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conformational change either allowing or preventing the nuclear receptor and coactivator to bind
other cofactors to induce or suppress transcription75,78-80.

1.7 Physiological Roles of VA
1.7a Cell Proliferation and Differentiation: Retinoids have been known for decades
now for their ability to slow cell growth to promote the differentiation of many cell types81-83.
Retinoids primarily regulate gene transcription to alter cell proliferation and differentiation
through the activation of their nuclear receptors (RAR and RXR)74. This can be done either by
the receptors binding to specific response elements in the promoter or enhancer region of target
genes or by interfering with other transcription factors84,85. In particular, all-trans- and 9-cis-RA
seem to be the primary regulators of gene expression and possess the dynamic role in the
modulation of cell proliferation and differentiation86. The retinoids elicit their effects on cells by
either directly altering the expression of proteins involved in proliferation and differentiation or
indirectly by altering the expression of their receptors and/or binding proteins87. A deficiency in
VA can result in cell abnormalities and defects in cell maturity as evidenced by proper stem cell
differentiation not occurring in the absence of VA82. Furthermore, VA is required for the proper
progression of spermatogenesis in the testis for male fertility by all-trans-RA suppressing Sertoli
cell proliferation and assisting in differentiation, particularly during puberty88.
RA has been shown to be a regulator in the proliferation and differentiation of cancer
cells by altering the progression of the cell cycle. The treatment of RA in various cancer cell
lines have shown that RA can have anti-proliferative effects by down-regulating the expression
of cyclin-dependent kinase (CDK) and c-myc while up-regulating their inhibitors to halt the cell
cycle at the G0/G1 phase89. HL-60 cells are a cell model system commonly used to study acute
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Figure 1.4 Schematic depiction of a typical nuclear receptor. See section 1.6 for description.
A – variable N-terminal region; B – central conserved DNA binding domain; C- non-conserved
hinge domain; D- carboxy-terminal ligand binding domain.
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myeloid leukemia and in this cell line it has been shown that RA can induce their differentiation
from a promyelocytic leukemic state into granulocytes which could have therapeutic benefits90,91.
In-vitro studies have shown that all-trans-RA has the capability to induce not only the
differentiation, but also the apoptosis of a variety of tumor cells including glioma cells92,93.
Similar results have been found in HepG2 cells, hepatoma cell line commonly used to investigate
liver cancer, also by regulating cyclin-cdk activities94,95. RA and cAMP when used in
combination have been shown to be more effective at slowing the growth and inducing the
differentiation of hepatocellular carcinoma cells than either of the molecules when used
independently96. Interestingly, all-trans-RA has shown to induce the proliferation and
differentiation of brain tumor stem cells, but the differentiation is incomplete allowing the cells
to form brain tumor spheres97.
RA has also been shown to be an inducer of skeletal muscle as well as smooth muscle
cell differentiation. In a study optimizing the differentiation of human epithelial stem cells into
skeletal muscle, it was found that RA enhanced skeletal myogenesis by increasing the expression
of the myogenic regulatory factors (MRFs) MyoD and myogenin which are two key
transcriptional mediators of muscle cell differentiation98. Transforming growth factor (TGF-)
is a known inhibitor of myogenic differentiation by inhibiting the expression of MyoD and
myogenin99. However, in the mouse C2C12 skeletal muscle satellite cell line, RA alleviated the
anti-myogenic effect of TGF-1, allowing for myoblast differentiation100. RA has been shown to
not only enhance skeletal myogenesis in myoblasts, but also in various stem cell lines as well as
in chick limbs101-103. The treatment of mouse embryonic stem cells with RA led to increases in
skeletal myogenesis by upregulating the expression of skeletal muscle progenitor factors as well
as MyoD and myogenin104. In-vitro smooth muscle cell data has shown that all-trans-RA
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modulates the proliferation, migration, and actin expression in the cells through an RARdependent signaling pathway105. Human arterial smooth muscle cells treated with all-trans-RA
displayed decreases in their proliferation and migration attributed to the RA influencing
differentiation as well as extracellular matrix synthesis and degradation106.
1.7b Growth and Development: Early studies investigating VA supplementation and
deficiency in animals showed that VA status affects growth and development107-109. Studies in
the 1930s had shown that maternal deprivation of VA would result in severe congenital
malformations or in fetal death109,110. RA is known to be involved in the signal transduction
pathways regulating embryonic development as well as the development of the central nervous
system (CNS)110,111. Sufficient levels of VA are required for the proper segmentation and
patterning of the hindbrain as well as the forebrain112. The absence of VA during development
can have detrimental effects such as allowing epithelial stem cells to proliferate, but not
differentiate into the normal phenotype for proper epithelial lining113. VA deficiency has been
shown to lead to abnormalities in the heart, liver, ocular tissues, and reproductive system114-117. It
is important to note that the opposite is also detrimental during developmental periods. When
teratogenic levels of RA are administered to pregnant mammals it has been shown to affect the
CNS leading to disorders such as microcephaly, microphthalmia, and spina bifida118,119. Overall,
teratogenic doses of VA has been shown to have detrimental effects on a number of tissues
including the heart, bone, brain, and eyes120,121.
1.7c Vision: The effects of VA on vision was first shown thousands of years ago with the
treatment of night blindness with animal liver, an organ enriched with VA and it derivatives, but
it would not be until the early 1900s that studies distinctly showed the presence of VA in the
retina2,122. It was discovered that RAL is the form of VA present in the retina and that this VA
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derivative can transition between the cis- and trans-isoforms within the retina123-126.
Furthermore, it was during this period in the evolutionary elucidation of the vision cycle that
rhodopsin was characterized and its mechanism of synthesis revealed127. VA was also found to
be critical for the development of the cornea as individuals with diets deficient in VA typically
develop xerophthalmia128. Over time there were more studies conducted on eye structure and
mechanisms required for vision, therefore, the process that we now know as the retinoid visual
cycle has been largely revealed. This cycle relies primarily on retinal pigment epithelial (RPE)
cells, photoreceptor cells, and Müller cells. RPE is a monolayer of epithelial cells adjacent to the
outer region of the photoreceptors, separating the photoreceptor cells from the microvascular
network. Therefore, RPE cells assist in the uptake of all-trans-ROL from the choroid blood
vessels to be converted to 11-cis-RAL for the introduction into photoreceptors to combine with
opsin to form visual pigment129,130. Rod cells and cone cells are together classified as
photoreceptor cells which contain the transmembrane pigment rhodopsin and they face the
microvascular network19. Finally, Müller cells are a type of glial cell that spans across the
photoreceptor cells and contains cellular retinaldehyde binding protein (CRALBP) and cellular
retinol binding protein (CRBP) that are pertinent to the visual cycle19,131,132.
In the visual cycle all visual pigment will contain opsin that is combined with the
chromophore 11-cis-RAL to form rhodopsin19. The opsin portion is used to determine the
wavelength that the pigment responds to while the 11-cis-RAL will assists in the shape change
due to light exposure. In a series of steps termed “bleaching” the activation of rhodopsin by light
exposure will isomerize 11-cis-RAL to all-trans-RAL which will now dissociate from opsin and
move into the cytosol of the photoreceptor cells19. Once in the photoreceptor cells all-trans-RAL
is converted to 11-trans-ROL by RDH8 and RDH12, so that the 11-trans-ROL can be
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transported to the RPE133,134. Once in the RPE cell, the 11-trans-ROL will either be stored or
bind to CRBP I and it will be esterified by LRAT to form a RE135. The RE will be hydrolyzed by
RPE65 to produce 11-cis-ROL which will bind to CRABPI, so that it can be oxidized to 11-cisRAL by 11-cis-ROL dehydrogenase136. This visual cycle is completed by the transport of 11-cisRAL back to the photoreceptor cells to bind with opsin to form rhodopsin19.
1.7d Immunity, Infection, and Inflammation: The role of VA in immunity has been
studied for decades with VA being shown to be a major factor in assisting in host defense against
bacterial and viral diseases along with the status of VA having a major impact on the chronic
inflammatory response137. VA and retinoids play a role in innate immunity, cell-mediated
immunity, and humoral-mediated immunity138,139. Like most other micronutrients, a deficiency
in VA can increase the risk for infection while supplementation can prevent morbidity and
mortality particularly in children140,141. VA, particularly RA, has been shown to up-regulate the
production of cytokines favoring the generation of T-helper type 2 (TH2) cells and down-regulate
the T-helper type 1 (TH1) response while VA deficiency will have the opposite effect142-145. The
Th2 response is responsible for protecting against non-invasive infections and is required to
promote antibody production and maturation as well as for the deactivation of macrophages
which are immune cells commonly recruited to sites of inflammation146. The TH1 is responsible
for protection against intracellular infections and its response leads to the activation of
macrophages and production of inflammatory cytokines, thus promoting cytotoxicity146. RA has
been shown to induce the expression of various immune cells including, but not limited to Bcells, T-cells, neutrophils, dendritic cells, and macrophages147. RA is required for the proper
development and maturity of B-cells and subsequently antibody production by assisting in the
regulation of B-cell proliferation and differentiation147,148. RA has been shown to repress the
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transcription of genes involved in the NF-B signaling pathway as well as IL-2, both of which
are typically up-regulated during periods of inflammation149-151. RA has also been identified as a
suppressor of IFN- and TNF- gene expression which is an example of the RA-mediated Th2
anti-inflammatory response145,152. A deficiency in VA will impair antibody production and
promotes a TH1 inflammatory response by suppressing the production of anti-inflammatory
cytokines while increasing the production of pro-inflammatory cytokines137,153-155. Conversely,
in-vitro data has shown the supplementation of VA will dose-dependently increase the
expression of anti-inflammatory cytokines IL-4, IL-5, and IL-13, thus promoting the TH2
response155,156.
RA also seems to play a role in mucosal immunity as RA has been shown to reduce TGF expression in the intestinal epithelial cells, contributing to the intestine’s anti-inflammatory
responses157. A deficiency in VA can therefore impair both the humoral and cellular immunity of
the intestinal mucosa resulting in susceptibility to infections158. T-cells, neutrophils,
macrophages, and natural killer (NK) cells all have altered responses during periods of VA
deficiency and chronic marginal VA status159-162. It should be noted that certain infections can
possibly lead to a deficiency in VA due to decreasing appetite and nutrient intake, possibly
causing nutrient malabsorption, nutrient loss through vomiting and diarrhea, and altering typical
nutrient utilization138,163-165.

2. Insulin Signaling, Glucose Transporters, and Metabolic Disorders
2.1 Insulin Overview and Signaling Pathway
Insulin is a peptide hormone secreted from the pancreatic -cells primarily in response to
the increase in glucose due to meal consumption. Frederick Banting and John Macleod were
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awarded the Nobel Prize for the discovery of insulin in 1923 and it was in 1958 that Frederick
Sanger won the Nobel Prize in chemistry for determining the protein structure of insulin – the
first protein to have its sequence determined166. Insulin is first synthesized as a single
polypeptide chain referred to as preproinsulin. Preproinsulin contains a 24-residue signal peptide
that assists with the delivery of the newly formed protein to the rough endoplasmic reticulum
(RER) where the signal peptide is then cleaved to produce proinsulin167. Within the cisternal
space of the lumen in the RER, folding of proinsulin leads to the formation of three disulfide
bonds which is required for the transport of proinsulin to the Golgi complex. Here, proinsulin is
cleaved by endo- and exo-nucleases to release a fragment referred to as C-peptide and the mature
insulin product which is two polypeptide chains, A- and B-chains, which are linked together by
two disulfide bonds167,168. This mature insulin product will be packaged within granules inside
pancreatic -cells awaiting for metabolic stimulus for its release. The effects of insulin are most
prominent in the liver, adipose tissue, and muscle. Insulin primarily stimulates anabolic
functions: (1) insulin will decrease circulating fatty acids by inhibiting the activity of hormonesensitive lipase which degrades triacylglycerol (TAG) in adipose tissue and it will increase the
transport and metabolism of glucose in adipose cells to assist with TAG synthesis; (2) insulin
will decrease glycogenolysis and gluconeogenesis in liver; (3) insulin will promote amino acid
uptake and protein synthesis; (4) insulin will promote glucose uptake in target cells expressing
insulin receptors and promote the formation of glycogen169,170.
As shown in Figure 1.5, the release of insulin from the -cells is mediated first by the
entry of glucose into the -cell through the glucose transporter 2 (GLUT2)171. Once in the cell,
glucose will enter glycolysis leading to a rise in the ATP:ADP ratio which will close the ATPsensitive potassium channel172. This will prevent potassium ions (K+) from leaving the cell and
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the buildup of K+ will lead to depolarization of the cell membrane resulting in opening of
voltage-sensitive calcium ions (Ca2+) allowing the Ca2+ to enter the cell by facilitated
diffusion172-175. Once the intracellular concentration of Ca2+ rises, the enzyme phospholipase C
(PLC) becomes activated. PLC will cleave the membrane phospholipid phosphatidyl inositol 4,5bisphophate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 will bind
to receptor proteins found in the ER plasma membrane to assist with Ca2+ entry into the cells via
IP3 gated channels. With the significant increases in Ca2+ in the -cells, the insulin stored within
the secretory vesicles will be released via exocytosis173.
Once insulin binds to insulin receptors on target cells (myocytes and adipocytes), there is
a signaling cascade that follows to change the metabolism of the target cell. Insulin will bind to
the extracellular -subunit of the insulin receptor which leads to a conformation change in the
receptor leading to the activation of a kinase domain in the intracellular -subunit176,177. This
kinase can now phosphorylate tyrosine residues on the C-terminus of the receptor as well as in
the insulin receptor substrate (IRS)178. There are six known IRS’s with IRS-1 proposed as the
major IRS in skeletal muscle and IRS-2 as the main IRS in liver179. IRS can now bind to and
activate phosphatidylinositol 3-kinase (PI3K) which is recruited to the plasma membrane and
will convert PIP2 and ATP into PIP3 and ADP. The increases in PIP3 will lead to the
recruitment of Akt (also referred to as protein kinase B, PKB) by interacting with the pleckstrin
homology domain of Akt180. PIP3 also recruits PIP3-bound phosphoinositide-dependent protein
kinase-1 (PDK1) to the plasma membrane which will phosphorylate and activate Akt181. PIP3
has also been shown to recruit and activate the mammalian target of rapamycin complex-2
(mTORC2) by a mechanism yet to be fully established. mTORC2, like PDK1 will phosphorylate
Akt which inactivates glycogen synthase kinase (GSK) by phosphorylating the - and -subunit
22

of the enzyme182,183. By inhibiting GSK, glycogen synthase phosphatase (GSP) can activate
glycogen synthase (GS)181. This allows GS to continue producing glycogen and Akt will allow
for vesicle fusion, resulting in the translocation of a specific GLUT (GLUT4 in the case of
muscle and adipose tissue) to the plasma membrane for glucose entry into the cell184.

2.2 Glucose Transporters
It was in 1948 that the concept of glucose transporters were first hypothesized due to the
obvious requirement of glucose transport across lipid bilayers185. It would not be revealed until
30 years later that a specific protein embedded in the plasma membrane of erythrocytes was
responsible for mediating the glucose uptake186,187. Since this discovery there have been 14
members of the GLUT protein family identified in humans, all of which are encoded by the
soluble carrier family 2 (SLC2) genes188,189. The GLUT family has been categorized into three
classes based on their sequence similarity: 1) Class 1 includes GLUT1-4, GLUT14; 2) Class 2
includes GLUT5, GLUT7, GLUT9, and GLUT11; 3) Class 3 includes GLUT6, GLUT8,
GLUT10, GLUT12, and GLUT13188. All of the GLUTs characterized to date have been shown
to contain roughly 500 amino acid residues arranged in a 12 membrane-spanning helical
structure that allows both its amino and carboxyl terminals to be positioned in the
cytoplasm188,190. Furthermore, the GLUTs helical structure contains seven conserved glycine
residues, two conserved tryptophan residues, and two conserved tyrosine residues188. A substrate
binding site will located on the outside of the cell, but a binding site can also be inside the cell if
the transporter functions bidirectionally189. Once glucose or a related hexose binds to the
substrate binding site a conformational change in the GLUT occurs allowing glucose to be
transported and released on the other side of the membrane190. GLUTs 1-4 have been the most
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Figure 1.5 Schematic depiction of glucose stimulated insulin secretion within pancreatic cells. See section 2.1 for description. Abbreviations: ADP, adenosine diphosphate; ATP,
adenosine triphosphate; G6P, glucose-6-phosphate; GLUT2, glucose transporter type 2.
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studied and characterized, therefore, the following sections contain a brief summary on their
distribution and physiological importance as well as a summary on the known actions of
GLUT6.
2.2a GLUT1: Glucose transporter 1 (GLUT1) is a 492 amino acid residue protein.
encoded by the SLC2A1 gene in humans191. GLUT1 functions as a high affinity glucose
transporter expressed at high levels in erythrocytes and endothelial cells in fetal tissue along with
most other tissues through adulthood to assist with the transport of glucose across tissues with
endothelial and epithelial barriers including the blood-brain barrier192-194. GLUT1 is the primary
GLUT isoform regulating the transfer of glucose from maternal to fetal tissues in humans195.
GLUT1 is known to be expressed at higher levels during states of reduced glucose and
expression in membranes is decreased with high levels of glucose, thus to maintain a low-level
basal glucose uptake192. In addition to glucose, GLUT1 has been shown to transfer substrates
such as galactose, glucosamine, and mannose as well as vitamin C in the reduced ascorbate
state196. Due to the brain’s dependence on glucose for fuel, a disruption in proper GLUT1
regulation and impaired glucose transport to the brain can have dire consequences. A mutation in
the SLC2A1 gene can lead to an autosomal dominant diseases termed GLUT1 deficiency
syndrome (GDS) which can result in developmental delay, ataxia, dystonia, and neurobehavioral
symptoms197. The current therapy for GDS is replacing an individual’s typical diet with a
ketogenic diet to supply alternative fuel sources197. Within skeletal muscle, GLUT1 is thought to
be primarily responsible for the uptake of glucose during basal (non-insulin dependent)
conditions198. GLUT1 mRNA expression levels have also been shown to be increased during
prolonged treatment of muscle cells with insulin199. In a study in which skeletal muscle biopsies
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(vastus lateralis) was obtained from either lean, nondiabetic obese, or subjects with T2DM, it
was shown that GLUT1 protein expression levels were significantly decreased in T2DM200.
2.2b GLUT2: Glucose transporter 2 (GLUT2) is a 524 amino acid residue protein
encoded by the gene SLC2A2 and is expressed by kidney and small intestinal epithelial cells,
astrocytes, hepatocytes, and pancreatic -cells192,201. Besides being a glucose transporter, GLUT2
is also known to transport fructose, galactose, and mannose all with low affinity, but will
transport glucosamine with high affinity202,203. The bidirectional function of GLUT2 is of utmost
importance in hepatocytes during the fed and fasting state by regulating the uptake of glucose for
glycolysis, but also for the release of glucose during gluconeogenesis192. Periods of high glucose
concentrations will stimulate the activation and translocation of GLUT2 to allow for the entry of
glucose into the pancreatic -cells to stimulate the production and release of insulin192. Diabetic
rodent models have shown that the presence of high glucose, but low insulin levels lead to
increased GLUT2 expression levels in the intestine and liver, however, these same conditions
lead to decreased GLUT2 mRNA levels in the pancreas204-206. Mutations in the SLC2A2 gene is
known to cause an autosomal recessive disorder called Fanconi-Bickel syndrome which is
characterized by hepatomegaly, short stature, and renal dysfunction resulting in aminoaciduria
and glucosuria207.
2.2c GLUT3: Glucose transporter 3 (GLUT3) is a 496 amino acid residue protein
encoded by the gene SLC2A3208. GLUT3 is a high-affinity transporter expressed primarily in
neurons, but has also been shown to be expressed in the testis, placenta, and skeletal
muscle192,209,210. GLUT3 is similar to GLUT1 as it is also often regarded as a facilitator of
constitutive glucose uptake as well as it will transport galactose, mannose, and reduced
ascorbate192,211. Although GLUT1 and GLUT3 are both expressed in brain tissue, GLUT3 is the
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primary mediator of glucose uptake in neurons212. GLUT3 has also been shown to be of
importance in embryonic development and work along with GLUT1 in transporting glucose from
the placenta to the fetus213,214. GLUT3 has also been implicated in playing a key role in glucose
uptake during fetal skeletal muscle development as well during adult skeletal muscle fiber
regeneration215,216. GLUT3 mRNA and protein levels have been shown to be increased in rat
myoblasts during the fusion stage of differentiation, however, GLUT3 mRNA and protein levels
were decreased once the cells reached the state of myotube contraction216. In a study utilizing
small interfering RNA (siRNA) to target GLUT3 showed that the knockdown of GLUT3
expression in L6 muscle cells significantly reduced glucose uptake217. This same study
demonstrated that GLUT3 protein expression was increased by insulin-like growth factor-1
(IGF-1) in L6 cells217. The treatment of L6 cells with insulin for 18 hours increased GLUT3 and
GLUT1, but not GLUT4 protein expression levels218.
2.2d GLUT4: Glucose transporter 4 (GLUT4) is a 509 amino acid residue protein found
in adipose tissue, skeletal muscle, and cardiac muscle191. It is encoded by the SLC2A4 gene in
humans219. Besides the transport of glucose, GLUT4 will also transport glucosamine and
dehydroascorbic acid (DHA) across the plasma membrane189,220. GLUT4 is often referred to as
the insulin-stimulated glucose transporter as its expression and translocation is stimulated by the
binding of insulin to its receptor in target cells221. Since GLUT1 has been shown to assist with
skeletal muscle glucose uptake during a basal state, GLUT1 will reside in the plasma membrane
during this period with GLUT4 residing within the intracellular membrane compartment of the
cell222,223. Due to its widespread tissue distribution and role in maintaining whole body glucose
homeostasis, GLUT4 may be the most studied membrane transporter. Exercise has been shown
to enhance skeletal muscle insulin sensitivity by increasing the transcriptional expression of
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SLC2A4 resulting in enhanced glucose uptake224,225. Conditions that correlate with insulin
resistance such as obesity and T2DM have been linked to impaired GLUT4 regulation226.
GLUT4 gene expression has been shown to be decreased during diabetes and this is regulated in
a tissue-specific manner with the expression decreasing more rapidly in adipose tissue than in
skeletal muscle227,228. However, the exact mechanisms leading to the GLUT4 impairment remain
unknown due to the complex signaling events mediated by insulin as well as other potential
mediators that can alter GLUT4 regulation. It has been shown that GLUT4 is expressed
predominately within type 1 skeletal muscle fibers and the expression of GLUT4 within these
fibers is significantly reduced in subjects with T2DM229,230. Mice with muscle-specific knockout
of GLUT4 displayed signs of insulin resistance such as decreased glucose uptake, however,
muscle glycogen content was increased231.
2.2e GLUT6: Glucose transporter 6 (GLUT6) is a 507 amino acid residue protein
encoded by the SLC2A6 gene in humans which was formerly referred to as GLUT9232. Limited
research has been performed on the characterization of GLUT6. GLUT6 has been shown to be
expressed within the spleen, brain, and leukocytes as well as in muscle and adipose
tissue189,233,234. The primary physiological substrate of GLUT6 has not been clearly elucidated
yet nor has the kinetics of its transport and translocation activities. In rat adipose tissue, GLUT6
was shown to not be stimulated by insulin for the translocation to the plasma membrane233.
GLUT6 is thought to be maintained intracellularly by an N-terminal dileucine motif233. No
stimuli are known to promote the translocation of GLUT6 to the plasma membrane of cells.
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2.3 Insulin Resistance
2.3a Insulin Resistance Overview: It was in 1960 that the insulin radioimmunoassay
was developed which helped pave the way for understanding the effects of insulin on glucose
homeostasis under diverse conditions235,236. With insulin playing such a vital role in participating
in the regulation of macronutrient metabolism, any disturbance in insulin signaling can have
detrimental outcomes. In individuals with metabolic stresses such as those that are overweight
and obese, the insulin released in response to meal consumption may only have suboptimal
responses when compared to healthy, lean individuals. The exact mechanisms leading to insulin
resistance are not fully elucidated, but research has pointed to defects in the activation of the
insulin receptor and downstream proteins, or issues with proper GLUT function and
translocation237. Furthermore, impairment of insulin signaling has been postulated to occur due
to systemic inflammation and dysregulated lipid metabolism – both characteristics of obesity as
well as diabetes238. It is also important to note that insulin resistance has been shown to exist
during other disease states such as HIV and rheumatoid arthritis239,240. Tissues such as muscle
and adipose are those primarily affected by defects in insulin activity due to these tissues being
insulin dependent in regards for proper glucose transport.
2.3b Insulin Resistance in Muscle: Due to its mass, muscle is considered the major
tissue for the insulin-mediated glucose uptake, any disturbance in the insulin signaling pathway
or GLUT4 translocation can have dire consequences. Insulin sensitivity has been shown to be
impaired in muscle tissue during a state of obesity due to the increased presence of proinflammatory cytokines241. In-vitro studies have shown that inflammatory cytokines are capable
of inducing insulin resistance in muscle cells242,243. Similar results have been shown in-vivo by
the infusion of cytokines into humans with the test subjects displaying decreases in glucose
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uptake and glycogen synthesis244. This impairment in glucose uptake and glycogen synthesis due
to insulin resistance appears to be largely mediated by reduced intracellular glucose absorption
due to either decreased synthesis of GLUT4 or impairment in insulin:GLUT4 signaling245.
2.3c Insulin Resistance in Adipose Tissue: Adipose tissue accounts for about 10% of
whole body glucose uptake246. Within adipose tissue, insulin resistance is often associated with
the accumulation of activated macrophages and pro-inflammatory cytokines as well as
impairment of GLUT4 translocation238,246. The elevation in pro-inflammatory cytokines are
associated with attenuating the insulin signaling pathway within tissue247,248. For example, when
adipocytes were treated with TNF-, the cells displayed decreases in insulin signaling along with
decreases in glucose uptake249,250. Overnutrition can promote such cytokine production by
maintaining a constant supply of nutrient metabolites such as FFA’s that can stimulate the
synthesis of cytokines within immune cells248. Furthermore, having dysregulation of nutrient
metabolism as well as hormonal balance can predispose individuals to the development of
obesity251. Similar to skeletal muscle, GLUT4 translocation has also been shown to be impaired
in adipocytes of diabetic and insulin resistant individuals246. A state of insulin resistance will also
impair insulin signaling itself in adipocytes via decreased expression of IRS-1 as well as PI3K
and Akt246.

2.4 Metabolic Disorders
2.4a Obesity: The pathogenesis of obesity has been shown to be multifactorial with
genetic, environmental, and nutritional factors all contributing to the development of the
disease251. The early onset of obesity has been shown to be partially attributed to the
dysregulation appetite-regulating hormones such as leptin252. It was first identified that obesity
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was a state of inflammation when obese mouse tissue contained significantly higher levels of
TNF- in adipose tissue compared to the tissue of lean controls253. Furthermore, common
pathways involved in inflammatory signaling such as inhibitor of kappa kinase (IKK) and c-jun
N-terminal kinase (JNK) have been shown to have increased levels of activation in obese tissues
compared to tissues of lean controls254,255. Therefore, an additional feature of the inflammatory
state of obesity is the infiltration of immune cells such as macrophages that will secrete proinflammatory cytokines256. Even though there is an obvious connection between elevated
nutrition intake and obesity, the exact mechanisms in which overnutrition leads to obesity and
other metabolic disorders are not fully understood. It is reasonable to believe that the
accumulation of specific nutrients resulting from overnutrition can lead to the infiltration and
activation of immune cells in certain tissues.
Body mass index (BMI) is a relative measure of body fat in a person, which is calculated
via dividing a person's weight by the square of the person's height. The reference ranges for BMI
are as follows: 1) Underweight ≤ 18.4 kg/m2; 2) Normal weight 18.5 – 24.9 kg/m2; 3)
Overweight 25 – 29.9kg/m2; 4) Obese 30 – 34.9 kg/m2; 5) Severely obese 35 – 39.9 kg/m2; 6)
Morbid obese ≥ 40 kg/m2 257. The presence of obesity leads to an inflammatory state and has
been associated with the development of other diseases such as heart disease, certain cancers,
sleep disorders, arthritis, and type 2 diabetes mellitus (T2DM)257-259. The presence of these
obesity-related diseases are subsequently linked to reduced life expectancy and death. Since
excessive nutrient intake and lack of physical activity are two of the driving forces leading to
obesity, caloric restriction and exercising are common natural treatments for obesity260.
Individuals may also choose to use drugs and/or supplements that support weight lost or may
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choose surgery that will reduce stomach volume and/or bowel length to reduce nutrient
absorption, but obesity surgery can result in adverse side effects261-263.
2.4b Diabetes Mellitus: The condition known as diabetes is one that has been on a
staggering rise especially within the past 20 years. Collectively, diabetes is a term referring to a
state of high blood glucose levels over a prolonged period that can lead to multiple complications
if left untreated. With insulin being the primary hormone responsible for the regulation of
glucose uptake in skeletal muscle and adipose tissue, any disturbance in its secretion or
interaction with its receptors are signs that a form of diabetes is present. There are three main
types of diabetes: 1) Type 1 Diabetes Mellitus (T1DM) which stems from autoimmune
destruction of the pancreatic -cells that results in absolute insulin deficiency and predominately
begins during adolescents even though individuals up to 30 years old can develop the disease, 2)
T2DM is characterized by hyperglycemia, hyperinsulinemia, accumulation of TAG in cells, and
a reduced ability to oxidize lipids for their removal, 3) Gestational diabetes which has similar
characteristics to T2DM, but occurs during pregnancy and typically ceases after264. Typical
symptoms of diabetes includes polydipsia, polyphagia, and polyuria265. Even though T1DM and
T2DM differ in regards to development they both can result in a variety of pathological
conditions including nephropathy, neuropathy, and myopathy. The muscles of adolescents that
are diabetic can experience irreversible damage due to the development of the disease occurring
during the major growth period266. Patients will be diagnosed with diabetes if they meet at least
one of the following criteria: 1) Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl); 2)
Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) two hours following a 75 g oral glucose consumption;
3) Symptoms associated with diabetes and a casual plasma glucose ≥ 11.1 mmol/l (200 mg/dl);
4) Glycated hemoglobin (HbA1C) ≥ 6.5%267,268.
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T1DM accounts for roughly 10% of all diabetic cases, but the prevalence has continued
to increase for the last quarter century269. T1DM is known as an autoimmune-mediated disease
resulting from an infiltration of immune cells such macrophages and TH cells that will secrete
pro-inflammatory cytokines at high concentrations for long durations resulting in decreases in cell function, eventually leading to cell death270-272. Individuals with T1DM often have
symptoms as hyperglycemia, ketoacidosis, and hypoglycemia265. T2DM currently accounts for
roughly 90% of all diabetic cases in the world and it has been projected that the condition known
as T2DM will affect 8% of the worldwide population by 2030273. The American Diabetes
Association (ADA) suggests that the current Western lifestyle encompasses a diet that is high in
dietary fat and a sedentary activity level which could part explain the T2DM epidemic264.
Therefore, like obesity, T2DM is considered a multifactorial disease with genetic,
environmental, and lifestyle factors all contributing to its manifestation. T2DM is characterized
by the presence of insulin resistance that is often accompanied by reduced insulin secretion,
thought to also be due to inflammation and -cell death274. T2DM shares many of the symptoms
with T1DM, but while those with T1DM will require insulin injections for the rest of their lives,
it is strongly believed that through dietary and lifestyle intervention that T2DM can be reversed
due to a reduction in overweight and obesity258,275.

2.5 VA and Pancreatic-cell Function
The islets of Langerhans in the pancreas contain the -cells which are essential for the
regulation of glucose due to their secretion of the anabolic hormone, insulin169. Studies have
linked VA and -cell function by showing that in islets collected from rats fed a VAD diet
displayed impaired glucose-stimulated insulin secretion and decreases in -cell mass276,277.
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However, when VA was re-established in the diet this impairment was reversed, suggesting that
retinoids assist in regulating insulin secretion276. Furthermore, high levels of retinoid-associated
proteins such as TTR, RBP, CRBPI, and CRABPI have been found within pancreatic islets278. In
rats subjected to streptozotocin (STZ)-induced diabetes development, treatment with retinyl
palmitate alleviated the diabetes development by supporting the prevention of -cell death279.
The treatment of rat insulinoma RINm5F cells as well as pancreatic islets collected from both
adult and fetal rats with all-trans-RA led to increases in glucokinase (GCK) gene expression and
increases in insulin secretion at both high and low glucose concentrations280,281. This increase in
insulin secretion can be at least partially attributed to the increase in proinsulin mRNA levels in
RINm5F cells and insulin mRNA levels in isolated human islets with all-trans-RA
treatment280,282. All-trans-RA treatment in INS-1 cells was associated with increases in GLUT2
gene expression which is essential for glucose entry into the -cells283. Conversely, the treatment
of mice with 9-cis-RA led to glucose intolerance and attenuated glucose-stimulated insulin
secretion during periods of high glucose284,285. Furthermore, treatment of rodent islets with 9-cisRA is associated with decreases in GCK and GLUT2 activity284. Retinoid nuclear receptors are
thought to associated with the regulation in -cell insulin secretion by RA due to the
identification and characterization of a RARE sequence in the human insulin gene promoter282.
Therefore, it is plausible that all-trans-RA and RAR are assisting in glucose homeostasis under
normal conditions, but during periods of hyperinsulinemia 9-cis-RA and RXR assist with
preventing excessive insulin secretion.
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3. Skeletal Muscle
3.1 Skeletal Muscle Physiology
3.1a Skeletal Muscle Structure and Contraction: Skeletal muscle refers to a number of
muscle fibers that are joined together by connective tissue. Each muscle fiber is a single,
cylindrical muscle cell that is formed by the fusion of multiple mononucleated and
undifferentiated cells termed myoblasts (Figure 1.6). The differentiation of myoblasts into
myotubes is a highly regulated process involving the expression of distinct families of genes
including MRFs and myocyte enhancer factors (MEFs)286. The differentiation of the myoblasts
are typically complete by birth and continue to grow in size into adulthood with no new fibers
actually formed from myoblasts286. Instead, if new fibers are required to be formed following
exercise or injury, then it is from another undifferentiated cell type known as muscle satellite
cells, which like myoblasts will undergo differentiation287-289. However, this cell type alone will
not restore severely damaged muscle to full strength, but it is through the coupling of the satellite
cell proliferation and hypertrophy of the remaining muscle tissue to compensate for loss of
muscle tissue290.
Skeletal muscle is assembled as a striated pattern involving numerous thick and thin
filaments in the cytoplasm that form myofibrils. The fibers are assembled in a repeating pattern
of light and dark bands due to the presence of the thick and thin filaments. The thick filaments
are composed mainly of the protein myosin and the thin filaments are primarily composed of
actin, but also contains the proteins troponin and tropomyosin291,292. It is the collection of these
proteins along with other accessory factors such as calcium that allows for muscle contraction
through the activation of cross-bridges293. The process of skeletal muscle contraction is termed
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the “sliding filament theory” and it was first described in the early 1950s294-296. There are
numerous steps involved in the contraction of skeletal muscle: 1) An action potential originating
in the CNS will propagate down an axon terminal in a motor neuron; 2) Once the action potential
reaches the neuromuscular junction it triggers the influx of calcium into the axon terminals; 3)
The calcium influx will trigger the release of acetylcholine (ACh) from the axon terminals; 4)
ACh will diffuse from axon terminals and bind to nicotinic ACh receptors on the neuromuscular
motor end plate which will stimulate an influx of Na+ to depolarize the membrane and produce
another action potential; 5) The action potential will move along the transverse tubules (Ttubules) in the fiber and depolarizes the dihydropyridine (DHP) receptors to open the ryanodine
receptor channels to stimulate the release of Ca2+ from the laterals sacs of the sarcoplasmic
reticulum; 6) Ca2+ will bind to troponin on the actin thin filaments which will initiate a
conformational change in troponin to release the inhibitory subunit of troponin that is bound to
tropomyosin, allowing tropomyosin to move away from and expose the myosin (cross-bridge)
binding site on actin; 7) An energized myosin on the thick filament can now bind to actin which
will stimulate the release of ADP and inorganic phosphate from myosin resulting in the “power
stroke” motion; 8) ATP will then bind to myosin, breaking the link between actin and myosin,
thus separating the cross-bridge from actin; 9) ATP bound to myosin will be hydrolyzed to
energize the myosin cross-bridge by moving it into the “cocked” position; 10) Cross-bridges
repeat steps 7-9 to produce the “sliding” movement of thin filaments past thick filaments, this
will continue as long as ATP is available and Ca2+ is bound to troponin; 11) Cytosolic levels of
Ca2+ will decrease as Ca2+-ATPase activity transports Ca2+ back into the sarcoplasmic reticulum,
therefore the removal of Ca2+ from troponin will allow tropomyosin to block the binding sites
again and the myosin cross-bridge ceases allowing the muscle fiber to relax294-298. This is similar
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to periods of rest to where cytoplasmic calcium concentrations are low in muscle and myosin
cross-bridges are not bound to actin. ATP has three primary roles in the skeletal muscle
contraction process: 1) Provides energy through its hydrolysis for cross-bridge movement; 2) Its
binding to myosin will break the link between myosin and actin allowing the cycle to repeat; 3)
The hydrolysis of ATP by Ca2+-ATPase in the sarcoplasmic reticulum provides energy for
calcium ion transport into the reticulum to lower the cytosolic calcium levels and allowing the
contraction to end and the muscle to relax298,299.
3.1b Skeletal Muscle Regeneration: Damaged skeletal muscle tissue must be repaired in
a process that requires a specific cell-type referred to as satellite cells. This regeneration will
begin simultaneously with the inflammatory response that is occurring due to the damaged
muscle fiber (Figure 1.6)300. This process is typically considered to take place in four distinct
stages: 1) Activation of satellite cells; 2) Proliferation of myoblasts; 3) Differentiation of cells; 4)
Return to quiescence301. The activation of the satellite cells occurs when the cells enter the cell
cycle with this process primarily studied by measuring changes in morphology and protein
markers302. A quiescent satellite cell will contain only a few organelles with a limited amount of
cytoplasm whereas an activated satellite cell will contain more enlarged organelles and much
more cytoplasm302,303. The binding of hepatocyte growth factor receptor (HGFR) with its ligand,
hepatocyte growth factor (HGF), is typically viewed as an interaction marking the activation of
satellite cells303,304. The second stage of regeneration is marked by the proliferation of myoblasts
which is linked to the increased expression of muscle regulatory factors including MyoD and
myf5305,306. The proliferating myoblasts will then withdraw from the cell cycle and start fusing
with each other as well as with existing fibers to form new fibers in the process of
differentiation307. Differentiation is typically marked by the increased expression of myogenic
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regulatory and enhancer factors myogenin, MEF2, and MRF4 as well as by the increases in
muscle tissue creatine kinase (CK) activity307-310. The events that occur after differentiation it is
still under debate as it is not totally clear if some of the satellite cells that became activated reenter into quiescence or if the pool of satellite cells is re-populated by daughter cells. What is
better established is the events taking place to mark the end of differentiation such as the
increased expression of differentiation-repressing proteins including myostatin and other TGF-
family members311. The TGF- members are known to have a negative role on myoblast
differentiation by increasing MyoD degradation, suppressing the function of MEF2, and
decreasing the expression of myogenin as well as myosin heavy chain (MHC)312-314. Together,
the interplay between differentiation activation and repression factors allows for the proper
regeneration and repair of skeletal muscle.
3.1c Types of Skeletal Muscle Fibers: Skeletal muscle fibers are distinguished by their
maximal rate of cross-bridge cycling and by which pathway they use for generating energy
(ATP) (Table 1.1). Fibers that contain myosin will differ in the maximal rate in which they split
ATP such that fibers containing myosin with high ATPase activity are considered to be fast
fibers, also called type II fibers, whereas fibers containing myosin with low ATPase activity are
termed slow or type I fibers315. The second method used for classifying skeletal muscle fibers is
based on their process for generating ATP315. Oxidative fibers contain a high number of
mitochondria, therefore, they have a high capacity for oxidative phosphorylation. Oxidative
fibers are also referred to as red muscle fibers due to the high levels of myoglobin which give the
fibers a dark red color as well as an adequate supply of oxygen315. A second fiber type, termed
glycolytic fibers, are much lower in mitochondria number, but contain high concentrations of
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Figure 1.6 Schematic depiction of skeletal muscle regeneration and differentiation process.
See section 3.1 for description.
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glycolytic enzymes as well as large stores of glycogen315. Unlike oxidative fibers which have an
abundance of myoglobin, glycolytic fibers have limited amounts of myoglobin and oxygen,
therefore, these fibers are also referred to as white muscle fibers. Three types of skeletal muscle
fibers have been established based on their maximal rate of cross-bridge cycling and energy
processing: 1) Slow-oxidative fibers (Type I) – these fibers have low ATPase activity with high
oxidative capacity; 2) Fast-oxidative-glycolytic fibers (Type IIa) – have high ATPase activity
with high oxidative capacity and intermediate glycolytic capacity; 3) Fast-glycolytic fibers (Type
IIb) – have high ATPase activity with high glycolytic capacity315. These three types of fibers also
differ in their capacity to resist fatigue as Type IIb fibers fatigue rapidly while Type I fibers are
very resistant to fatigue and Type IIa have an intermediate capacity to resist fatigue. Type I
fibers will be the first recruited during weak contractions, followed by Type IIa and finally Type
IIb for strong contractions316,317. Of course, exercise will have an impact on fiber type by altering
muscle strength and susceptibility to fatigue. During short bouts of high-intensity exercise the
muscle fiber’s diameter will increase due to increased synthesis of actin and myosin, thus
resulting in increased strength318-321. For long bouts of low-intensity exercise the muscle fiber’s
mitochondrial content will increase leading to improved endurance321,322.
3.1d Skeletal Muscle Energy Metabolism and Substrate Utilization: Due to skeletal
muscle being a tissue that rapidly goes from a state of rest to contractility, the breakdown of ATP
must be a highly-organized process. For a fiber to maintain a state of contractility or is going
through a cycle of contractility such as during exercise, then ATP must be produced as rapidly as
it is hydrolyzed. This is going to require an adequate supply of macronutrients and
micronutrients to assist with the formation of ATP. There are a number of ways that ATP can be
produced in skeletal muscle: 1) Oxidative phosphorylation of ADP in the mitochondria of the
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muscle cell; 2) Substrate-level phosphorylation of ADP in the cytosol of the muscle cell; 3)
Phosphorylation of ADP to creatine phosphate (CP). During the beginning of a contraction, CP
provides a readily available source of phosphate to assist in the formation of ATP in a reversible
reaction catalyzed by CK323. The production of ATP from CP is a restricted reaction due to the
limited supply of CP in the cell. Therefore, after the first few seconds of contractility another
source must be used to support the production of ATP. For the first ten or so minutes of
moderate level of muscular activity the ATP that is produced is primarily by oxidative
phosphorylation324,325. Stored muscle glycogen has been shown to be the primary source of
glucose for fueling oxidative phosphorylation326. As muscular activity continues for the next
thirty minutes or so, it is blood glucose and fatty acids that contribute to ATP production through
glycolysis and oxidative phosphorylation327,328. An activity beyond this point is going to rely
more heavily on fatty acids for ATP production as the muscle’s glucose utilization will decrease
without dietary replenishment327,328. The glucose used for glycolysis in muscle cells are obtained
from two sources – muscle glycogen stores and blood glucose. With increases in muscular
activity intensity there is a shift in ATP production from aerobic glycolysis to anaerobic
glycolysis which subsequently results in lactic acid production via lactate dehydrogenase
(LDH)329,330. Following intense muscular activity, individuals will breathe heavily due to the fact
that there is going to be an increased demand for oxygen to metabolize the lactic acid that has
accumulated and return blood oxygen levels back to pre-activity levels331,332.
Muscular fatigue can result from a variety of factors depending on the type of activity
performed. With short bouts of high-intensity muscular activity the onset of fatigue has been
attributed primarily to three mechanisms: 1) Lactic acid accumulation in muscle; 2) Cross-bridge
cycling inhibition; 3) Action potential conduction failure. With the buildup of lactic acid
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resulting in excessive hydrogen ion levels, there are alterations in muscle protein activity,
including actin and myosin as well as those involved in muscle cell differentiation. The
accumulation of ADP and inorganic phosphate can also be problematic by slowing the rate of
cross-bridge attachment from actin, therefore, decreasing the overall rate of cross-bridge cycling.
Sarcoplasmic reticulum calcium release can be prevented if muscle action potential fail to be
conducted along the T-tubules of the muscle fiber from the accumulation of potassium ions. This
increased volume of potassium ions can disturb the repolarization/depolarization equilibrium
leading to inactivation of the sodium channels, therefore, failing to produce the action potential
to stimulate cross-bridge cycling. With long bouts of low-intensity muscular activity it is the
depletion of fuel substrates that seem to play the primary role in inducing muscular fatigue.
Decreases in muscle glycogen, low blood glucose levels, and dehydration are all factors
implicated in causing fatigue in low-intensity activity.

3.2 Diabetic Myopathy
3.2a Diabetic Myopathy Overview: Diabetic myopathy is a condition that is typically
overlooked, probably due to the numerous other conditions associated with diabetes, but the
decrease in skeletal muscle is detrimental to physical well-being. It is known that skeletal muscle
is the body’s largest site for glucose uptake and utilization, therefore a decrease in muscle cell
number and function can negatively impact whole body glucose homeostasis. In T1DM mice it
has been shown that the disease can result in reduced skeletal muscle mass, poor muscle
capillarization, and reduced muscle regeneration333-335. Typically, intracellular lipids can serve as
an available energy source during physical activity, but with a high dietary fat intake and
elevated levels of plasma fatty acids the fat accumulation is associated with the development of

42

Table 1.1 Skeletal Muscle Fiber Classification and Characterization
Characteristic

Type I Fibers (slowoxidative)

Type IIa Fibers (fastoxidative)

Type IIb Fibers (fastglycolytic)

Myosin-ATPase
Activity

Low

High

High

Contraction Rate

Slow

Fast

Fast

Fatigue Resistance

High

Intermediate

Low

Activity Type
Promoting Fiber
Activation
Fiber Force
Production

Aerobic (marathon
running)

Aerobic/ Long-term
Anaerobic (400 m race)

Anaerobic
(powerlifting)

Low

High

Very High

Mitochondrial
Number and
Oxidative
Phosphorylation
Capacity
Capillary Density

High

High

Low

High

Intermediate

Low

Myoglobin Content

High

High

Low

Fiber Color

Red

Red

White

Glycogen Content

Low

Intermediate

High

Major Storage Fuel

TAG

CP, Glycogen

CP, Glycogen

Fiber Diameter

Small

Intermediate

Large

Abbreviations: TAG, triacylglycerol; CP, creatine phosphate.

43

insulin resistance. This can be specifically harmful in prediabetic individuals suffering from
decreased insulin secretion and reduced mitochondrial function as the addition of insulin
resistance would now class the individuals as being type 2 diabetic. Obesity, which is a common
characteristic of T2DM is associated with impaired mitochondrial function and enhanced
mitochondrial damage due to the presence of reactive oxygen species (ROS). Intracellular fatty
acids are prone to peroxidation and these lipid peroxides can induce oxidative damage to cells
including muscle cells. Insulin resistance indicates that there is a reduced state of responsiveness
of tissues including skeletal muscle to the circulating insulin, thus without insulin binding to its
receptors on muscle cells then glucose cannot enter the cell to provide energy in the form of
ATP. The coupling of the insulin resistance with the increases in reactive oxygen species can be
damaging to muscle tissue in type 2 diabetic individuals.
3.2b Factors Contributing to Diabetic Myopathy:
3.2b-1 Oxidative Stress and Mitochondrial Dysfunction: The presence of
oxidative stress is evident in both T1DM and T2DM as it has been directly correlated to elevated
glucose concentrations336. It is common for diabetic individuals to suffer from alterations in
muscle metabolism including having a decreased inner myofibril mitochondrial content as well
as abnormal lipid deposition in the muscle cells leading to the muscle becoming obstinate as it
will not readily switch between carbohydrate and fat oxidation in response to insulin like it
typically would in a non-diabetic individual337-339. This can lead to a variety of functional
impairments including a decline in muscular strength and eventually atrophy. This muscular
damage is most likely due to ROS decreasing the expression of important myogenic factors
required for muscle proliferation, differentiation, and regeneration. Oxidative stress has been
shown to impair glucose uptake in muscles and decreases insulin secretion from the pancreatic 44

cells340,341. Oxidative stress can result from either an excessive oxidative load or from inadequate
balance of nutrients favoring pro-oxidant actions where there is an imbalance between prooxidant reactions and the presence of anti-oxidants. The increase in oxidative stress can lead to
the production of harmful substances termed free radicals that can either be of oxygen origin
(superoxide, hydrogen peroxide, hydroxyl radical) or of nitrogen origin (peroxynitrite and
nitrogen dioxide). The reduced presence of anti-oxidants subsequent with the decrease in antioxidant enzyme activity is correlated with the severity of insulin resistance as well as the reduced
ability of muscle cells to oxidize lipids342,343. This increased oxidative stress can also lead to the
production of pro-inflammatory cytokines that can lead to dysregulation in muscle metabolism.
These cytokines, which are also referred to adipokines or myokines, can alter fuel usage by
either up-regulating or down-regulating hormones such as insulin. A number of cytokines such
as interleukin-1 (IL-1, TNF-, and IFN- have been implicated in the autoimmune process
that leads to the destruction of the pancreatic -cells and subsequent diagnosis of T1DM344.
T2DM is often associated with obesity which on its own is becoming a global epidemic.
In obese diabetic individuals the lipids from the diet can excessively accumulate in skeletal
muscle and can alter insulin signaling as well as muscle maintenance and regeneration. Having
uncontrolled diabetes and subsequent poor glucose control can be detrimental to the fundamental
role of muscle and its cells as it has been shown that by exposing skeletal muscle cells to high
levels of glucose that the muscle cells will actually differentiate into adipocytes345. Fatty acids
that are obtained from the diet are oxidized in tissues such as skeletal muscle to be further
metabolized and used for metabolic processes, but an increase in muscle lipid content is
associated with a reduction in muscle lipid oxidation, thus promoting lipid deposits which is
often identifiable by increases in intramyocellular fat and triglycerides levels346. Therefore, the
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increases in muscle cell lipid content seen in obesity can impair fatty acid oxidation itself and
play a role in the development of insulin resistance. In obese diabetic individuals that suffer from
insulin resistance the fatty acid metabolism in skeletal muscle seems to shift from oxidation to
esterification and/or peroxidation. The ability of the muscle to select the proper fuels for
metabolism is altered during insulin resistance as the ability to shift between fatty acid and
carbohydrate oxidation is lost347. The increased concentration of lipid in muscle cells have been
associated with mitochondrial respiratory chain defects, particularly decreases in the expression
of various genes involved in oxidative phosphorylation, thus decreased production of ATP348.
Furthermore, the structural integrity of the mitochondria of the cells itself can be damaged due to
the increased presence of ROS during diabetes349.
3.2b-2 Inflammation: The concept of inflammation in skeletal muscle is
multifaceted as inflammation typically occurs after an injury, but it can also be activated upon
stress such as that discussed in section 3.2b-1 with oxidative/lipid-induced stress. The process of
inflammation has to coordinate with myogenic differentiation to achieve muscle regeneration.
After a muscle has endured some sort of injury or stress there is recruitment of pro-inflammatory
macrophages termed M1 macrophages that will remove debris and promote muscle cell
proliferation. As diabetes progresses so does a multitude of pro-inflammatory factors that
contributes to the detrimental effects diabetes has on muscle and many of these factors can be
secreted by immune cells such as the M1 macrophages. One such inflammatory protein is TNF-
and it is known not only to be associated with diabetes development and progression, but it has
also been found to alter glucose uptake in muscle cells as well as promote insulin
resistance350,351. High levels of TNF- exist in visceral adipose tissue in obese individuals, but
diabetic individuals have high levels circulating in plasma as well as in skeletal muscle241,352.
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TNF- is thought to promote cells entering the cell cycle for proliferation instead of
differentiation, meaning that they simple replicate instead of forming muscle fibers353. TNF- is
also a potent inducer of mitochondrial ROS which can have detrimental effects on the
mitochondrial membrane leading to cell death and an attraction of inflammatory cells to promote
inflammation354. During the later stages of muscle repair and regeneration there are antiinflammatory cytokines termed TGF- and IL-10 that are being secreted from M2 macrophages
(anti-inflammatory macrophages) that promote muscle differentiation instead of
proliferation355,356.
IL-6 is a cytokine that seems to have more controversy surrounding it. It has been shown
that IL-6 can alter insulin signaling in hepatocytes and adipocytes leading to impaired glucose
uptake by GLUT4 thus promoting increases in blood glucose levels357. Even though IL-6 is often
seen as a pro-inflammatory cytokine it can also have anti-inflammatory functions which can lead
to the confusion in affecting glucose uptake and muscle metabolism. It does seem that in most
studies demonstrating negative effects of IL-6 on insulin signaling is in adipocytes or
hepatocytes, whereas the positive effects of IL-6 on insulin signaling seems to occur in muscle
cells357-359. One can easily see that the interaction between skeletal muscle cells and immune
cells have to be finely orchestrated in order for proper muscle regeneration to occur, so if you
take a state of chronic inflammation such as during the early stages of T1DM or because of
obesity then there is constant increased levels of circulating pro-inflammatory cytokines such as
TNF- that will have distinct roles in muscle metabolism, but the end result is typically the same
– atrophy248.
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3.3 Physical Activity
Physical activity (PA) continues to receive an increasing amount of publicity as one of
the primary lifestyle factors that can prevent and reverse the effects of T2DM, but also
significantly decrease the various detrimental effects that T1DM has on the body. The US
Physicians Health Study reported that substantial decreases in the relative risk of T2DM can be
achieved with lifelong regular physical activity360. Numerous studies have indicated that PA can
exert beneficial effects such as increasing glucose uptake in muscle, increasing fatty acid
oxidation, increasing insulin sensitivity, and at least partially restore normal metabolic
control361,362. GLUT4 translocation has been shown to be increased in response to acute bouts of
exercise while chronic exercise training will increase GLUT4 expression363. Exercise training
will also enhance glucose transport by increasing signaling activity at the IRS protein level as
well as by increasing PI3K expression361.
It was as recent as 1990 that the American College of Sports Medicine (ACSM) first
published guidelines for recommendation of resistance training which is particularly important
for diabetic individuals that suffer from diabetic induced myopathy. The current PA
recommendations for diabetic individuals according to both ACSM and ADA are 1) 150 minutes
or more of moderate-level activity a week and 2) perform resistance training at least 2 times a
week on non-consecutive days364. Aerobic training is of utmost importance for diabetic
individuals since this population is susceptible to a number of other conditions including
nephropathy, neuropathy, and cardiovascular disease, therefore, one would expect that with
aerobic training there would be increased blood flow, capillarization, and oxygen delivery which
would decrease the presence of such conditions. Resistance training has also been shown to
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improve glycemic control in patients with T2DM as well as decrease their risk for cardiovascular
disease365.

3.4 VA and Muscle
Limited research has been performed on the effects of VA in the form of RA on
macronutrient metabolism in skeletal muscle. Most of the literature regarding RA and skeletal
muscle cells is in regards to differentiation of muscle cells. It has been shown that RA as well as
insulin can induce differentiation of skeletal muscle myoblasts to form myotubes98,366. In regards
to protein metabolism, rats that are deficient in VA display decreased rates of protein synthesis
with concomitant increases in proteolysis rate, but when VA is present at toxic levels only for
acute period’s proteolysis is also increased, thus favoring the development of myopathy in VA
deficient and toxic states367-369. Intracellular FA’s are prone to peroxidation and these lipid
peroxides can induce oxidative damage to cells including muscle cells370. RA has been shown to
increase the expression of genes regulating fatty acid oxidation and thermogenesis in mouse
skeletal muscle, thereby demonstrating a possible anti-inflammatory mechanism of RA in
skeletal muscle371. In regards to carbohydrate metabolism, the treatment of undifferentiated
mouse myoblasts with RA led to an increase in glucose uptake in which the authors postulated
was through AMP activated protein kinase (AMPK)372. Therefore, it is obvious that more studies
need to be conducted in determining the mechanisms regulating macronutrient metabolism in
differentiated skeletal muscle cells and the products produced by the actions of these nutrients.

3.5 Commonly Used In-Vitro Myogenic Model Systems
3.5a Rat L6 Cells: L6 cells are immortal primary culture cells isolated from the thigh
muscle of newborn rats373. These myoblasts were shown to divide two-three times before fusing
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together into multinucleated muscle fibers and that under the appropriate maintenance
conditions, these cells can be cultured for months at a time as well as kept in a frozen state
without losing their differentiation potentialities and viability373. In addition to studying
differentiation, this cell model system has been shown to be useful in studying skeletal muscle
glucose metabolism. L6 myotubes have been used to successfully investigate muscle GLUT
regulation in response to a variety of treatments including insulin, retinoids, and inositol
derivatives374-376. In response to insulin, these cells have been shown to exhibit a greater degree
of glucose uptake and GLUT4 translocation than other in-vitro murine skeletal muscle model
systems377,378. This suggests that L6 myotubes may be the most efficient in-vitro model for
studying muscle glucose metabolism.
3.5b Rat L8 Cells: Rat L8 cells like L6 cells are also isolated from the thigh muscle of
newborn rats379. This cell line has been used for the investigation of myoblast differentiation,
glucose metabolism, and insulin signaling mechanisms380-384. GLUT1 has been shown to be the
primary glucose transporter in this myoblast cell line, therefore, most of the research on L8
glucose regulation has been to investigate the mechanisms involving the GLUT1 translocation
and activity382,383. One such mechanism to be elucidated in the regulation of glucose transport in
L8 myoblasts is the role of hexose 6-phosphate in mediating the subcellular redistribution of
GLUT1385.
3.5c Mouse C2C12 Cells: The immortal adherent C2C12 cell line is a subclone of the
established C2 myoblast cell line isolated from the thigh muscle of a two month old female C3H
mice386,387. These cells are known to differentiate quickly forming contractile myotubes
expressing muscle proteins, therefore, these cells have been used to study agents that can affect
the differentiation process as well as skeletal muscle glucose metabolism and insulin
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signaling100,314,388. For example, these cells have been used to study the mechanisms regulating
GLUT4 transcription and regulation389. Interestingly, the treatment of C2C12 cells with bone
morphogenetic protein-2 (BMP-2), which is a member of the TFG- family of proteins, will
convert the cell line from having a myoblastic fate to an osteoblastic cell390.

4. Glycogen Metabolism and Regulation
4.1 Glycogen Overview
The ability to acquire and store energy is essential for an organism to face environmental
challenges such as the lack of readily available nutrients. Glycogen, the highly branched
polysaccharide , serves as the primary storage form of glucose391. The liver and skeletal muscle
are the major storage sites of glycogen in human body. As shown in Figure 1.7, glycogen in the
liver and skeletal muscle is used differently392. The role of glycogen within the skeletal muscle is
to provide glucose for energy production while the primary role of glycogen in the liver is to
supply glucose in the blood for the use in other tissues392. During the fed-state, the entry of
dietary nutrients into the blood leads to the secretion of the anabolic hormone, insulin, from the
pancreatic β-cells 392. The activation of insulin signaling pathway increases the activities of
enzymes involved in glycogenesis including GS, and in turn, enhance glycogenesis in
hepatocytes and muscle cells393,394. During a fasting state, the entry of dietary nutrients into
blood stops, and the pancreas reduces insulin and increases glucagon secretion, a process that
reduces glycogenesis and enhances glycogenolysis392. GS and glycogen phosphorylase (GP) are
primary enzymes for glycogenesis and glycogenlysis, respectively395. The hepatic glycogenolysis
provides a source of glucose to be released into the blood395. Unlike the liver, muscle lacks
glucose-6-phosphatase activity which results in the use of glucose inside muscle cells396.
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The conversion of glucose to glycogen is an ordered process that has been studied
extensively. UTP-glucose-1-phosphate uridylyltransferase catalyzes the conversion of glucose-1phosphate to uridine diphosphate (UDP)-glucose in the expenditure of uridine triphosphate
(UTP)397. At the core of the glycogen molecule is a protein homodimer known as glycogenin.
Glycogenin has two tyrosine residues that will accept glucose moiety from UDP-glucose393.
Therefore, glycogenin serves two roles in the process of glycogen synthesis: 1) the anchoring
core molecule for glycogen formation, and 2) the initiating enzyme to begin the growing
glycogen chain. UDP released from the reaction is recycled for the reformation of UTP. Glucose
molecules are first linked by (14) glycosidic bonds until the formation of a branch393. After
roughly eight to ten glucose units have been linked via (14) glycosidic linkage, the enzyme
GS takes over the elongation process. After the glycogen molecule grows in length, the glycogen
branching enzyme will catalyze the transfer of a terminal fragment of six to ten glucose moieties
from a non-reducing end to the C-6 hydroxyl group of a glucose moiety closer to the interior of
the glycogen molecule, forming an (16) glycosidic bond397,398. With the increase of
branching points in glycogen particles, it allows more non-reducing end for hydrolysis by
glycogen phosphorylase (GP) at the same time and increases particle’s solubility, which helps
more efficient glucose storage398.
As shown in Figure 1.7, the activities of GS and GP are regulated covalently and
allosterically. The activities of GS and GP are regulated in the liver and skeletal muscle
covalently through phosphorylation and through allosteric effectors such as intracellular glucose6-phosphate (G6P) and ATP levels394,399. G6P can either be used to enter the glycolytic pathway
or converted to glucose-1-phosphate (G1P) by phosphoglucomutase397. Intracellular increases in
G6P will assist in the activation of GS and inactivation of GP, therefore, favoring glycogen
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synthesis397. During periods of elevated energy (ATP) levels, GP will remain dephosphorylated
in favor of glycogen formation400. Within skeletal muscle, when adenosine monophosphate
(AMP) levels rise due to factors such as exercise, GP is phosphorylated to promote the formation
of G1P, which can then enter the glycolytic pathway400.
Glycogenesis and glycogenolysis are regulated by catabolic and anabolic hormones. As
shown in Figure 1.8, the anabolic hormone insulin initiates its action after binding to the insulin
receptor, a process that starts an intracellular signaling cascade. The binding of insulin and its
receptor brings closer of the two insulin receptor β-subunits, which is a tyrosine kinase, and leads
to auto-phosphorylation of tyrosine residues on each other401. Subsequently, activated β-subunits
phosphorylate IRS proteins, with IRS-1 being the primary IRS in skeletal muscle, which recruits
and activates PI3K401. Activated PI3K catalyzes the conversion of the membrane-associated PIP2
and ATP into PIP3 and ADP. The increases in PIP3 leads to the recruitment of Akt, a
serine/threonine protein kinase, by interacting with its pleckstrin homology domain180. PIP3 also
recruits PDK1 to the plasma membrane which phosphorylates Akt at Thr308181,402. mTORC2
will phosphorylate Akt at Ser473 leading to its activation403. In muscle cells, the insulin
stimulation leads to an increase in amount of GLUT4 on the cell membrane, which is
translocated from intracellular storage vesicles224. Akt will inactivate glycogen synthase kinase-3
(GSK-3) by phosphorylating specific sites on the enzyme182,183. By inhibiting GSK-3, glycogen
synthase phosphatase (GSP) can activate GS by dephosphorylation181,404. The insulin signaling
cascade is also associated with the activation of protein phosphatase 1 (PP1) which will lead to
the dephosphorylation and activation of GS while inactivating GP, favoring glycogen
formation405.
Adrenaline, also referred to as epinephrine, and glucagon are catabolic hormones that
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Figure 1.7 Differential regulation of glycogen metabolism within the (A) liver and (B)
skeletal muscle. See section 4.1 for description. The hormones or metabolites that positively or
negatively affect the activities of Glycogen Synthase (GS) or Glycogen Phosphorylase (GP) are
indicated as (+) and (-), respectively. Abbreviations: G6P, Glucose 6-Phosphate; ATP, Adenosine
Triphosphate.
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stimulate an intracellular signaling cascade to promote glycogenolysis as shown in Figure 1.8.
Upon their secretion, glucagon binds to G-protein coupled receptors (GPCRs) located on the
surface of liver cells, whereas, adrenaline will bind to GPCRs on the surface of liver and muscle
cells. The binding results in a conformation change that leads to the Gs subunit of the stimulated
G protein complex to exchange guanine diphosphate (GDP) for guanine triphosphate (GTP) and
Gs is released from the heterotrimeric complex406. The activated Gs will activate adenylyl
cyclase, which, in turn, catalyzes the conversion of ATP into cyclic adenosine monophosphate
(cAMP). The increase in cAMP level will activate protein kinase A (PKA)406. PKA is a complex
that encompasses two regulatory subunits and two catalytic subunits. Once cAMP binds to the
regulatory subunits, the complex dissociates, allowing the catalytic subunits of PKA to interact
with and phosphorylate specific residues on a number of proteins407. Phosphorylase kinase and
GS are two such proteins. The phosphorylation and activation of phosphorylase kinase by PKA
will lead to the activation of GP, which results in glycogen breakdown408. PKA will also inhibit
the acetylation of GP, which decreases PP1’s ability to bind to, dephosphorylate, and inactivate
GP409. The phosphorylation of GS by PKA will result in reducing its activity, thus abrogating
glycogen synthesis410.

4.2 Recent Progresses on Factors Contributing to Skeletal Muscle Glycogen
Synthase Regulation
As insulin regulates the activities of enzymes for glycogenesis and glycogenolysis,
glycogen metabolism is altered in diabetes411. There are numerous other conditions that can arise
from or be associated with irregularities in skeletal muscle glycogen regulation412. The key
events in the synthesis of glycogen have been well characterized, and factors affecting muscle
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glycogen synthesis have drawn attention for the past decade. The focus of this review is to
identify factors that can potentially promote or abrogate the activities of GS as demonstrated by
scholarly articles published within the past 10 years.
Studies were identified by searching the PubMed electronic database from June 2015 to
February 2016. The search terms included were: skeletal muscle, glycogen, glycogen synthase.
Time constraints were set on the date of publication with January 2005-February 2016 being
eligible for inclusion. Only articles published in English were reviewed. Identified abstracts were
screened for duplicates. Abstracts identified were reviewed and full articles for abstracts meeting
criteria were retrieved and further evaluated.
Only original research studies reporting the influence of a manipulation that either
decreases or increases in GS gene expression, protein level, and/or GS activity in which
statistical significance was reported, were considered for inclusion. Both in-vivo and in-vitro
study designs were eligible for inclusion. There was no restriction on type of subjects involved in
in-vivo studies to be included in this review. There was no restriction on length of experimental
manipulation to be included in the review.
For the included studies, general study characteristics (author, year of publication, study
design, comparison groups, and testing duration), characteristics of study population (for humans
– age, gender, disease state; for animals - species, strain, disease state), experimental
manipulation (exercise, diet, compound treatment), and study outcomes (regulation of GS gene
expression, protein levels, and/or activity) were extracted from the included studies. Matthew
Goff independently extracted data from each study. Discrepancies regarding data extraction in
studies were resolved by discussion with Dr. Guoxun Chen.
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Figure 1.8 Hormonal regulation of glycogen metabolism within skeletal muscle. See section
4.1 for description. Abbreviations: cAMP, cyclic adenosine monophosphate; GPCR, g-protein
coupled receptor; GSK-3, glycogen synthase kinase-3; IR, insulin receptor; IRS, insulin receptor
substrate; PKA, protein kinase A; PP1, protein phosphatase 1; PI3K, phosphatidylinositol 3kinase.

57

All extracted studies were divided into two categories based upon the study outcomes:
promotion or abrogation of GS regulation. All identified studies had to report on at least one of
the following outcomes: promotion or abrogation of GS gene expression, protein level, and/or
activity. Studies that reported only on upstream or downstream factors of GS, but did not
specifically report significant findings on GS were excluded from this review.
4.2a Factors Promoting GS Regulation: Factors leading to the positive regulation of
GS has been of much interest within the past decade in both human (Table 1.2) and animal
(Table 1.3) model systems.
4.2a-1 Behavior and Physical Activity: As shown in Table 1.2, a study
investigating the effects of a 6-month weight loss and aerobic activity program in elderly insulinresistant men found that glucose utilization in them improved413. This is most likely due to the
reported increase in insulin-induced GS activity413. Similar results were seen in rat skeletal
muscle, in which insulin and muscle contraction have an additive effect on induction of GS
activity that correlated to decreases in GS phosphorylation414. It has been shown that exerciseinduced activation of muscle GS in obesity and T2DM is associated with dephosphorylation of
GS at sites Ser7, Ser10, Ser640, and Ser644415. These results were further confirmed in another
study using obese individuals displaying normal glucose tolerance and T2DM subjects with their
GS fractional activity (GS activity in the presence of G6P divided by total GS activity) being
increased and GS phosphorylation decreased post-exercise416. In obese individuals with T2DM
and obese non-diabetic individuals, a 10-week endurance exercise regime increased protein
content of Akt, Tre-2/USP6, BUB2, Cdc16 domain family, member 4 (TBC1D4), AMPK, GS,
and GLUT4 in their vastus lateralis muscle417. Furthermore, in 12 elderly male subjects who
completed an 8-week exercise training, GS and glycogen content were increased in their vastus
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lateralis muscle418. The dephosphorylation of GS at Ser7/10/640 was enhanced after the exercise
intervention418. Another group who investigated the effects of endurance training on glucose
metabolism in skeletal muscle found that in middle-aged males who regularly perform endurance
physical activity had significantly higher GS protein levels than that of healthy sedentary
controls419. Post-menopausal obese women with impaired glucose tolerance, who performed
either a 6-month period of caloric restriction (subtract 500 calories daily from their typical diet)
or caloric restriction + aerobic exercise (3x/week for 45min), those who performed both exercise
and caloric restriction had greater GS activity than those with only the caloric restriction420.
Collectively, these results indicate that repetitive muscular contraction may be beneficial in
obese, insulin-resistant, and elderly individuals in regards to the regulation of glucose.
To understand the mechanisms for exercise-induced increases in muscle glycogen, the
effects of exercise training on glycogen regulatory proteins in female Sprague Dawley rats
performing voluntary wheel running for 1, 4, or 7 weeks were investigated421. It was found that
rat muscle glycogen and GS did not change after 1 week of training, but increased significantly
after 4 and 7 weeks. Consistent with the GS activity, one of its primary activators, PP1 activity
was also significantly increased after 4 and 7 weeks of training421. Exercise is also associated
with a phenomenon known as glycogen overcompensation which prepares the body for bouts of
strenuous exercise. When the tibialis anterior of rabbits were stimulated for 24 hours to mimic
exercise, glycogen level increased and remained at least 50% greater than the basal level for 6
hours after stimulation422. The increase in glycogen correlated with a decrease in GP activity and
an increase in the GS activity due to its dephosphorylation422.
4.2a-2 Components in Signal Transduction Pathways: Mice with the musclespecific knockout of GLUT4 have been shown to have increased GS activity and decreased GP
59

activity following an overnight fasting (basal state), whereas contraction-induced glycogen
breakdown remains normal231. The GLUT4 knockout mice display reductions in glucose
transport that are associated with reductions in the IRS-1/Akt-PI3K signaling pathway. However,
the increases in GS during basal state in these mice are correlated to increases in the activity of
PP1 and protein levels of hexokinase II, muscle-specific regulatory subunit (RGL), and protein
targeting to glycogen (PTG) compared to wild-type mice231. Therefore, the catalytic activity of
PP1 of mice in fasting state seems to dominate over the actions of GSK-3 effects, allowing for
the increase in muscle glycogen content.
Of the AMPK heterotrimeric complex, the 3 subunit is specifically expressed in skeletal
muscle423. Transgenic mice with skeletal muscle-specific overexpressing the 3 AMPK subunit
had increased glycogen content and GS activity, and decreased GP activity423. Another group
who developed a murine model of chronic skeletal muscle AMPK activation, found a selective
increase in skeletal muscle glycogen content424. This increase in glycogen content was attributed
to the catalytic -subunit of AMPK424.
A study aimed to elucidate the role of the GSK-3 in insulin resistance of human skeletal
muscle cells from nondiabetic subjects found that the reduction of GSK-3 expression resulted
in an increase of the insulin-induced glucose uptake and GS fractional velocity. However, the
same effects were not witnessed in the basal state425.
In a study investigating insulin-stimulated GS activity in human skeletal muscle, the
increase in GS activity was positively associated with phosphorylation of Akt at Thr308 site and
total Akt expression while both proteins were shown to be negatively associated with NH2terminal GS phosphorylation426. The authors reported no association with the activation of GS
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with the phosphorylation of Akt at Ser473 site or with IRS-1-PI3K signaling426. In cultured
human skeletal muscle cells, it was shown that the knockdown of GSK-3 using siRNA had no
effect on total GS activity. However, GS phosphorylation was decreased due to the absence of
GSK-3 leading to increase in GS fractional velocity at the basal as well as insulin-stimulated
states427.
Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by
deficiency of lysosomal acid -glucosidase (GAA). Muscle lysates collected from GAA-/- mouse
strains had elevated GS, glycogenin, hexokinase, and G6P, and decreased GP activity in the
absence of AMP428. It has been shown that recombinant human GAA (rhGAA) can improve the
clinical outcomes of Pompe disease with variable results429. The co-administration of rapamycin
(mTORC1 inhibitor) with rhGAA in a GAA knockout mouse model led to reduction of glycogen
content in muscle more than rhGAA or rapamycin alone, suggesting inhibition of mTORC1
signaling can provide outcome benefits in certain GSDs429.
4.2a-3 Cytokines: Interleukin-6 (IL-6) is a cytokine that has both anti- and proinflammatory actions depending on the tissue affected430. A group who used primary human
skeletal muscle cells to investigate the role of IL-6 in muscle cell differentiation and glucose
metabolism found that chronic exposure of the cells to IL-6 (25 ng/mL) resulted in an increase in
glucose uptake and incorporation into glycogen which was associated with increased gene
expression levels of GLUT4 and GS431. The effect that IL-6 had on glucose metabolism was
attributed to the regulation of the PI3-kinase pathway since the PI3-kinase inhibitor LY294002
suppressed the aforementioned IL-6 effects431.
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Another cytokine that has an impact on glucose metabolism and insulin resistance is
adiponectin. Plasma adiponectin has been found to be significantly reduced in T2DM subjects
compared to obese and lean subjects432. In these same subjects, plasma adiponectin level was
positively associated with insulin-stimulated glucose disposal and oxidation, and stimulation of
skeletal muscle GS activity, but negatively associated with lipid oxidation after adjustment for
body fat432.
A protein known as skeletal muscle and kidney-enriched inositol phosphatase (SKIP) is a
phosphatase that converts PI(3,4,5)P3 to PI(3,4)P2, which negatively regulates the insulininduced glycogen synthesis in skeletal muscle433. It has been shown that overexpression of the
wild-type SKIP gene in differentiating mouse C2C12 skeletal muscle cells leads to decreases in
the insulin-stimulated glycogen synthesis. However, using siRNA that targeted the SKIP gene
allowed insulin to induce the phosphorylation of Akt and GSK-3β with the subsequent
dephosphorylation and activation of GS433. Obviously, the SKIP gene could be of much research
interest in discovering possible therapeutic interventions for GSDs.
The molecular actions of oxidant stress on insulin signaling and glucose transport have
been studied in isolated soleus muscle of lean Zucker rats. It was found that oxidant stress (100
mU/mL glucose oxidase) alone led to significant increases in basal glucose transport, glycogen
synthesis, and GS activity concomitant with increases in the phosphorylation of insulin receptor,
Akt at Ser473, and GSK-3 at Ser9434. However, oxidant stress had negative effects on the
insulin-stimulated glucose transport and glycogen synthesis434.
The effects of transcription factor E3 (TFE3) was examined in transgenic mice who
selectively expressed TFE3 in their skeletal muscle to better understand its effects on skeletal
muscle glucose regulation435. The glycogen content in skeletal muscle of TFE3 transgenic mice
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was more than twofold higher than that of wild-type mice, and this effect was associated with an
upregulation of the mRNA expression levels of GLUT4, hexokinase II, and GS. Interestingly,
these transgenic mice also displayed enhanced insulin sensitivity and exercise endurance
capacity435.
4.2a-4 Nutritional Factors: When mice were fed an experimental diet containing
whey protein hydrolysates (WPH), a mixture of whey amino acids (WAAs), or casein for 5
weeks, the gastrocnemius muscle glycogen level was significantly higher in the WPH group than
in the WAA or casein group436. Furthermore, the WPH group exhibited significantly higher total
GS protein level and lower phosphorylated GS level than the WAA or control group had436.
A study using rat L6 skeletal muscle cells found that linoleate (1 mM) can increase GS
protein in insoluble, but not cytosolic or membrane fractions during both the basal and insulinstimulated state437. This effect was associated with an increases of GS protein in insoluble
fractions of L6 cells, but not in cytosolic or membrane fractions437. Studies have shown that the
plant derived oleanolic acid (OA) can have antidiabetic effects438,439. One study investigated the
effects of OA in skeletal muscle of streptozotocin-induced diabetic male Sprague Dawley rats440.
Following treatment with insulin (4 IU/kg), OA (80 mg/kg), or the combination of OA + insulin
for 14 days, GS activity was significantly increased in diabetic rats receiving both OA and
insulin compared with non-diabetic and diabetic controls440.
4.2a-5 Pharmaceutical Reagents: Women with polycystic ovary syndrome
(PCOS) typically display reduced insulin-mediated glycogen synthesis in skeletal muscle441.
After a 16-week treatment with pioglitazone (30 mg/day), patients with PCOS displayed
improved insulin-stimulated glucose metabolism and GS activity. This action was attributed to
restoration of insulin’s ability to dephosphorylate GS441.
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4.2b Factors Abrogating GS Regulation: Studies performed in the past decade have
elucidated a number of factors that regulate GS negatively in both human (Table 1.4) and animal
(Table 1.5) model systems.
4.2b-1 Genetic Defects: It has been reported that a frameshift mutation in PPP1R3A, the
gene encoding RGL resulted in decreased skeletal muscle GS activity with concomitant increases
in GP activity in mice442. Humans expressing this variant have low basal and postprandial
muscle glycogen content442. Pompe disease is a rare condition characterized by abnormal
glycogen regulation leading to myopathy443,444. In an effort to find ways to decrease skeletal
muscle glycogen accumulation seen with Pompe disease, a group of researchers discovered that a
phosphorodiamidate morpholino oligonucleotide (PMO) designed to invoke exon skipping in the
transcript for muscle specific GS led to a dose-dependent decrease in GS transcripts in the
quadriceps of mice445. This resulted in the reductions of skeletal muscle GS level and activity in
the mice445.
4.2b-2 Components in Signal Transduction Pathways:
4.2b-2a AMPK Pathway: In isolated rat muscle treated for 40 minutes
with the AMPK activator 5-aminoimidazole-4-carboxamide-1--D-ribonucleoside (AICAR, 2
mM) and insulin (1 M), insulin-stimulated GS activity was decreased whereas lactate release
was markedly increased446. Similar results were seen in another study in which rat soleus muscle
was treated for 30 minutes with AICAR (2 mM) before insulin (100 nM) was added to the
samples for 45, 60, and 75 minutes447. AICAR treatment significantly suppressed insulinstimulated glycogen synthesis which correlated with the increase in the phosphorylation of
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Table 1.2 Factors Positively Impacting GS Regulation in Studies Using Human Materials
Factor/
Manipulation
Physical
Activity/Muscle
Contraction

Participants/Model
System
Obese subjects with
or without T2DM
(examined vastus
lateralis muscle)

Treatment/Manipulation;
Duration
On a cycle ergometer for 60
minutes at an intensity
(~70% VO2max) followed
with 1-3 hour of recovery
period

Findings

Proposed Mechanisms

Citation

↑ GS activity
↓ GS phosphorylation at
Ser7/10/640/644

Exercise increases substrate affinity and
decreases GSK-3 activity.

415

Lean and obese
subjects with normal
glucose tolerance,
obese subjects with
T2DM (examined
vastus lateralis
muscle)

On a cycle ergometer for 40
minutes at an intensity
(~70% VO2max)

↓ Glycogen content and GS
phosphorylation at
Ser7/641/645/649/653/657
↑ GS activity

Exercise increases GS affinity for
UDP-glucose and decreases GS
phosphorylation at
Ser7/641/645/649/653/657.

416

Obese subjects with
or without T2DM
(examined vastus
lateralis muscle)

On cycle ergometer with
four to five sessions of
20 to 35 min per week at an
average intensity
(~65% VO2max) – 10 weeks

↑ GS activity and GS
protein level

Exercise can increase TBC1D4
signaling and influence key
insulin-signaling protein levels.

417

Healthy, elderly male
subjects (examined
vastus lateralis
muscle)

On cycle ergometers twice
per week, strength and
mobility training once per
week and a 5 km walk once
a week.
– 8 weeks

↑ Glycogen content and GS
Exercise enhances glucose uptake and
protein level
decreases GS (Ser7/10/640)
↓ GS phosphorylation at Ser7/10/640
phosphorylation.

Middle-aged
sedentary or regularly
active subjects
(examined vastus
lateralis muscle)

Male subjects who performed ↑ GS protein level
endurance training
Duration – 4 to 7 days
between screening day and
experimental (biopsy) day

Mechanism not described in detail,
however, having a high VO2max may
influence insulin sensitivity in
muscle.

418

419
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Table 1.2 Continued
Factor/
Manipulation
Calorie
Restriction +
Physical Activity

GSK-3
Repression

GSK-3
Repression

Participants/Model
System
Older,
overweight/obese
insulin-resistant
subjects (examined
vastus lateralis
muscle)

Treatment/Manipulation;
Duration
Aerobic exercise training
(treadmill at 50-70% VO2max
for 20 to 50 minutes) +
weight loss (restrict intake
by 500 calories/day). - 6
months

Findings

Proposed Mechanisms

Citation

↑ GS activity (vs. baseline)

Calorie restriction + physical activity
may enhance whole-body insulin
sensitivity.

413

Healthy, overweight,
or obese
post-menopausal
women with
normal or impaired
glucose
tolerance (examined
vastus lateralis
muscle)
Human skeletal
muscle cells
isolated from
nondiabetic
subjects (biopsy
samples of the
vastus lateralis)
Human skeletal
muscle cells
obtained from
nondiabetic
subjects (biopsy
samples of the
vastus lateralis)

Women exercised at >85%
heart rate reserve for 45
minutes, 3x per week and/or
were instructed to reduce
their caloric intake by
500 kcal/day. – 6 months

↑ GS activity (in women with
Calorie restriction + physical activity
impaired glucose tolerance who may enhance whole-body insulin
exercised and restricted calories sensitivity.
vs. restricted calories alone)

420

Antisense oligo against
GSK-3were used for 6
hours to knockdown
expression in differentiating
cells. Insulin (33 nM) for 30
minutes.

↑ insulin-stimulated GS
fractional velocity

GSK-3 repression may enhance
insulin actions while overexpression
can lead to insulin signaling
impairment.

425

Transfection of cultured
Muscle cells with siRNA
against GSK-3 for 4 hours.
Insulin (33 nM) for 30
minutes.

↑ basal and insulin-stimulated
GS fractional velocity

GSK-3 expression can affect GS
activity in both basal and
insulin-stimulated state, with GSK-3
repression allowing for activation of
GS.

427
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Table 1.2 Continued
Factor/
Manipulation
IL-6

Adiponectin

Pioglitazone

Participants/Model
System
Human skeletal
muscle cells
obtained from
nondiabetic
subjects (biopsy
samples of
rectus abdominus)
Lean subjects, obese
subjects with or
without T2DM
(examined vastus
lateralis muscle)
Obese women with
PCOS
(examined vastus
lateralis muscle)

Treatment/Manipulation;
Duration
IL-6 (5, 25, or 100 ng/ml).
treatment for 20 minutes, 3
hours, or 8 days

Findings

Proposed Mechanisms

Citation

↑ Glycogen synthesis
(IL-6 ≥ 5 ng/mL)
↑ GS mRNA expression
(IL-6 25 ng/mL, 8 days)

IL-6 increases glycogen synthesis via a
PI3-kinase-dependent mechanism.

431

Plasma adiponectin may improve the
ability to switch from lipid to glucose
oxidation, and enhance muscle insulin
sensitivity.

432

Euglycemic-hyperinsulinemic ↑ insulin-stimulated GS
clamp performed for 4 hours fractional velocity (positive
association with plasma
adiponectin levels)
Euglycemichyperinsulinemic clamp
performed for 3 hours.
Treatment with either
pioglitazone (30 mg) or
placebo once daily
– 16 weeks

↑ insulin -stimulated GS
activity and dephosphorylation
of GS at Ser7/640/644

Pioglitazone enhances insulin sensitivity 441
and GS activity by promoting
insulin-mediated dephosphorylation of
GS at Ser7/640/644.

Abbreviations: GS, glycogen synthase; GSK, glycogen synthase kinase; IL-6, interleukin-6; mRNA, messenger ribonucleic acid; PCOS,
polycystic ovary syndrome; T2DM, type 2 diabetes mellitus; TBC1D4, Tre-2/USP6, BUB2, Cdc16 domain family, member 4; UDP,
uridine diphosphate; ↑ = significant increases due to factor/manipulation; ↓ = significant decreases due to factor/manipulation.
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Table 1.3 Factors Positively Impacting GS Regulation in Animal Studies
Factor/
Manipulation
Physical Activity/
Muscle
Contraction

GLUT4
Repression

Participants/Model
System
Male Wistar rats
(examined
epitrochlearis
muscle)

Treatment/Manipulation;
Duration
Muscles were kept rested
or contracted electrically
while incubating with or
without insulin (10
mU/mL) for 30 minutes

Findings

Proposed Mechanisms

Citation

↑ insulin-stimulated GS
activity
↓ GS phosphorylation at
Ser645/649/653/657

Muscle contraction can increase
AMPK phosphorylation at Thr172
and decrease GS phosphorylation at
Ser645/649/653/657.

414

Female Sprague
Dawley rats
(examined triceps
and epitrochlearis
muscles)

Two groups- rats in the
untrained group were
housed individually in
plastic cages and rats in the
trained group were housed
in wheel cages. Trained
either for 1 week, 4 weeks,
or 7 weeks.

↑ Glycogen content after 4
and 7 weeks (triceps)
↑ GS activity after 4 and
7 weeks (triceps)

Physical activity may enhance insulin
sensitivity and PP1 activity.

421

Female white New
Zealand rabbits
(examined tibialis
anterior muscle)

Electrostimulations to
mimic contraction were
applied for 1 hour or 24
hours. After stimulation,
animals were allowed to
recover for 0, 1, 6, 12, or
24 hours.

↑ Glycogen content during
a 6-hour recovery phase
after a 24-hour stimulation
↑ GS activity
↓ GP activity and GS
(Ser640) phosphorylation

Prolonged muscle contraction can
increase GS activity by decreasing GS
phosphorylation at Ser640 while
decreasing GP activity.

422

Wild-type and
muscle-specific
GLUT4-knockout
mice. Parent strains
- 129SV and
C57Bl/6J mice
(examined
soleus,
gastrocnemius, and
tibialis anterior
muscles)

Transgenic mice with
muscle-specific GLUT4
knockout. Electrical
stimulation to mimic
contraction. Mice were
studied at 4 to 12 months
of age.

↑ Glycogen content
↑ GS activity (tibialis
anterior and gastrocnemius)
↓ GS phosphorylation at
Ser641 (gastrocnemius)
↓ GP activity (tibialis
anterior and gastrocnemius)

Decreased muscle glucose transport
was associated with decreasing GS
phosphorylation at Ser641 and GP
activity.

231
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Table 1.3 Continued
Factor/
Manipulation
AMPK
Overexpression

Participants/Model
System
Wild-type and
transgenic mice
with AMPK3 or
AMPK3 R225Q
mutant
overexpressions
Parent strain – FVB
mice
(examined EDL,
soleus,
gastrocnemius, and
tibialis anterior
muscles)

Treatment/Manipulation; Findings
Duration
Mice were compared at 8 to ↑ Glycogen content (both
10 weeks of age.
transgenic models; EDL,
gastrocnemius,
and tibialis anterior)
↑ GS activity (both
transgenic models in
presence of G6P;
gastrocnemius)
↓ GP activity (wild-type
AMPK3 mice;
gastrocnemius)

Proposed Mechanisms

Citation

Mechanism not described in detail,
however, postulated that AMPK could
alter the function of the AMPK
subunit’s glycogen-binding domain in
stimulating the activity of the glycogen
debranching enzyme.

423

Wild-type and
AMPK
overexpressing mice
(examined EDL,
soleus,
quadriceps,
gastrocnemius, and
tibialis anterior
muscles)

Mice were compared at 9 to ↑ Glycogen content
12 weeks of age.
(quadriceps, gastrocnemius,
and tibialis anterior)
↑ GS activity
(gastrocnemius)

With AMPK overexpression, there
was reduction of G6P content which
may result from increased G6P
utilization and glycogen synthesis.

424

SKIP Repression

Mouse C2C12
muscle cells

↑ insulin-stimulated
glycogen synthesis and
dephosphorylation of GS
at Ser641

SKIP negatively regulates the
insulin-signaling pathway.
Repression of SKIP allows for
insulin-stimulated glycogen synthesis.

433

Oxidant Stress

Female lean Zucker
rats at 9–10 weeks
of age (examined
soleus muscle)

Transfection of cultured
C2C12 cells with siRNA
against SKIP gene for 48
hours. Insulin (10 and 100
nM) for 30 minutes.
Isolated muscle incubated
for 2 hours in the absence
or presence of 100 mU/mL
glucose oxidase without or
with 5 mU/ml insulin

↑ basal glycogen synthesis
and GS activity

Oxidant stress increased
phosphorylation of insulin receptor,
Akt at Ser473, and GSK-3 at Ser9.

434

69

Table 1.3 Continued
Factor/
Manipulation
Whey Protein
Hydrolysates

Participants/Model
System
Male ddY mice
(examined
gastrocnemius
muscle)

Treatment/Manipulation;
Duration
Mice fed 1 of 3 test diets
for 5 weeks using AIN-93
protocol: control diet,
control + 39.550 g/kg of
whey amino acids, control
+ 50.00 g/kg of whey
protein hydrolysates.

Findings

Proposed Mechanisms

Citation

↑ Glycogen content (whey
protein hydrolysates > whey
amino acids > control)
↑ GS mRNA expression and
GS protein level (whey
protein hydrolysates)
↓ GS phosphorylation at
Ser641 (whey protein
hydrolysates)

Consumption of whey protein decreases
GS phosphorylation at Ser641 and
could decrease 6-phosphofructokinase
(regulatory glycolytic enzyme) activity
to increase GS and glycogen content.

436

Linoleate

Rat L6 skeletal
muscle cells

↑ basal and
insulin -stimulated GS
protein level (insoluble
fraction)

GS was sequestered from activation by
insulin treatment due to lipid treatment.

437

OA

Control and
STZ-induced
diabetic male
Sprague-Dawley rats
(examined
hindquarter muscle)

Differentiating myotubes
pre-treated for 16 hours
with 1 mM linoleate in the
absence or presence of
insulin (100 nM) for 1 hour.
Rats were treated with
insulin (4 IU/kg), OA (80
mg/kg), or the combination
of OA + insulin in acute
(60 minutes) and
sub-chronic (14 days)
studies.

↑ GS activity after
insulin + OA in diabetic
group

OA enhances insulin signaling pathway
including phosphorylation of Akt at
Ser473

440

Abbreviations: AMPK, 5’-AMP-activated protein kinase; EDL, extensor digitorum longus; GP, glycogen phosphorylase; GS,
glycogen synthase; G6P, Glucose-6-phosphate; mRNA, messenger ribonucleic acid; OA, oleanolic acid; PP1, protein phosphatase 1;
SKIP, skeletal muscle and kidney-enriched inositol phosphatase; STZ, streptozotocin; TFE3, transcription factor E3; ↑ = significant
increases due to factor/manipulation; ↓ = significant decreases due to factor/manipulation.
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GS447. The AICAR treatment in this study also led to a significant increase in lactate production
in rat soleus muscles447.
Another study investigated the mechanism by which AMPK activation regulates muscle
glycogen levels used AICAR, insulin, and adrenaline treatments on the extensor digitorum
longus (EDL) muscle of C57BL/6 mice448. After the treatment for 40 minutes, AICAR (2 mM)
resulted in a modest but significant decrease in GS activity while no change in GS or GP
phosphorylation was detected. However, treatment with adrenaline (10 M) led to a strong
increase in phosphorylation of GS at Ser8 and Ser11, and in phosphorylation of GP at Ser15
which correlated with a decrease in GS activity448. This same study measured the effect of
AICAR on GS activity in EDL muscle isolated from transgenic mice with mutant AMPK2
(kinase dead, K45R mutation) or wild-type mice. In unstimulated muscle, the GS activity in
AMPK2 mutant mice was significantly higher than wild-type littermates. This was correlated
with a decrease in phosphorylation of GS at sites Ser8 and Ser641. Furthermore, AICAR
treatment failed to reduce GS activity in AMPK2 mutant mice whereas wild-type mice had a
significant decrease448. It has also been shown in primary human muscle cell cultures that a 5hour insulin treatment (300 nM) led to impairment in GS dephosphorylation at Ser640/644 as
well as GS fractional activity449. However, treatment with AICAR (2 mM) restored the glycogen
synthesis and GS activation in the 5-hour insulin-treated cells449.
4.2b-2b cAMP Pathway: In a study that investigated the effect of
adrenaline on insulin-mediated regulation of glucose metabolism in human tibialis anterior
muscle found that in the presence of adrenaline (infusion rate of 0.05 g/kg/min for 240
minutes), insulin could not activate GS or dephosphorylate GS at Ser641450. The day after
adrenaline infusion, an increase in plasma lactate concentration was associated with a decrease in
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muscle glycogen content450. In the soleus muscle of male Wistar rats, it was shown that the
insulin-stimulated GSK-3 Ser9 phosphorylation was accompanied by decreases in GS
phosphorylation as expected451. However, adrenaline (10 M)-stimulated GSK-3 Ser9
phosphorylation was associated with an increase in GS phosphorylation451.
The major skeletal muscle glycogen targeting subunit (GM) of PP1 has also been
investigated in regards to control by various hormones452. GM−/− mice had increased
phosphorylation of GP at Ser14 and GS at Ser7, Ser640, and Ser644 along with a decrease in
insulin-stimulated GS activity compared to GM+/+ mice452. This indicates that the GM subunit of
PP1 complex is the major phosphatase complex that leads to the dephosphorylation of these sites
in-vivo. Adrenaline (0.5 mg/g) treatment for only 15 minutes led to a significant increase in GP
activity while decreasing GS activity in control mice452. However, the same treatment conditions
yielded no significant changes in GP or GS activity in GM−/− mice, suggesting that the GM
subunit of PP1 is required for adrenaline’s actions452.
4.2b-2c Akt Pathway: Individuals with T2DM display lower GS activity
and increased GS phosphorylation during the recovery period post-exercise, which implies these
individuals have impaired response to exercise415. Compared to non-diabetic controls, patients
with T2DM undergoing an euglycemic-hyperinsulinemic clamp displayed an impairment of the
insulin-stimulated glucose disposal and glucose oxidation during euglycemia453. This effect was
associated with impairment of insulin-stimulated GS activity and decrease of GS
dephosphorylation with reduction of Akt phosphorylation at Thr308 and Ser473. During
hyperglycemia, the insulin-stimulated glucose disposal and oxidation normalized, however, the
dephosphorylation of GS as well as phosphorylation of Akt at Thr308 and Ser473 remained
impaired453. Women with PCOS have the risk of developing insulin resistance in skeletal muscle.
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Compared to women without PCOS, women with PCOS display the reduction of insulinstimulated GS activity and dephosphorylation of GS441.
4.2b-3 Aging: Aging also seems to play a role in altering GS level and glycogen
accumulation. It has been shown that the older rats (24 months) displayed reduced GS and GP
activity, lower muscle GS protein levels, and increased phosphorylation of GS in soleus muscle
than young mice (6 months) 454. Along with aging, extended bed rest occurs. One group who
investigated the mechanisms behind physical inactivity–induced insulin resistance in the skeletal
muscle (vastus lateralis) of 12 healthy male subjects after 7 days of bed rest found that the ability
of insulin to activate GS was reduced455. They found that phosphorylation of GS at Ser7 and
Ser10 increased following bed rest455. Interestingly, in rat soleus muscle during the basal state,
oxidant stress (100 mU/mL glucose oxidase) increased GS activity. However, GSK-3 remained
active in the presence of both oxidant stress and insulin434. The presence of oxidant stress also
significantly inhibits the insulin-induced glucose transport and glycogen synthesis434.
4.2b-4 Hormones: In human muscle cells treated with or without 25 mM glucose
for 24 hours in combination with angiotensin (1 M), glucose deprivation plus angiotensin
increased levels of ERK½ phosphorylation and GSK-3β (Ser9) phosphorylation456. However,
only those treated with high glucose and angiotensin displayed an increase in GS
phosphorylation at Ser640/641 which correlated with a decrease in GS activity456.
Glucocorticoids such as dexamethasone have been known to have an impact on glucose
and fat metabolism, which could lead to alterations such as insulin resistance and
dyslipidemia457,458. In the red and white gastrocnemius muscle of rats, the administration of
dexamethasone (1 mg/rat/day) increased glycogen concentration while reducing GS activity in
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both muscle fiber types459. Rat treated with dexamethasone and sucrose had decreased muscle
glycogen content compared with the dexamethasone alone group. However, this effect was also
associated with a decrease in GS activity similar to that seen in animals treated with the
dexamethasone alone 459.
4.2c Perspectives: Although the glycogen synthesis pathway has been studied
extensively, there seems to be more to be investigated. For example, GSK-3 is known as a major
regulator of GS activation through phosphorylation. Using GSK-3 knock-in mice with GSK-3
and - genes being replaced with mutant forms (GSK-3/S21A/S21A/S9A/S9A), it has been shown
that the insulin-mediated inhibition of GSK-3 is not a rate-limiting step in skeletal muscle
glycogen synthesis460. Even though insulin failed to promote the activation of GS in these GSK3/ mutant mice, the glycogen content within the skeletal muscle of these mice were similar to
their wild-type controls460.
One determinant of GS activity is the existing amount of glycogen within the muscle as
well as muscle fiber type461,462. As demonstrated in rodents, a low glycogen content was
associated with decrease in GS phosphorylation and a high glycogen content was associated with
decrease in GS activation463-465. One group has shown that epinephrine stimulates glycogenolysis
in Wistar rat skeletal muscles with normal and high, but not low, glycogen content. The
glycogenolysis actually being associated with decreases in GS phosphorylation and increases in
GS activity466. This demonstrates an association between GS activation and glycogen content in
this condition.
Physical activity has also been shown to affect glycogen content in rodents with the
phosphorylation of GS being reduced 30 minutes’ post-exercise, but returning to baseline at 90
minutes’ post-exercise467. As described previously, physical activity can result in the
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Table 1.4 Factors Negatively Impacting GS Regulation in Studies Using Human Materials
Factor/
Manipulation
Pro-longed Insulin
Treatment

Participants/Model
System
Human skeletal muscle
cells

Treatment/Manipulation;
Duration
Insulin (300 nM) – 5 hours

Findings

Proposed Mechanisms

Citation

↑ Glycogen content
↓ GS activity and
glycogen synthesis rate

449

Adrenaline

Male and female healthy
subjects (examined tibialis
anterior muscle)

↓ insulin-stimulated
glycogen synthesis, GS
activity, and
dephosphorylation of GS
at Ser641

T2DM

Obese male subjects with or
without T2DM (examined
vastus lateralis muscle)

Adrenaline (0.05
g/kg/minute) or saline
infusion for 240 minutes.
Euglycaemichyperinsulinemic clamp for
120-240 minutes
Exercise on a cycle ergometer
for 60 minutes at an intensity
(~70% VO2max) followed with
1-3 hour of recovery period

Pro-longed insulin treatment
could result in a negative
feedback mechanism on insulin
signaling pathway
Adrenaline blocks insulinmediated GS activation most
likely due to preventing
dephosphorylation of GS at
Ser641.

↓ GS activity
↑ GS P-Ser7/10 during
recovery period
(diabetic vs. obese)

Muscle GS phosphorylation
regulation in T2DM is impaired
in response to recovery from
exercise.

415

Following overnight fast, lean
and obese controls underwent
a euglycemic-hyperinsulinemic
clamp (4-hour) with tracer
glucose and combined with
indirect calorimetry; diabetic
patients were clamped twice
with either a euglycemic or an
isoglycemic- hyperinsulinemic
clamp (fixing glucose
concentrations to each
individual's spontaneous
fasting glucose concentration)
separated by 4–6 weeks
Euglycemic-hyperinsulinemic
clamp performed for 3 hours.

↓ insulin-stimulated GS
activity during
euglycemia
↓ insulin-stimulated
dephosphorylation of
GS at Ser7/10 during
euglycemia and
hyperglycemia

T2DM impairs insulin-stimulated 453
glycogen synthesis involving
Akt phosphorylation at Ser473
and Thr308, and
dephosphorylation of GS at
Ser7/10.

↓ insulin-stimulated GS
activity and
dephosphorylation of GS
at Ser7/10 (PCOS vs.
control)

PCOS decreased the
insulin-mediated
dephosphorylation of GS at
Ser7/10.

Obese subjects with or
without T2DM, and lean
non-diabetic subjects
(examined vastus lateralis
muscle)

PCOS

Obese women with or
without PCOS
(examined vastus
lateralis muscle)

450

441

75

Table 1.4 Continued
Factor/
Manipulation
Physical
Inactivity
High glucose +
Angiotensin

Participants/Model
System
Healthy male subjects
(examined vastus lateralis
muscle)
Human skeletal muscle
Cells

Treatment/Manipulation;
Duration
Bed rest (all transport of
subjects took place in
wheelchairs) – 7 days
Muscle cells were incubated
with or without 25 mM glucose
for 24 hours.
Angiotensin treatment (1 M)–
20 minutes

Findings

Proposed Mechanisms

Citation

↓ GS activity
↑ GS phosphorylation at
Ser7/10
↓ GS activity
↑ GS phosphorylation at
Ser640/641

Physical inactivity/bed rest impairs 455
muscle insulin signaling and
dephosphorylation of GS at Ser7/10.
Angiotensin reduced ERK½
456
phosphorylation at Thr202/Tyr204
and impaired dephosphorylation of
GS at Ser640/641.

Abbreviations: BMI, body mass index; ERK, extracellular regulated signal kinase; GS, glycogen synthase; GSK, glycogen synthase
kinase; T2DM, type 2 diabetes mellitus; ↑ = significant increases due to factor/manipulation; ↓ = significant decreases due to
factor/manipulation.
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Table 1.5 Factors Negatively Impacting GS Regulation in Animal Studies
Factor/
Manipulation
PPP1R3A
Mutation

GS-PMO

AICAR

Participants/Model
System
Wild-type and mutant
(premature stop
mutation in PPP1R3A)
mice Parent strain –
Chimeric mice crossbed with C57BL/6J
mice (examined
muscle not specified)
C57BL/6 + GAA-/mice
(examined quadriceps
muscle)

Male Sprague-Dawley
Rats (examined
epitrochlearis muscles)
Male Albino-Wistar
rats (examined soleus
and epitrochlearis
muscles)

Treatment/Manipulation;
Duration
Tissues collected during ad
libitum. Age used not
described.

Findings

Proposed Mechanisms

Citation

↓ Glycogen content and
GS activity
↑ GP activity

The reduction in GS activity was most
likely due to the inability of PP1 to
colocalize with GS and to bind to
glycogen.

442

GS-PMO administered at 15 or
30 mg/kg bodyweight by tail
vein injection once every 2
weeks for a total of 12 weeks,
muscle isolated 2 weeks after
stopping treatment
AICAR (2 mM) and insulin
(1 M)– 40 minutes

↓ Glycogen content, GS
activity, GS mRNA
expression, and GS protein
level

GS-PMO forces exon skipping in
the processing of Gys1 mRNA,
leading to a premature termination
codon.

445

↓ basal and insulinstimulated GS activity

AICAR treatment favors an increase in
glycolytic flux instead of glycogen
synthesis.

446

AICAR (2 mM) and insulin
(100 nM) – 45, 60, and 75
minutes (preincubated with
AICAR 30 minutes before
insulin added)

↓ insulin-stimulated
glycogen synthesis and
glycogen content (soleus
muscle)
↑ GS phosphorylation at
Ser641 (45 minutes,
soleus muscle)

AICAR treatment led to a timedependent reduction in Akt
phosphorylation at Thr308 and
activation of GSK-3/.

447
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Table 1.5 Continued
Factor/
Manipulation
Adrenaline

Age

Oxidant Stress

Participants/Model
System
C57BL/6 J mice
(examined EDL muscle)

Treatment/Manipulation;
Duration
Adrenaline (10 M) – 40
minutes

Findings

Proposed Mechanisms

Citation

↓ GS activity
↑ GS phosphorylation at
Ser8/11, GP activity, and
GP phosphorylation at
Ser15

Adrenaline impairs dephosphorylation
of GS at Ser8/11 while promoting GP
phosphorylation at Ser15.

448

Male Wistar rats
(examined soleus
muscle)

Adrenaline (10 M)– 30
minutes

↑ GS (Ser645/649/653/657) Adrenaline impairs dephosphorylation
phosphorylation
of GS at Ser645/649/653/657 most
likely through PKA signaling pathway,
which may also lead to decreases in
PP1 activity.

451

Wild-type and null GM
allele (deletion
encompassing 1st exon
encoding PP1) mice
Parent strain:
C57BL/6 mice
(examined hind limb
muscles)
Male Fischer 344 rats
(examined soleus and
tibialis anterior
muscles)
Female lean Zucker rats
(examined soleus
muscle)

Adrenaline (0.5 mg/g) for 15
minutes, insulin (150 mU/g)
for 20 minutes, or saline
intraperitoneal injections

↓ GS activity
↑ GP activity

Adrenaline’s effects may be attributed
to decrease in PP1 activity and/or
increase in phosphorylase kinase
activity.

452

Old (24 months) rats compared
to young (6 months) rats
maintained ad libitum or
calorie restricted
Isolated muscle from 9-10
week old rats incubated for 2
hours in the absence or
presence of 100 mU/mL
glucose oxidase, without or
with 5 mU/ml insulin.

↓ GS and GP activity and
GS protein levels (soleus)
↑ GS phosphorylation at
Ser640 (soleus)
↓ insulin-stimulated GS
activity and glycogen
synthesis

Aging negatively affects GS and GP
activity in soleus muscle, which may be
associated with impairment of
dephosphorylation of GS at Ser640.
Oxidant stress was found to be
associated with decreased
phosphorylation of insulin receptor,
Akt at Ser473, and GSK-3 at Ser9.

454

434
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Table 1.5 Continued
Factor/
Manipulation
GM Null Allele

Participants/Model
System
Wild-type and null GM
allele (deletion
encompassing 1st exon
encoding PP1) mice
Parent strain –
C57BL/6 mice
(examined hind limb
muscles)
Dexamethasone Male Sprague–Dawley
rats (examined
gastrocnemius muscle)

Treatment/Manipulation;
Duration
Adrenaline (0.5 mg/g) for 15
minutes, insulin (150 mU/g) for
20 minutes, or saline via
intraperitoneal injection

Findings

Proposed Mechanisms

Citation

↓ insulin-stimulated GS
activity (null GM mice)
↑ GS phosphorylation at
Ser7/640/644 and GP
phosphorylation at Ser14
(null GM mice)

Decreased PP1 activity allows for GS
and GP phosphorylation which may
also be attributed to increases in
phosphorylase kinase activity.

452

4 groups: saline, 10% sucrose
drinking solution,
dexamethasone (1 mg), and
dexamethasone + sucrose –
7 days.

↑ Glycogen content
(dexamethasone alone)
↓ GS activity
(dexamethasone and
dexamethasone + sucrose)

Dexamethasone may regulate GSK-3
and/or CAMKII activity.

459

Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide-1--D-ribonucleoside; AMPK, 5’-AMP-activated protein kinase; CAMKII,
calmodulin kinase II; EDL, extensor digitorum longus; GP, glycogen phosphorylase; GS, glycogen synthase; mRNA, messenger
ribonucleic acid; PKA, protein kinase A; PMO, phosphorodiamidate morpholino oligonucleotide; PP1, protein phosphatase 1; ↑ =
significant increases due to factor/manipulation; ↓ = significant decreases due to factor/manipulation.
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enhancement of GS activity. On the other hand, it is also well known that during vigorous
physical activity, endurance or strength training, the skeletal muscle relies a great deal on the
breakdown of glycogen, as well as fat, to provide adequate energy468. Besides depletion of
muscle glycogen stores, skeletal muscle protein degradation will also occur during such physical
activity469. The depletion of glycogen will result in the increase of proteolysis to get amino acids
and -oxidation of fatty acid from muscle fat, and reduction of pyruvate oxidation470. Therefore,
nutritional strategies should be implemented during the post-recovery period to maximize
skeletal muscle glycogen and protein synthesis. Besides for the importance of replenishing
endogenous substrate stores, optimal nutritional intake can assist in facilitating the repair of
damaged muscle471. For athletes, nutrition can play a key role in determining the adequate period
of time between competitions for complete muscle recovery. Similarly, pre-physical activity
nutrition can have a major impact on metabolism and activity during performance472. Further
research is needed to optimize pre- and post-physical activity nutritional strategies involving the
investigation of the regulation of key enzymes in glycogenesis such as GS, GP, and GSK-3.
From a pharmaceutical standpoint, having a greater understanding of the regulation of
glycogen synthesis could be beneficial to a number of individuals suffering from a variety of
diseases. With the millions of insulin-resistant men and women, the development of glycogen
regulating enzyme activators/inhibitors could help alleviate the formation of other conditions
such as myopathy. GP inhibitors, for instance, have been receiving attention for being possible
therapeutic agents for diabetes and cancer473. The regulation of GSK-3 is also a topic of interest
among many due to GSK-3 regulation being connected to a number of conditions such
Alzheimer’s disease, cancer, diabetes, and general muscle wasting474,475. Therefore, GSK-3
inhibition may provide therapeutic effects to a broad range of conditions.
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5. Conclusion
There is much still being discovered regarding glucose metabolism in skeletal muscle.
VA as well as insulin play key roles in the regulation of macronutrient metabolism in humans.
With the majority of the physiological functions of VA being exerted through the actions of RA,
having a greater understanding of how RA works within different organs and tissues can lead to
possible therapeutic advancements. With skeletal muscle accounting for the largest site of
glucose usage we believe that further investigations into how a fat-soluble vitamin such as VA
and its derivative (RA) can affect this process. This requires research in: (1) the interactions
between RA and insulin in regulating skeletal muscle glucose usage; (2) the role of VA (RA) in
macronutrient metabolism during periods of metabolic stress (e.g. hyperinsulinemia) due to
conditions such as obesity and T2DM. By having a greater understanding of how a natural
compound such as VA can influence macronutrient metabolism, especially during disease states,
possible therapeutic strategies can be developed to combat the development and reverse the
detrimental outcomes of such metabolic diseases.
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CHAPTER II. RA AND INSULIN PROMOTE
GLUCOSE USAGE IN L6 SKELETAL MUSCLE
CELLS
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1. Introduction
The skeletal muscle as a whole is the largest organ of the body by mass, for this reason it
has the biggest capacity for glucose utilization476. The regulation of skeletal muscle glucose
metabolism can affect whole body glucose homeostasis significantly. Skeletal muscle
metabolism can be regulated by a number of factors including hormonal and nutritional stimuli
as well as exercise and microvasculature structure477-479. Metabolic disorders such as obesity and
type 2 diabetes mellitus (T2DM) are often associated with disturbances in the regulation of
skeletal muscle glucose metabolism480. Even though the pathogenesis of metabolic syndrome,
obesity, and T2DM have not been fully elucidated, insulin resistance has been established as a
key risk factor480. In healthy individuals, insulin is released postprandially and will promote
glucose usage in hepatic, adipose, and skeletal muscle cells for either storage or further
metabolism170. Therefore, any dysregulation in skeletal muscle’s response to insulin’s actions
can negatively impact whole body glucose metabolism481. Insulin sensitivity has been shown to
be impaired in skeletal muscle during a state of obesity due to factors such as an increase in proinflammatory cytokines as well reactive oxygen species241. Impairment in glucose uptake and
glycogen synthesis in skeletal muscle due to insulin resistance has also been shown to be
associated with reduced intracellular glucose absorption due to impairment of insulin-induced
GLUT4 translocation245.
Vitamin A (VA, also referred to as retinol, ROL) is an essential lipophilic micronutrient
that is implicated in the regulation of glucose, protein, and lipid metabolism482,483. There are two
stepwise cytosolic enzymatic reactions that convert ROL into retinoic acid (RA, all-trans RA or
9-cis RA). RA can then enter the nucleus and modulates gene expression through the activation
of retinoid acid receptors (RAR) and retinoid-X-receptors (RXR)50,484,485. RAR and RXR share a
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common ligand, 9-cis-RA, whereas all-trans-RA only binds to RAR61. While 9-cis-RA binds to
both RAR and RXR, this ligand seems to be only produced endogenously and there is no proof
that all-trans-RA goes through isomerization to form 9-cis-RA62. The majority of the literature
investigating the effects of RA on skeletal muscle focus on its ability to be an inducer of muscle
cell differentiation by increasing the expression of key myogenic regulatory factors as well as
inhibitor of anti-myogenic factors98,100. It has been shown that RA can promote insulinstimulated glucose uptake and increase GLUT4 mRNA levels in L6 skeletal muscle cells376.
However, limited research has been performed on the effects of VA and its metabolites on
glucose metabolism in skeletal muscle.
The aim of this study was to investigate the effects of ROL, retinal (RAL) and RA on L6
skeletal muscle cell glucose utilization. Effects of RA or insulin on L6 skeletal muscle cells have
been investigated previously 374,376. We demonstrate that RA and insulin, cooperatively promote
glucose utilization in L6 cells. Furthermore, we demonstrate that the RA-mediated effect is
mimicked by an RAR agonist, suggesting that RA promotes glucose utilization within skeletal
muscle by activation of the RAR signaling pathway, but not through induction of GLUT4
expression.

2. Materials & Methods
2.1 Reagents
Dulbecco's Modified Eagle Medium (DMEM) and penicillin/streptomycin were
purchased from Mediatech (Manassas, VA, U.S.A.). Fetal bovine serum (FBS) was purchased
from Life Technologies (Grand Island, NY, U.S.A.). Horse serum (HS) was purchased from
Hyclone Laboratories (Logan, UT, U.S.A.). For glucose measurement, Glucose Liquicolor kit
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was purchased from StanBio Laboratory (Boerne, TX, U.S.A.). T0101317 (T1317) was from JStar Research (South Plainfield, NJ, U.S.A.). LG268 was synthesized in the core facility at the
University of Texas Southwestern Medical Center at Dallas. All-trans retinoic acid, all-trans
retinol, all-trans retinal, TTNPB, and insulin were purchased from Sigma (St. Louis, MO,
U.S.A.). BCA protein assay kit and ECL Western Blotting Substrate were purchased from Pierce
(Rockford, IL, U.S.A.). Immobilon®-PSQ PVDF membrane was purchased from EMD
Millipore (Billerica, MA, U.S.A.). Polyvinylpyrrolidone (PVP) was purchased from Amresco
(Solon, OH, U.S.A.). For immunoblotting, GLUT1 (#1340) and GLUT4 (#1346) were purchased
from Chemicon Industries (Temecula, CA, U.S.A.). -Actin (#4970), and goat anti-rabbit IgG
(#7074) were purchased from Cell Signaling Technology (Danvers, MA, U.S.A.).

2.2 L6 rat skeletal muscle cell culture and differentiation
Rat L6 cells were incubated in 60 mm dishes at 37°C and 5% CO2. For subculture, L6
cells were maintained in DMEM with 4.5 g/L (25 mM) glucose supplemented with 10% FBS +
1% penicillin/streptomycin. When cells reached ~100% confluence, medium was changed to
DMEM containing 25 mM glucose with 2% HS + 1% penicillin/streptomycin to induce
differentiation. In the glucose dosage experiment, when cells reached ~100% confluence,
medium was changed to DMEM containing 5 mM, 15 mM, or 25 mM glucose with 2% HS + 1%
penicillin/streptomycin.

2.3 Glucose & pH Measurements
Once L6 cells reached ~100% confluence, DMEM medium with 10% FBS was switched
to DMEM + 2% HS containing the indicated reagents as described in figure legends. Following
the initial day of treatment (day 0), the medium from each 60 mm dish was collected and
replaced with a fresh medium containing the same reagents every 2 days. The collected medium
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was used for glucose and pH measurements. The pH measurement was conducted immediately
using a pH meter (Oakton Instruments, Vernon Hills, IL, U.S.A.) after the medium was collected
into 15 mL plastic tubes, and sealed with rubber corks. For glucose measurements, 500 L of
collected medium was distributed into 1.5 mL Eppendorf tubes. The samples were centrifuged at
12,000 x g for 5 minutes to remove cell debris. The medium was diluted 10-fold with deionized
H20 and the glucose amount in the medium was measured using the StanBio Glucose Liquicolor
kit. Briefly, in separate 1.5 mL Eppendorf tubes, 500 L of glucose reagent was added to each
tube and incubated for 5 minutes at 37°C. Following the incubation period, one glucose reagent
containing tube received 5 L deionized H20 to serve as blank control, one tube received 5 L of
glucose standard, and the remaining tubes received 5 L of diluted medium. The samples were
incubated for 5 minutes at 37°C and then loaded in a clear 96-well plate for analysis on
Glomax® Multi+Detection System (Promega, Madison, WI, U.S.A.) at a wavelength of 500 nm.
Values were derived by comparing the absorbance of the unknown (u) with that of the standard
(s): Glucose (mg/dL) = ((Au x 10)/As) x 100). For the pH and glucose measurements, DMEM
containing 2% HS alone served as control for comparison to respective treatment conditions. The
pH level of the control group was arbitrarily set as 100% with data expressed as percentage
change of pH. The glucose level of the control group was arbitrarily set as 100% with data
expressed as percentage of relative glucose levels.

2.4 Protein Isolation and Immunoblotting
Whole cell lysate was prepared by washing L6 cells once with ice-cold PBS and lysing
the cells in 400 μL ice cold whole-cell lysis buffer and subsequently scraped into chilled 1.5 mL
centrifugation tubes. The lysates were vortexed vigorously and placed on ice for at least 20
minutes. Lysates were then centrifuged at 12,000 x g for 15 minutes at 4°C and supernatant
86

collected into clean 1.5 mL Eppendorf tubes and stored at -80°C. Protein was quantified by
Pierce BCA protein assay kit using manufacturer recommendations and analyzed using
Glomax® Multi+Detection System. Total cell protein (40 g) was then separated on an 8% SDSPAGE gel and transferred to Immobilon®-PSQ PVDF membrane39. Membranes were blocked
using 1% PVP in 1x TBST for 1 hour at room temperature and then probed with specific
antibodies diluted in 1% PVP in 1x TBST overnight at 4°C486. After that, the membranes were
washed three times for 5 minutes each with 1x TBST and then incubated 1-2 hours with goat
anti-rabbit IgG conjugated with horseradish peroxidase (1/2000 dilution in 1% PVP in 1x
TBST). Following secondary incubation, three more 5 minute washes with 1x TBST were
carried out followed by visual detection using ECL Western Blotting Substrate on ChemiDoc
Software System (BIO-RAD Laboratories, Hercules, CA, U.S.A.). Quantification analysis was
performed using Image Lab version 2.0.1 software (BIO-RAD Laboratories, Hercules, CA,
U.S.A.). The density of a protein band was determined by subtracting the background in an area
of the same size immediately in front of protein band. The ratio of the densities of specified
proteins to -Actin in the same treatment group was calculated and used for statistical analysis.

2.5 Statistical Analysis
All experiments have been conducted in triplicate. One-way ANOVA with LSD posthoc statistical analysis and Students t-test was performed using SPSS version 22 statistical
software (IBM, Armonk, NY, U.S.A.). Data were presented as means ± S.E.M. A p-value less
than 0.05 was considered statistically significant.
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3. Results
3.1 Changes of pH and glucose levels in media of L6 cells treated with ROL,
RAL, or RA
L6 cells at confluence were treated with 1 µM ROL, RAL, or RA for 4 to 14 days. After
4 days of treatment with RA, both medium pH (Figure 2.1A) and glucose (Figure 2.1B) levels
were significantly decreased compared to that of the control group. This trend with RA
continued out to day 14. On the other hand, treatment with RAL did not start producing
significant reductions in medium pH (Figure 2.1A) and glucose levels (Figure 2.1B) until day 10
of treatment. Treatment of L6 cells with ROL did not yield significant changes in medium pH
and glucose levels at any day measured (Figure 2.1A-B).

3.2 Changes of pH and glucose levels in media of L6 cells treated with
increasing doses of insulin in the absence or presence of 1 M RA
Next, we performed an insulin dose curve (0.1 - 100 nM) in the absence or presence of 1
µM RA as shown in Figure 2.2. This allowed us to determine whether insulin was capable of
altering medium pH and glucose levels similar to that seen with RA, and whether there is a
synergy between RA and insulin. Starting at day 2, insulin (1 – 100 nM) was capable of
significantly reducing medium pH (Figure 2.2A) and glucose (Figure 2.2B) levels compared to
control. Insulin (1 – 100 nM) with the addition of RA (1 M) at day 2 resulted in significant
reductions in medium pH (Figure 2.2A) and glucose levels (Figure 2.2B) compared to RA alone.
After 4 days of treatment, insulin (10 nM) + RA led to significant reduction in medium pH
(Figure 2.2C) and glucose levels (Figure 2.2D) compared with the control, RA, and 10 nM
insulin groups. Similar results were observed after the treatment for 6 days with 10 nM insulin +
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RA maintaining significant reductions in medium pH (Figure 2.2E) and glucose levels (Figure
2.2F). However, after 6 days of treatment with 1 nM insulin, this dose no longer produced
significant reductions in medium pH (Figure 2.2E) and glucose levels (Figure 2.2F) compared to
control, whereas 10 nM insulin did. Therefore, the remaining experiments were performed using
insulin at a concentration of 10 nM.

3.3 Changes of pH and glucose levels in media of L6 cells treated with
increasing doses of RA in the absence or presence of 10 nM insulin
To determine that appropriate dose of RA to use for further experimentation, an RA dose
curve (0.3 – 10 M) was performed with or without insulin (10 nM). As shown in Figure 2.3,
after 2 days of treatment, RA alone did not lead to significant reductions in medium pH (Figure
2.3A) or glucose levels (Figure 2.3B) at any dose tested. However, treatment with 10 M RA +
insulin led to significant reductions in medium pH (Figure 2.3A) and glucose levels (Figure
2.3B) compared to control, insulin, and 10 M RA after 2 days. After 4 days of treatment, RA (1
– 10 M) caused significant reductions in medium glucose levels (Figure 2.3D). After 4 and 6
days of treatment, L6 cells treated with insulin + RA (1 – 10 M) significantly reduced pH
(Figures 2.3C and 2.3E) and glucose levels (Figures 2.3D and 2.3F) compared to control, insulin,
and RA (1 – 10 M). RA at 1 M had significantly reduced both medium pH (Figure 2.3E) and
glucose levels (Figure 2.3F) after 6 days of treatment, with 3 and 10 M RA having no additional
effect. Therefore, the remaining experiments were performed using RA at a concentration of 1
M.
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Figure 2.1. Changes of pH and glucose levels in media of L6 cells treated with ROL, RAL,
or RA. L6 cells were maintained in 60 mm dishes until ~100 confluence and were subjected to
differentiation with 2% HS alone (control), 2% HS + ROL (1 M), 2% HS + RAL (1 M), or 2%
HS+ RA (1 M). The medium was collected from each dish and replaced every 2 days with its
respective treatment condition. The collected medium was pipetted into 15 mL tubes sealed with
rubber corks for pH measurements using a standard pH meter and into 1.5 mL Eppendorf tubes
for glucose measurements using the StanBio Glucose Liquicolor kit. A. Changes of medium pH
after the indicated treatments for 4, 6, 8, 10, 12, and 14 days. B. Changes of medium glucose
after the indicated treatments for 4, 6, 8, 10, 12, and 14 days. The pH level of the control group
was arbitrarily set as 100% with data expressed as percentage change of pH. The glucose level
of the control group was arbitrarily set as 100% with data expressed as percentage. All p-values
≤ 0.05; for (A) a>b, c>d, e>f, g>h>i, j>k, l>m; for (B) a’>b’, c’>d’, e’>f’, g’>h’, i’>j’>k’,
l’>m’>n’. One-way ANOVA statistical analysis was performed using SPSS software. Data is
presented as means ± S.E.M (n=3).
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Figure 2.2. Changes of pH and glucose levels in media of L6 cells treated with increasing
doses of insulin and 1 M RA. Cells were maintained in 60 mm dishes and were subjected to
differentiation with 2% HS alone (control), 2% HS + RA (1 M), 2% HS + insulin (0.1-100 nM),
or 2% HS + RA + insulin. The medium was collected from each dish and replaced every 2 days
with its respective treatment condition. The collected medium was pipetted into 15 mL tubes
sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 2, 4, and 6 days, respectively. B, D,
and F. Changes of medium glucose after the indicated treatments for 2, 4, and 6 days,
respectively. The pH level of the control group was arbitrarily set as 100% with data expressed as
percentage change of pH. The glucose level of the control group was arbitrarily set as 100%
with data expressed as percentage. All p-values ≤ 0.05; for (A) a>b>c, a’>b’>c’; for (B) a>b>c,
a/b>c, a’>b’>c’, a’>b/c’; for (C) a>b>c>d, a’>b’>c’>d’; for (D) a>b>c, a’>b’>c’, a/b’>c’; for (E)
a>b, a’>b’>c’; for (F) a>b, a’>b’, using one-way ANOVA. * for comparing those that received
RA to those that did not receive RA using Students t-test statistical analysis with SPSS software.
Data is presented as means ± S.E.M (n=3).
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Figure 2.2 Continued
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Figure 2.3. Changes of pH and glucose levels in medium of L6 cells treated with increasing
doses of RA and 10 nM insulin. Cells were maintained in 60 mm dishes and were subjected to
differentiation with 2% HS alone (control), 2% HS + insulin (10 nM), 2% HS + RA (0.3-10 M),
or 2% HS + insulin + RA. The medium was collected from each dish and replaced every 2 days
with its respective treatment condition. The collected medium was pipetted into 15 mL tubes
sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 2, 4, and 6 days, respectively. B, D,
and F. Changes of medium glucose after the indicated treatments for 2, 4, and 6 days,
respectively. The pH level of the control group was arbitrarily set as 100% with data expressed as
percentage change of pH. The glucose level of the control group was arbitrarily set as 100%
with data expressed as percentage. All p-values ≤ 0.05; for (A) a’>b’>c’; for (B) a’>b’; for (C)
a’>b’>c’, a’>b/c’; for (D) a>b, a’>b’; for (E) a>b, a’>b’; for (F) a>b>c, a’>b’, using one-way
ANOVA. * for comparing those that received insulin to those that did not receive insulin using
Students t-test statistical analysis with SPSS software. Data is presented as means ± S.E.M (n=3
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3.4 Changes of pH and glucose levels in medium of L6 cells treated with 1 M
RA, LG268, TTNPB, or T1317 with or without 10 nM insulin
To determine if the RA-mediated effect on medium pH and glucose changes in L6 cells
was due to the activation of specific nuclear receptors, the effects of 1 M of LG268 (RXR
agonist), TTNPB (RAR agonist), or T1317 (LXR agonist) were tested. As shown in Figure 2.4,
after 4 days of treatment, both RA and TTNPB led to significant reductions in medium pH and
glucose levels compared to the control group. After 4 days of treatment, RA + insulin
significantly reduced medium pH (Figure 2.4C) and glucose levels (Figure 2.4D) compared to
the control, insulin, and RA alone. Similar results were also seen with TTNPB + insulin after 4
and 6 days of treatment (Figure 2.4E-F). Treatment of L6 cells with LG268 and T1317 produced
similar results to that seen with the control group (Figure 2.4). Likewise, the addition of insulin
to LG268 and T1317 produced similar results to that seen with insulin (Figure 2.4). Therefore,
we conclude that the RA-mediated effect on medium pH and glucose changes in L6 cells was
due to the activation of RARs.

3.5 Medium pH and glucose levels in L6 cells treated with 1 M each RA or
TTNPB with or without 10 nM insulin at increasing glucose concentrations
To investigate whether the RA and insulin-mediated effects on medium pH and glucose
changes were dependent on glucose availability and concentration, L6 cells were treated with
increasing concentrations (5, 15, and 25 mM) of glucose for 2, 4 and 6 days. As shown in Figure
2.5. after 2 days of treatment, the L6 cells with 15 and 25 mM glucose displayed significant
reductions in medium pH and glucose levels in those treated with insulin, RA + insulin, and
TTNPB + insulin (Figure 2.5C-F). However, this effect was most likely due to insulin’s actions
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Figure 2.4. Changes of pH and glucose levels in media of L6 cells treated with 1 M each
RA, LG268, TTNPB, or T1317 with or without 10 nM insulin. Cells were maintained in 60
mm dishes and were subjected to differentiation with 2% HS alone (control), 2% HS + insulin
(10 nM), 2% HS + RA (1 M), 2% HS + RA + insulin. 2% HS + LG268 (1 M), 2% HS +
LG268 + insulin, 2% HS + TTNPB (1 M), 2% HS + TTNPB + insulin, 2% HS + T1317 (1
M), 2% HS + T1317 + insulin. The medium was collected from each dish and replaced every 2
days with its respective treatment condition. The collected medium was pipetted into 15 mL
tubes sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 2, 4, and 6 days, respectively. B, D,
and F. Changes of medium glucose after the indicated treatments for 2, 4, and 6 days,
respectively. The pH level of the control group was arbitrarily set as 100% with data expressed as
percentage change of pH. The glucose level of the control group was arbitrarily set as 100%
with data expressed as percentage. All p-values ≤ 0.05; for (A) a>b; for (B) a>b; for (C) a>b>c;
for (D) a>b>c, a>b/c; for (E) a>b>c; for (F) a>b>c. One-way ANOVA statistical analysis was
performed using SPSS software. Data is presented as means ± S.E.M (n=3).
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as RA or TTNPB alone did not have significant effect compared to the control (Figure 2.5C-F).
After 4 days of treatment, L6 cells treated with insulin, RA, and TTNPB led to significant
reductions in medium pH and glucose levels compared to the control at both 15 and 25 mM
glucose (Figure 2.6C-F). The medium containing 25 mM glucose displayed significant
reductions in medium pH (Figure 2.6E) and glucose levels (Figure 2.6F) in RA + insulin
compared with control, insulin, and RA after 4 days of treatment. Similar results were seen with
TTNPB + insulin (Figure 2.6E-F). The medium containing 15 mM glucose only displayed
significant reductions in glucose levels (Figure 2.6D) in RA + insulin and TTNPB + insulin
groups compared to the control and their respective counterpart (RA and TTNPB), but not
insulin after 4 days of treatment. After treatment for 6 days, both medium containing 15 and 25
mM glucose displayed significant reductions in medium pH and glucose levels in RA + insulin
group compared to the control, insulin, and RA alone (Figure 2.7C-F). Similar results were seen
with the treatment of TTNPB + insulin (Figure 2.7C-F). No significant changes were observed in
medium containing 5 mM glucose (Figures 2.5-7). This suggests that the RA, TTNPB, and
insulin-mediated effects on medium pH and glucose changes depend on glucose availability and
concentration.

3.6 Decreases of GLUT1 and GLUT4 protein expression levels in L6 cells
treated with RA + Insulin for 6 days
With GLUT1 being known as the glucose transporter utilized in skeletal muscle cells
under basal conditions and GLUT4 being known as the insulin-stimulated glucose transporter
that will translocate from vesicles to the plasma membrane in skeletal muscle cells for glucose
uptake in response to insulin stimulation, we measured whether there was any change of GLUT1
and GLUT4 expression levels in L6 cells treated with RA and insulin. Surprisingly, the protein
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Figure 2.5. Medium pH and glucose levels in L6 cells following 2 days of treatment with 1
M each RA or TTNPB with or without 10 nM insulin at increasing glucose concentrations.
Cells were maintained in 60 mm dishes and were subjected to differentiation with 2% HS alone
(control), 2% HS + insulin (10 nM), 2% HS + RA (1 M), 2% HS + RA + insulin, 2% HS +
TTNPB (1 M), 2% HS + TTNPB + insulin. The treatments were made in medium containing
either 5, 15, or 25 mM glucose. The medium was collected from each dish and replaced every 2
days with its respective treatment condition. The collected medium was pipetted into 15 mL
tubes sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 2 days. B, D, and F. Changes of
medium glucose after the indicated treatments for 2 days. The pH level of the control group was
arbitrarily set as 100% with data expressed as percentage change of pH. The glucose level of the
control group was arbitrarily set as 100% with data expressed as percentage. All p-values ≤ 0.05;
for (C-F) a>b. One-way ANOVA statistical analysis was performed using SPSS software. Data is
presented as means ± S.E.M (n=3).
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Figure 2.6. Medium pH and glucose levels in L6 cells following 4 days of treatment with 1
M each RA or TTNPB with or without 10 nM insulin at increasing glucose concentrations.
Cells were maintained in 60 mm dishes and were subjected to differentiation with 2% HS alone
(control), 2% HS + insulin (10 nM), 2% HS + RA (1 M), 2% HS + RA + insulin, 2% HS +
TTNPB (1 M), 2% HS + TTNPB + insulin. The treatments were made in medium containing
either 5, 15, or 25 mM glucose. The medium was collected from each dish and replaced every 2
days with its respective treatment condition. The collected medium was pipetted into 15 mL
tubes sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 4 days. B, D, and F. Changes of
medium glucose after the indicated treatments for 4 days. The pH level of the control group was
arbitrarily set as 100% with data expressed as percentage change of pH. The glucose level of the
control group was arbitrarily set as 100% with data expressed as percentage. All p-values ≤
0.05; for (C) a>b>c, a>b/c; for (D) a>b>c, a>b/c; for (E) a>b>c>d; for (F) a>b>c. One-way
ANOVA statistical analysis was performed using SPSS software. Data is presented as means ±
S.E.M (n=3).
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Figure 2.7. Medium pH and glucose levels in L6 cells following 6 days of treatment with 1
M each RA or TTNPB with or without 10 nM insulin at increasing glucose concentrations.
Cells were maintained in 60 mm dishes and were subjected to differentiation with 2% HS alone
(control), 2% HS + insulin (10 nM), 2% HS + RA (1 M), 2% HS + RA + insulin, 2% HS +
TTNPB (1 M), 2% HS + TTNPB + insulin. The treatments were made in medium containing
either 5, 15, or 25 mM glucose. The medium was collected from each dish and replaced every 2
days with its respective treatment condition. The collected medium was pipetted into 15 mL
tubes sealed with rubber corks for pH measurements using a standard pH meter and into 1.5 mL
Eppendorf tubes for glucose measurements using the StanBio Glucose Liquicolor kit. A, C, and
E. Changes of medium pH after the indicated treatments for 6 days. B, D, and F. Changes of
medium glucose after the indicated treatments for 6 days. The pH level of the control group was
arbitrarily set as 100% with data expressed as percentage change of pH. The glucose level of the
control group was arbitrarily set as 100% with data expressed as percentage. All p-values ≤
0.05; for (C-F) a>b>c. One-way ANOVA statistical analysis was performed using SPSS
software. Data is presented as means ± S.E.M (n=3).
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expression levels of GLUT1 and GLUT4 were significantly decreased in L6 cells treated with
insulin in comparison with the control group. RA alone did not change GLUT1 and GLUT4
expression levels. However, the treatment of L6 cells with RA + insulin caused further reduction
of GLUT1 and GLUT4 protein levels compared to control, insulin, and RA (Figure 2.8). This
demonstrates that RA and insulin work together to reduce the expression levels of GLUT1 and
GLUT4 in L6 cells.

4. Discussion
With the skeletal muscle playing a pivotal role in whole body glucose homeostasis, our
study was aimed to understand how skeletal muscle cells respond to nutritional and hormonal
stimuli. Recently, the insulin-stimulated glucose uptake via GLUT translocation has been a topic
researched extensively487,488. Factors such as nutrient availability, contraction, and growth factors
can influence the insulin-stimulated glucose uptake and disposal in skeletal muscle489. Although
studies have shown that RA plays a role in favoring muscle cell differentiation from myocyte to
myotube, there are a limited number of studies investigating the effects of RA and other retinoids
on skeletal muscle glucose utilization482,490,491.
The changes in medium pH levels within this study was reciprocated with changes in
medium glucose levels. Therefore, we believe that the decreases seen in medium glucose levels
are due to increased glucose utilization within the muscle cells and the changes in medium pH
are indicative of increased cell metabolism. In Figure 2.1, the changes of medium pH and
glucose levels in L6 cell treated with the retinoids mimicked what you may expect with VA
metabolism. RAL led to significant reductions in medium pH and glucose levels after 10 days,
whereas ROL did not produce any significant differences (Figure 2.1). With the conversion of
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ROL to RAL to RA, we show that the RA treated L6 cells display significant reductions in
medium pH (Figure 2.1A) and glucose levels (Figure 2.1B) as early as 4 days after treatment
began. The effects seen with RA remained throughout the 14-day experiment time frame with the
RA treated L6 cells having a gradual decrease in medium pH and glucose levels. After 10 days of
treatment with RA, there was ~50% less medium glucose compared to control and this remained
through day 14 (Figure 2.1). These results indicate that RA provides the biological activity
within skeletal muscle as it does in many other tissues26,251.
Since insulin promotes glucose uptake and utilization in skeletal muscle, we performed
an insulin dose curve (Figure 2.2)492. The dose curve was performed to determine if insulin
elicited the same response seen with the retinoids and to determine a dose that would maintain
significant decreases in medium pH and glucose levels without compromising cell integrity. For
this reason, 10 nM insulin was chosen for the remaining experiments due to its ability to
maintain significant reductions in medium pH and glucose levels after day 2, 4, and 6 of
treatment (Figure 2.2). Similarly, an RA dose curve was performed to determine the
concentration closest to physiological relevance that would maintain significant reduction in
medium pH and glucose levels over a 6-day period (Figure 2.3). It was evident after 4 days of
treatment that 0.3 M RA alone had no effect on medium pH and glucose levels, however, 1 M
RA caused significant reductions in both medium pH and glucose level, with 3 and 10 M RA
having no additional effect (Figure 2.3). This results suggest that a relative high amount of RA is
needed to achieve the effect. So far, we do not have an explanation to this phenomenon. Whether
a low affinity receptor of RA or relatively rapid elimination of RA in L6 cells remains to be
determined.
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Figure 2.8. Decreases of GLUT1 and GLUT4 protein levels in L6 cells treated with insulin
and RA. A. A representative blot of protein levels of GLUT1, GLUT4, and -actin in L6 cells
treated with 2% HS (control), insulin (10 nM), RA (1 M), and RA + insulin for 6 days. B-C.
Quantification analysis of GLUT1 and GLUT4, respectively. Cells were maintained in 60 mm
dishes and were subjected to differentiation with 2% HS (control), insulin (10 nM), RA (1 M),
and RA + insulin. The medium was replaced every 2 days with its respective treatment condition.
On day 6 of treatment, whole cell lysate was collected as described in Materials & Methods.
Blots were visually detected using ECL Western Blotting Substrate on ChemiDoc Software
System. The ratio of the densities of specified proteins to -Actin in the same treatment group
was calculated and used for statistical analysis with control group set as 1. All p-values ≤ 0.05; *
indicates statistical significance. One-way ANOVA statistical analysis was performed using
SPSS software.
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Retinoids mediate their actions through the binding of specific nuclear receptors within
target cells493,494. Although RARs and RXRs are the classical nuclear receptors known to be
regulated by RA, other nuclear receptors such as liver-X-receptors (LXR) have been shown to be
activated by RA in various cell types495-497. Therefore, we treated L6 cells with 1 M of LG268
(RXR agonist), TTNPB (RAR agonist), and T1317 (LXR agonist) to determine if the RAmediated effect on medium pH and glucose changes were due to the activation of a specific
nuclear receptor signaling pathway (Figure 2.4). LG268 and T1317 had no effect on medium pH
and glucose levels on any day measured (Figure 2.4). However, TTNPB mimicked the responses
seen with RA alone and with insulin, suggesting that the RA-mediated effect is by activation of
the RAR nuclear receptor (Figure 2.4).
To confirm that the measurements in medium pH and glucose levels were actually due to
changes in available glucose in the medium, we performed a glucose dose curve experiment in
which the medium contained either 5, 15, or 25 mM glucose (Figures 2.5-7). L6 cells treated
with 5 mM glucose did not elicit a response from insulin, RA, or TTNPB on any day. However,
the L6 cells containing 15 and 25 mM glucose started displaying reductions in medium pH and
glucose levels after 2 days of treatment and continued through day 6 (Figure 2.5-7). This
suggests that the changes seen are due to the muscle cells taking in extracellular glucose into the
cells for either storage or metabolism, thus resulting in decreases in remaining medium glucose
levels.
GLUT4 is the glucose transporter commonly referred to as the insulin-stimulated glucose
transporter in skeletal muscle whereas GLUT1 is thought to regulate skeletal muscle glucose
uptake during basal conditions199,498. Therefore, it is interesting to find that following 6 days of
treatment, insulin alone and RA + insulin promoted reductions in both GLUT1 and GLUT4
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(Figure 2.8). This could imply that L6 cells respond to pro-longed insulin and RA treatment with
a homeostatic mechanism to decrease glucose uptake by decreasing GLUT1 and GLUT4 protein
levels. As far as we know, this is the first time that this phenomenon is reported. The underlying
mechanism deserves to be investigated.
Collectively, our results demonstrate that when L6 cells are treated with both RA and
insulin, there is an elevation of glucose utilization. The L6 cells were cultured in the presence of
2% house serum, indicating that they had been induced to differentiation and kept differentiation
media all the time. Currently, we have not determined whether L6 cells treated with insulin + RA
are more differentiated than those treated with 2% HS, which are already in differentiation
condition. An interesting project for future research might be whether to an increase in L6 cell
metabolism is influenced by the state of its differentiation. Nevertheless, we believe that the
regeneration and differentiation of skeletal muscle is a dynamic process and this study gives
insight into the metabolism taking place. Furthermore, we demonstrate that the RA-mediated
effect on L6 cells glucose utilization is in part due to the activation of the RAR signaling
pathway and is not dependent on GLUT4 under these treatment conditions.

5. Conclusion
By investigating the cross-talk between retinoids and insulin within skeletal muscle cells,
we can have a greater grasp on how this tissue regulates its glucose metabolism. If RA can work
cooperatively with insulin in regulating skeletal muscle glucose metabolism then this could
ultimately lead to the generation of new and improved therapies for insulin resistance and
diabetes.
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CHAPTER III. REGULATION OF GLYCOGEN
SYNTHASE AND GLUCOSE TRANSPORTERS BY
VITAMIN A AND INSULIN IN L6 CELLS AND RAT
SKELETAL MUSCLE TISSUE
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1. Introduction
Skeletal muscle mass accounts for ∼40% of the total body mass, therefore, it plays a
major role in energy balance and nutrient metabolism499. Disorders that are associated with
insulin resistance or insensitivity such as obesity and type 2 diabetes mellitus (T2DM) can
negatively impact skeletal muscle glucose metabolism500. During the postprandial state, insulin is
secreted from pancreatic β-cells and will inhibit hepatic glucose output while promoting glucose
uptake in the skeletal muscle487. The skeletal muscle cells can also take in glucose in a noninsulin mediated manner by muscular contractions performed during exercise501. By having a
greater understanding of the glucose uptake and utilization pathways within skeletal muscle, we
can determine the importance of diet and exercise on glucose homeostasis.
The actions of insulin are mediated through an intracellular signaling cascade. The
binding of insulin to its receptor on target cells leads to the phosphorylation of insulin receptor
substrate (IRS) proteins, with IRS-1 being the primary IRS in skeletal muscle, which recruits and
activates phosphatidylinositol 3-kinase (PI3K)401. Activated PI3K catalyzes the conversion of the
membrane-associated phosphatidylinositol-4,5-bisphosphate (PIP2) and ATP into
phosphatidylinositol-3,4,5-triphosphate (PIP3) and ADP. The increases in PIP3 leads to the
recruitment of Akt, a serine/threonine protein kinase, by interacting with its pleckstrin homology
domain180. PIP3 also recruits PDK1 to the plasma membrane which phosphorylates Akt at
Thr308181,402. Mammalian target of rapamycin complex-2 (mTORC2) will phosphorylate Akt at
Ser473 leading to its activation403. In muscle cells, the insulin stimulation leads to an increase in
amount of GLUT4 on the cell membrane, which is translocated from intracellular storage
vesicles to facilitate the uptake of glucose502,503. Glucose can then be metabolized through
glycolysis for energy production or it can be converted to glycogen for storage487,504.
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Glycogen is a highly branched polysaccharide that serves as the primary storage form of
glucose391. The liver and skeletal muscle are the major storage sites of glycogen in human body.
The role of glycogen within the skeletal muscle is to provide glucose for energy production
while in the liver the primary goal of glycogen is to supply glucose in the blood for the use in
other tissues392. The activation of insulin signaling pathway increases the activities of enzymes
involved in glycogenesis including glycogen synthase (GS), and in turn, enhance glycogenesis in
hepatocytes and muscle cells393,394. The insulin-mediated activation of Akt will inactivate
glycogen synthase kinase-3 (GSK-3) by phosphorylating specific sites on the enzyme182,183. By
inhibiting GSK-3, glycogen synthase phosphatase (GSP) can activate GS by
dephosphorylation181,404. The insulin signaling cascade will also lead to the activation of protein
phosphatase 1 (PP1) which can dephosphorylate and activate GS, thus promoting glycogen
formation405.
Vitamin A (VA, i.e. retinol, ROL) is an essential micronutrient that is implicated in the
regulation of macronutrient metabolism482. For biological activity, ROL proceeds through two
stepwise cytosolic enzymatic reactions that first forms retinal (RAL) and then retinoic acid (RA,
all-trans RA or 9-cis RA)493. RA can then enter the nucleus of target cells and modules gene
expression through the activation of specific nuclear receptors termed retinoid acid receptors
(RAR) and retinoid-X-receptors (RXR)50,484. RAR and RXR share a common ligand in 9-cis-RA
whereas all-trans-RA only binds to RAR61. Both of these classes of nuclear receptors will bind to
a retinoic acid response element (RARE) that is located in the promoter of various genes. The
RARE sequence consists of two consensus half sites (AGGTGA) that are separated by
nucleotides that arrange the site as either palindromic, inverted palindromic, or direct repeats75.
Once the ligand binds to its respective receptor a conformational change occurs that allows the
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receptor to interact with transcriptional cofactors that can alter the regulation of their target
genes64,494. While RA has been shown to play a role in carbohydrate, protein, and lipid
metabolism in tissues such as the liver and adipose, the regulation of nutrient metabolism by RA
in skeletal muscle is less clear482,497. It has been shown in rat L6 skeletal muscle cells that RA
can promote insulin-stimulated glucose uptake and increase GLUT4 mRNA levels376. Although
there are studies investigating the effects of RA on skeletal muscle, most of these studies focus
on muscle cell differentiation, therefore, the effects of RA on skeletal muscle glucose utilization
are largely unknown.
In the previous chapter, we have shown that RA synergized with insulin to induce the
glucose utilization in L6 cells. This induction was not due to the elevation of expression levels of
GLUT1 or GLUT4 in the treated cells. The aim of this study was to further investigate the effects
of VA in the form of RA on skeletal muscle cell glucose utilization and explore the underlying
mechanism of this induction in-vitro and in-vivo. For this purpose, we used L6 skeletal muscle
cells which have been previously shown to be responsive to both RA and insulin374,376. We
demonstrate that the treatment of RA and insulin, synergistically promote GS protein level, a
process through the activation of RAR. These in-vitro results were confirmed with an in-vivo
model of VA deficient (VAD) and sufficient (VAS) diabetic rats. The VAS rats that received
insulin injection displayed significantly higher levels of GS protein expression that correlated
with significantly lower levels of GS phosphorylation. Furthermore, L6 cells treated with RA +
insulin display significantly higher amounts of glucose release to indicate increases in stored
glycogen amounts. In addition, the treatment of RA + insulin in L6 cells altered the expression
levels of GLUT3 and GLUT6, indicating that other transport mechanisms may play a role in the
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uptake of glucose under these treatment conditions.

2. Materials & Methods
2.1 Reagents
Dulbecco's Modified Eagle Medium (DMEM) and penicillin/streptomycin were
purchased from Mediatech (Manassas, VA, U.S.A.). Fetal bovine serum (FBS) was purchased
from Life Technologies (Grand Island, NY, U.S.A.). Horse serum (HS) was purchased from
Hyclone Laboratories (Logan, UT, U.S.A.). For RNA extraction, RNA STAT-60™ was
purchased from Tel-Test (Friendswood, TX, U.S.A.). DNA-free™ kit and SYBR Green PCR
Master Mix were purchased from Applied Biosystems (Foster City, CA, U.S.A.). For cDNA
synthesis, Verso cDNA synthesis kit was purchased from Thermo Scientific (Pittsburg, PA,
U.S.A.). BCA protein assay kit and ECL Western Blotting Substrate were purchased from Pierce
(Rockford, IL, U.S.A.). Immobilon®-PSQ PVDF membrane was purchased from EMD
Millipore (Billerica, MA, U.S.A.). Polyvinylpyrrolidone (PVP) was purchased from Amresco
(Solon, OH, U.S.A.). LG268 was synthesized in the core facility at the University of Texas
Southwestern Medical Center at Dallas. Potassium hydroxide, isopropanol, all-trans retinoic
acid, all-trans retinol, all-trans retinal, TTNPB, insulin, and diethylpyrocarbonate (DEPC) were
purchased from Sigma (St. Louis, MO, U.S.A.). Perchloric acid was purchased from Alfa Aesar
(Ward Hill, MA, U.S.A.). Amyloglucosidase was purchased from Carolina Biological Supply
(Burlington, NC, U.S.A.). For immunoblotting, Total AKT (#9272), PO4-AKT Ser473 (#9271)
and Thr308 (9275), glycogen synthase (#3886), PO4-glycogen synthase Ser641 (#3891), GSK3 (#4337), PO4-GSK-3Ser21 (#9316), GSK-3(#9315), PO4-GSK3 Ser9 (#9323), GAPDH
(#5174), lactate dehydrogenase (#3582), pyruvate dehydrogenase (#3205), pyruvate kinase M1/2
(#3190), IRS-1 (#3407), IRS-2 (#4502), -Actin (#4970), and goat anti-rabbit IgG (#7074) were
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purchased from Cell Signaling Technology (Danvers, MA, U.S.A.). GLUT1 (#1340) and
GLUT4 (#1346) were purchased from Chemicon Industries (Temecula, CA, U.S.A.). GLUT3
(#38121) and GLUT6 (#43594) were purchased from One World Lab (San Diego, CA, U.S.A.).
IR- subunit (#06-492) was purchased Upstate Biotechnology, Inc. (Lake Placid, NY, U.S.A.).

2.2 L6 rat skeletal muscle cell culture and differentiation
Rat L6 cells were incubated in 60 mm dishes at 37°C and 5% CO2. For subculture, L6
cells were maintained in DMEM with 4.5 g/L (25 mM) glucose supplemented with 10% FBS +
1% penicillin/streptomycin. When cells reached ~100% confluence, medium was changed to
DMEM containing 25 mM glucose with 2% HS + 1% penicillin/streptomycin to induce
differentiation.

2.3 Animal Experiment
The skeletal muscle tissue samples were collected in another study, which will be
submitted for publication elsewhere (manuscript in submission). In brief, male Zucker lean (ZL)
rats at weaning (3 weeks old) were fed a VAS diet (#5755, TestDiet) or an isocaloric VAD diet
(#5822, TestDiet) diet. Rats were fasted for 24 hours, and received a single injection of 65 mg/kg
BM streptozotocin (STZ) via the tail vein and allowed to have their respective diet ad libitum.
The successful induction of STZ-induced diabetes was confirmed when plasma glucose level
was higher than 250 mg/dL. Then the VAS or VAD rats with STZ-induced diabetes were divided
into 2 groups. They were treated with saline (control, 100 μL, intramuscular injection, VAS-C or
VAD-C), or insulin (0.5 IU/100 g BM, intramuscular injection, VAS-INS or VAD-INS). Rats
were fed ad libitum for 3-4 hours and then euthanized for tissue sample collection. The
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procedures were approved by the Institutional Animal Care and Use Committee at the University
of Tennessee at Knoxville (Protocol numbers 1256 and 1899).

2.4 Muscle Sample Preparation
About 100 mg of frozen gastrocnemius tissues was homogenized for 1-2 minutes at
28,000 RPM using a Omni Tissue Master 240 (Omni International, Kennesaw, GA, U.S.A.) in 1
mL ice-cold protein lysis buffer (1% Triton X-100, 10% glycerol, 1% IGEPAL CA-630, 50 mM
Hepes, 100 mM NaF, 1 mM sodium molybdate, 1 mM sodium -glycerophosphate, 5 mM
sodium orthovanadate, 1.9 mg/mL aprotinin, 5 mg/ml leupeptin, 1 mM benzamide, 2.5 mM
PMSF, pH 8.0). The lysates were transferred to cold 1.5 mL Eppendorf tubes and kept on ice at
all times. The samples were vortexed for 10 seconds and maintained on ice for at least 20
minutes with vortexing every 5 minutes. After that lysates were centrifuged at 13,000 RPM for
15 minutes at 4°C. The supernatant was collected into clean 1.5 mL Eppendorf tubes and stored
at -80°C before being used. Protein content of the lysate was quantified using Pierce BCA
protein assay kit according to the manufacturer’s instruction and analyzed on Glomax®
Multi+Detection System (Promega, Madison, WI, U.S.A.).

2.5 RNA Isolation and cDNA synthesis
The methods for total RNA isolation and cDNA synthesis were described elsewhere505.
Briefly, 1 mL RNA STAT-60™ was added to one 60 mm dished with L6 cells. The RNA STAT60™ reagent was pipetted up and down quickly to homogenize the cells and transferred to a 1.5
mL tube. After that, 200 L of chloroform was added to each tube and the mixture was shaken
vigorously for 15 seconds. Following a 3-minute incubation period at room temperature, samples
were centrifuged at 12,000 × g at 4°C for 15 minutes. Roughly 500 uL of aqueous phase was
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transferred to a new 1.5 mL tube, and 500 uL of isopropanol was added to precipitate out the
RNA. Following a 10-minute incubation at room temperature, samples were centrifuged at
12,000 × g for 10 minutes at 4°C. The supernatant was discarded without disturbing the pellet
and 1 mL of 70% ethanol in DEPC-treated water was added. Samples were centrifuged at 7,500
× g for 5 minutes at 4°C. The supernatant was discarded without disturbing the pellet and the
pellet was air dried for 3 minutes. The pellet (RNA) was dissolved in 88 µL of DEPC water for
30 minutes at room temperature. The contaminated DNA in RNA samples was removed using
the DNA-free™ kit. Following the 30-minute incubation period, 10x DNase I buffer (0.1
volume) and 4 units of DNase in 2 µL were added to the RNA samples. Following gentle
mixing, the samples were incubated at 37°C for 30 minutes. After that, 10 µL DNase
Inactivation reagent (0.1 volume) was added and mixed well. Mixture was incubated at room
temperature for 2 minutes and then centrifuged at 10,000 × g at 4°C for 2 minutes. The
supernatant (~100 L DNA-free RNA) was transferred to a new 1.5 mL tube and quantified
using NanoDrop ND-1000 spectrophotometer and software (version 3.1.1, NanoDrop
Technologies Inc., Wilmington, DE, U.S.A.). First strand cDNA was synthesized using cDNA
synthesis kit. The reaction was carried out in a total volume of 100 μL, containing 2 μg of DNAfree RNA, 50 mM Tris-HCl, 75 mM KCl, 10 mM DTT, 8.5 mM magnesium chloride, 0.5 mM of
each dNTP (dATP, dCTP, dTTP, and dGTP), 2.5 mM random hexamer primers, 40 units of
RNase inhibitor, 125 units of Multiscribe reverse transcriptase. The conditions are 25°C for 10
minutes, 48°C for 30 minutes, and 95°C for 5 minutes. The newly synthesized cDNA was stored
at -20°C before being analyzed.
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2.6 Real-time PCR analysis
The gene expression level was determined by real-time PCR using SYBR Green. Each
SYBR Green based real-time PCR reaction contains, in a final volume of 14 L, cDNA from 14
ng of reverse transcribed total RNA, 2.33 pmol primers, and 7 L of 2x SYBR Green PCR
Master Mix. Triplicate PCR reactions were carried out in 96-well plates using 7300 Real-Time
PCR System (Applied Biosystems, Foster City, CA, U.S.A.). The conditions are 50°C for 2
minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1
minute. The data was normalized to the mRNA level of the control gene -actin. The data were
presented fold induction using ΔΔCt methods with the control treatment group set as 1. See
Table 3.1 in Appendix for primer sequences.

2.7 Protein Isolation and Immunoblotting
Whole cell lysate was prepared by washing L6 cells once with ice-cold PBS and lysing
the cells in 400 μL ice cold whole-cell lysis buffer and subsequently scraped into chilled 1.5 mL
centrifugation tubes. The lysates were vortexed vigorously and placed on ice for at least 20
minutes. Lysates were then centrifuged at 12,000 x g for 15 minutes at 4°C and supernatant
collected into clean 1.5 mL Eppendorf tubes and stored at -80°C. Protein was quantified by
Pierce BCA protein assay kit using manufacturer recommendations and analyzed using
Glomax® Multi+Detection System. Total protein (40 g) was then separated on an 8% SDSPAGE gel and transferred to Immobilon®-PSQ PVDF membrane39. Membranes were blocked
using 1% PVP in 1x TBST for 1 hour at room temperature and then probed with specific
antibodies diluted in 1% PVP in 1x TBST overnight at 4°C486. After that, the membranes were
washed three times for 5 minutes each with 1x TBST and then incubated 1-2 hours with goat
anti-rabbit IgG conjugated with horseradish peroxidase (1/2000 dilution in 1% PVP in 1x
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TBST). Following secondary incubation, three more 5 minute washes with 1x TBST were
carried out followed by visual detection using ECL Western Blotting Substrate on ChemiDoc
Software System (BIO-RAD Laboratories, Hercules, CA, U.S.A.). Quantification analysis was
performed using Image Lab version 2.0.1 software (BIO-RAD Laboratories, Hercules, CA,
U.S.A.). The density of a protein band was determined by subtracting the background in an area
of the same size immediately in front of protein band. The ratio of the densities of specified
proteins to -Actin in the same treatment group was calculated and used for statistical analysis.

2.8 Glucose Release Assay for the Measurement of Glycogen Content
For the measurement of cellular glycogen content, we adapted the glucose release method
developed to determine the tissue glycogen content506. Following the 6-days treatment in
differentiation medium containing the indicated reagents as described in the figure legends, L6
cells were washed twice with 2 mL of ice cold PBS and PBS was immediately removed. After
that, 400 L ice cold PBS was added to each dish and L6 cells were scraped into chilled 1.5 mL
Eppendorf tubes. Samples were centrifuged at 12,000 × g for 12 minutes at 4°C. The supernatant
was discarded without disturbing the pellet and the samples were placed on ice. For glycogen
precipitation, 35 L of ice cold perchloric acid (0.6 N) was added to each sample followed by
pipetting up and down to mix contents. For neutralization of perchloric acid, 5 L of potassium
hydroxide (5.4 N) was added and samples were mixed by pipetting up and down. 35 L of
amyloglucosidase (300 AGU/mL) was then added to each sample followed by pipetting to mix
each sample. The samples were then incubated for 2 hours at 40°C with occasional mixing.
Following incubation, the samples were centrifuged at 12,000 × g for 5 minutes at 4°C. The
glucose amount released was measured using the StanBio Glucose Liquicolor kit. Briefly, in
individual 1.5 mL Eppendorf tubes, 500 L of glucose reagent was added to each tube and
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incubated for 5 minutes at 37°C. Following the incubation period, one glucose reagent
containing tube received 5 L of blank control (35 L perchloric acid + 5 L potassium
hydroxide + 35 L amyloglucosidase), one tube received 5 L of glucose standard, and the
remaining tubes received 5 L of each mixed sample. The samples were incubated for 5 minutes
at 37°C and then loaded in a clear 96-well plate for analysis on Glomax® Multi+Detection
System at 500 nm wavelength. Values were derived by comparing the absorbance of the
unknown (u) with that of the standard (s): Glucose (mg/dL) = ((Au x 10)/As) x 100). L6 cells
treated with 2% HS alone served as control for comparison to respective treatment conditions.
Data was normalized to total protein and presented as both fold induction with the control group
being set as 1 and total glucose released in mg glucose/mg total protein.

2.10 Statistical Analysis
All experiments have been conducted in triplicate. One-way ANOVA with LSD posthoc statistical analysis was performed using SPSS version 22 statistical software (IBM, Armonk,
NY, U.S.A.). Data were presented as means ± S.E.M. A p-value less than 0.05 was considered
statistically significant.

3. Results
3.1 Expression levels of key proteins in insulin signaling pathway in L6 cells
treated with RA, LG268, or TTNPB without or with insulin
To understand the mechanism of enhanced glucose usage in L6 cells treated with RA and
insulin, L6 cells were treated with 1 M of RA, LG268 (RXR agonist) and TTNPB (RAR
agonist) with or without 10 nM insulin for 6 days with change of the same fresh medium every
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two days. After 6 days of treatment with RA, IRS-1 protein levels were significantly increased
compared to control, insulin, and RA + insulin (Figure 3.1A and 3.1C). Similar results were also
seen with TTNPB. IRS-2 protein levels were significantly increased with RA and RA + insulin
compared to control and insulin alone, however, no significant changes were seen with TTNPB
(Figure 3.1A and 3.1D). Phosphorylation of Akt at Thr308 was significantly increased in L6
cells with all groups treated with insulin compared to control (Figure 3.1A and 3.1E). RA +
insulin led to significant further increase in Akt (Thr308) phosphorylation compared to control,
insulin, and RA (Figure 3.1A and 3.1E). Interestingly, TTNPB treatment led to significant
increases in phosphorylation of Akt (Thr308) compared to control, and TTNPB + insulin
significantly increased phosphorylation at this site compared to control and insulin (Figure 3.1A
and 3.1E). LG268 + insulin also displayed increased phosphorylation of Akt (Thr308) compared
to control, insulin, and LG268 (Figure 3.1A and 3.1E).

3.2 Expression levels of key proteins in glycogen metabolic pathway in L6 cells
treated with RA, LG268, or TTNPB without or with insulin
The phosphorylation of GSK-3 at site Ser21 was increased with RA + insulin, TTNPB,
and TTNPB + insulin compared to control (Figure 3.2A-B). Similar results were seen with the
phosphorylation of GSK-3 at site Ser9 with the addition of RA also significantly increasing
phosphorylation at this site (Figure 3.2A and 3.2D). The phosphorylation of GS at site Ser641
was significantly reduced by the treatment of insulin, RA, RA + insulin, LG268 + insulin, and
TTNPB + insulin compared to control (Figure 3.2A and 3.2F). Total GS protein levels were
significantly increased by insulin, RA + insulin, and TTNPB + insulin compared to control
(Figure 3.2A and 3.2G). RA + insulin led to significant further increase in GS protein levels
compared to RA alone and insulin (Figure 3.2A and 3.2G). TTNPB + insulin led to significant
125

Figure 3.1. Abundance levels of key proteins in insulin signaling pathway in L6 cells treated
with RA, LG268, or TTNPB in the absence or presence of insulin for 6 days. A. A
representative blot of protein levels of total Akt, PO4-Akt Ser473 and Thr308, IRS-1, IRS-2, IR subunit and -actin in L6 cells treated with 2% HS (control), insulin (10 nM), RA (1 M), RA
+ insulin, LG268 (1 M), LG268 + insulin, TTNPB (1 M), TTNPB + insulin for 6 days. B-G.
Quantification analysis of IR-, IRS-1, IRS-2, PO4-Akt Thr308, PO4-Akt Ser473, and total Akt,
respectively. Cells were maintained in 60 mm dishes and were subjected to differentiation with
2% HS (control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin,
TTNPB (1 M), TTNPB + insulin. The medium was replaced every 2 days with its respective
treatment condition. On day 6 of treatment, whole cell lysate was collected as described in
Materials & Methods. Blots were visually detected using ECL Western Blotting Substrate on
ChemiDoc Software System. The ratio of the densities of specified proteins to -Actin in the
same treatment group was calculated and used for statistical analysis with control group set as 1.
All p-values ≤ 0.05; for (C) a>b>c; for (D) a>b; for (E) a>b>c, a>b/c. One-way ANOVA
statistical analysis was performed using SPSS software. Data are presented as means ± S.E.M
(n=3).
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Figure 3.1
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Figure 3.1 Continued
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Figure 3.2. Abundance levels of key proteins in glycogen signaling pathway in L6 cells
treated with RA, LG268, or TTNPB in the absence or presence of insulin for 6 days. A. A
representative blot of protein levels of GS, PO4-GS Ser641, GSK-3, PO4-GSK-3 Ser21,
GSK-3, PO4-GSK-3 Ser9 and -actin in L6 cells treated with 2% HS (control), insulin (10
nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin, TTNPB (1 M), TTNPB +
insulin for 6 days. B-G. Quantification analysis of PO4-GSK-3 Ser21, GSK-3, PO4-GSK-3
Ser9, GSK-3, PO4-GS Ser641, and GS, respectively. Cells were maintained in 60 mm dishes
and were subjected to differentiation with 2% HS (control), insulin (10 nM), RA (1 M), RA +
insulin, LG268 (1 M), LG268 + insulin, TTNPB (1 M), TTNPB + insulin. The medium was
replaced every 2 days with its respective treatment condition. On day 6 of treatment, whole cell
lysate was collected as described in Materials & Methods. Blots were visually detected using
ECL Western Blotting Substrate on ChemiDoc Software System. The ratio of the densities of
specified proteins to -Actin in the same treatment group was calculated and used for statistical
analysis with control group set as 1. All p-values ≤ 0.05; for (B) a>b>c, a/b>c; for (D) a>b>c,
a/b>c; for (F) a>b>c, a>b/c; for (G) a>b>c>d, a>b>c/d. One-way ANOVA statistical analysis was
performed using SPSS software. Data are presented as means ± S.E.M (n=3).
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increases in GS protein levels compared to TTNPB and insulin (Figure 3.2A and 3.2G).

3.3 Expression levels of key proteins in glucose usage pathway in L6 cells
treated with RA, LG268, or TTNPB without or with insulin
Following 6 days of treatment with either RA, TTNPB, or LG268 with or without insulin,
no significant changes were seen in the protein levels of GAPDH, LDH, PDH, or pyruvate
kinase (Figure 3.3).

3.4 Treatment of insulin enhances Gys1 gene mRNA expression in L6 cells
The treatments of insulin, RA + insulin, LG268 + insulin, and TTNPB + insulin in L6
cells led to significant increases in Gys1 gene expression compared to control (Figure 3.4A).
None of the ligands + insulin produced significant differences in Gys1 gene expression compared
to insulin (Figure 3.4A). RA led to significant reduction in Ldha gene expression compared to
insulin (Figure 3.4B). None of the treatments produced significant differences in Slc2a4 gene
expression levels (Figure 3.4C). Only TTNPB + insulin produced a significant increase in
Ppargc1a gene expression levels compared to control (Figure 3.4D). Ppargc1b gene expression
levels were increased by insulin, RA + insulin, and TTNPB + insulin compared to control
(Figure 3.4E). Similar to that seen with GS, this increase in Ppargc1b gene expression levels is
driven by the actions of insulin.

3.5 Glycogen content in L6 cells treated with RA, LG268, or TTNPB in the
absence or presence of insulin for 6 days
Following treatment of L6 cells with 1 M RA, LG268, or TTNPB in the absence or
presence of 10 nM insulin, cellular glycogen was measured using glucose release assay (Figure
3.5). Insulin alone led to significant increases of glycogen in L6 cells as shown in both fold
132

Figure 3.3. Abundance levels of key proteins in glucose usage pathway in L6 cells treated
with RA, LG268, or TTNPB in the absence or presence of insulin for 6 days. A. A
representative blot of protein levels of GAPDH, lactate dehydrogenase (LDH), pyruvate
dehydrogenase (PDH), pyruvate kinase mutase (PKM ½) and -actin in L6 cells treated with 2%
HS (control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin,
TTNPB (1 M), TTNPB + insulin for 6 days. B-E. Quantification analysis of GAPDH, PKM ½,
LDH, and PDH, respectively. Cells were maintained in 60 mm dishes and were subjected to
differentiation with 2% HS (control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M),
LG268 + insulin, TTNPB (1 M), TTNPB + insulin. The medium was replaced every 2 days
with its respective treatment condition. On day 6 of treatment, whole cell lysate was collected as
described in Materials & Methods. Blots were visually detected using ECL Western Blotting
Substrate on ChemiDoc Software System. The ratio of the densities of specified proteins to Actin in the same treatment group was calculated and used for statistical analysis with control
group set as 1. One-way ANOVA statistical analysis was performed using SPSS software. Data
are presented as means ± S.E.M (n=3).
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Figure 3.4. Treatment with insulin enhances Gys1 gene expression in L6 cells. A-E.
Expression levels of Gys1 (A) Ldha (B), Slc2a4 (C), Ppargc1a (D) and Ppargc1b (E) transcripts.
L6 cells in 60 mm dishes were incubated in medium containing 2% HS alone (control) or 2% HS
with insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin, TTNPB (1
M), or TTNPB + insulin. The medium was replaced every 2 days with its respective treatment
condition. On day 6 of treatment, RNA isolation and cDNA synthesis was performed as
described in Materials & Methods. Real-time PCR analysis was performed using Applied
Biosystems 7300 Real-Time PCR System. The data were normalized to the mRNA level of the
control gene -actin. The data were presented fold induction using ΔΔCt methods with the
control treatment group set as 1. All p-values ≤ 0.05; for (A) a>b; for (B) a>b; for (D) a>b; for
(E) a>b>c, a/b>b/c. One-way ANOVA statistical analysis was performed using SPSS software.
Data are presented as means ± S.E.M (n=3).
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induction and glucose release. The addition of RA + insulin or TTNPB + insulin produced
significantly higher levels of glycogen compared to insulin alone group (Figure 3.5). These
results demonstrated that insulin alone induced glycogen content, and insulin + RA or TTNPB
further increased the glycogen content in L6 cells after 6-days treatment, supporting the western
blot data of elevated GS protein expression and GSK phosphorylation. All these indicated that
the elevated glucose usage in L6 cells treated with insulin, RA and insulin + RA is through an
increase of GS expression and reduction of its phosphorylation, which promotes glycogen
synthesis. Interestingly, the effects seen with insulin were dramatically decreased with the
addition of LG268 (Figure 3.5).

3.6 Expression levels of key proteins in insulin signaling pathway in
gastrocnemius muscle of VAD and VAS STZ-induced diabetic rats treated
with saline or insulin
The protein levels of IRS-1 were significantly increased in the VAD-C rats compared to
the other groups (Figure 3.6A and 3.6C). However, the VAS-INS rats did have significantly
higher IRS-1 levels compared to VAS-C and VAD-INS rats (Figure 3.6A and 3.6C). Both the
VAS-C and VAS-INS groups had significantly higher phosphorylation of Akt at site Thr308
compared to both VAD groups (Figure 3.6A and 3.6E). The phosphorylation of Akt at site Ser473
was significantly lower in the VAD-C group compared to the other 3 groups (Figure 3.6A and
3.6F).
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Figure 3.5. Increased glycogen content expressed as fold induction (A) and glucose release
(B) in L6 cells treated with insulin, RA + insulin, and TTNPB + insulin. A. Representative of
glucose released presented as fold induction. B. Representative of total glucose released in mg
glucose/mg total protein. Cells were maintained in 60 mm dishes and were subjected to
differentiation with 2% HS alone (control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1
M), LG268 + insulin, TTNPB (1 M), or TTNPB + insulin. The medium was replaced every 2
days with its respective treatment condition. On day 6 of differentiation, glycogen measurement
in the form of glucose released was measured as described in Materials & Methods. The glucose
amount released was measured using the StanBio Glucose Liquicolor kit and analyzed Glomax®
Multi+Detection System. Data presented as either (A) fold induction with control group set as 1
or (B) total glucose released in mg glucose per mg total protein. All p-values ≤ 0.05; for (A-B)
a>b>c. One-way ANOVA statistical analysis was performed using SPSS software. Data are
presented as means ± S.E.M (n=3).
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Figure 3.6. Abundance levels of key proteins in insulin signaling pathway in gastrocnemius
muscle of VAD and VAS STZ-induced diabetic rats treated with saline or insulin. A. Protein
levels of total Akt, PO4-Akt Ser473 and Thr308, IRS-1, IRS-2, IR- subunit and -actin in VAD
or VAS STZ-diabetic ZL rats treated with saline or insulin. B-G. Quantification analysis of IR-,
IRS-1, IRS-2, PO4-Akt Thr308, PO4-Akt Ser473, and total Akt, respectively. Male ZL rats at
weaning were fed a VAS diet or an isocaloric VAD diet. Rats were fasted for 24 hours, and
received a single injection of STZ via the tail vein and allowed to have their respective diet ad
libitum. Then the VAS or VAD rats with STZ-induced diabetes were treated with saline (control,
100 μL, intramuscular injection, VAS-C or VAD-C) or insulin (0.5 IU/100 g BM, intramuscular
injection, VAS-INS or VAD-INS). Rats were fed ad libitum for 3-4 hours and then euthanized for
tissue sample collection. Muscle tissue protein isolation and western blotting procedure was
performed as described in Materials and Methods. Blots were visually detected using ECL
Western Blotting Substrate on ChemiDoc Software System. The ratio of the densities of
specified proteins to -Actin in the same treatment group was calculated and used for statistical
analysis by averaging each group with the VAD-C group arbitrarily set as 1 for control. All pvalues ≤ 0.05; * indicates statistical significance. One-way ANOVA statistical analysis was
performed using SPSS software. Data are presented as means ± S.E.M (n=3).
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3.7 Expression levels of key proteins in glycogen signaling pathway in
gastrocnemius muscle of VAD and VAS STZ-induced diabetic rats treated
with saline or insulin
The phosphorylation of GSK-3 at site Ser21 was significantly increased in the VADINS group compared to the saline controls (Figure 3.7A-B). However, total GSK-3 protein
levels were significantly lower in both VAD-INS and VAS-INS than that in VAD-C and VAS-C
groups, respectively. The phosphorylation of GSK-3 at site Ser9 was significantly increased in
the VAS-INS group compared to the other 3 groups (Figure 3.7A and 3.7D). Total GSK-3
protein levels were significantly lower in the VAS-INS group compared to the VAD-INS group
(Figure 3.7A and 3.7E). The phosphorylation of GS at site Ser641 was significantly higher in the
VAD-C group compared to the other 3 groups (Figure 3.7A and 3.7F). The VAS-INS group
displayed significantly lower phosphorylation of GS than the other groups (Figure 3.7A and
3.7F). The VAS-INS group did display significantly higher total GS protein levels compared to
the other 3 groups (Figure 3.7A and 3.7G).

3.8 Expression levels of key proteins in glucose uptake and usage pathway in
gastrocnemius muscle of VAD and VAS STZ-induced diabetic rats treated
with saline or insulin
GLUT1 protein levels was significantly higher in the saline treated animals compared to
those who received insulin (Figure 3.8A-B). However, GLUT4 protein levels were significantly
increased in the animals that received insulin (VAD-INS and VAS-INS) compared to those who
received saline (Figure 3.8A and 3.8C). The protein levels of GAPDH and PDH did not display
significant differences between the groups (Figure 3.8A, 3.8D and 3.8G). Pyruvate kinase was
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Figure 3.7. Abundance levels of key proteins in glycogen signaling pathway in
gastrocnemius muscle in VAD and VAS STZ-induced diabetic rats treated with saline or
insulin. A. Protein levels of GS, PO4-GS Ser641, GSK-3, PO4-GSK-3 Ser21, GSK-3, PO4GSK3 Ser9 and -actin in VAD or VAS STZ-diabetic ZL rats treated with saline or insulin. BG. Quantification analysis of PO4-GSK-3 Ser21, GSK-3, PO4-GSK-3 Ser9, GSK-3, PO4GS Ser641, and GS, respectively. Male ZL rats at weaning were fed a VAS diet or an isocaloric
VAD diet. Rats were fasted for 24 hours, and received a single injection of STZ via the tail vein
and allowed to have their respective diet ad libitum. Then the VAS or VAD rats with STZinduced diabetes were treated with saline (control, 100 μL, intramuscular injection, VAS-C or
VAD-C) or insulin (0.5 IU/100 g BM, intramuscular injection, VAS-INS or VAD-INS). Rats
were fed ad libitum for 3-4 hours and then euthanized for tissue sample collection. Muscle tissue
protein isolation and western blotting procedure was performed as described in Materials and
Methods. Blots were visually detected using ECL Western Blotting Substrate on ChemiDoc
Software System. The ratio of the densities of specified proteins to -Actin in the same treatment
group was calculated and used for statistical analysis by averaging each group with the VAD-C
group arbitrarily set as 1 for control. All p-values ≤ 0.05; * indicates statistical significance. Oneway ANOVA statistical analysis was performed using SPSS software. Data are presented as
means ± S.E.M (n=3).
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significantly higher in the VAD-C group compared to the other 3 groups (Figure 3.8A and 3.8E).
VAS-INS group also displayed higher pyruvate kinase protein levels compared to VAD-INS
group (Figure 3.8A and 3.8E). The protein levels of LDH was significantly higher in the VAD
groups compared to the VAS groups (Figure 3.8A and 3.8F).

3.9 GLUT1 and GLUT4 protein expression levels in L6 cells treated with RA,
LG268, and TTNPB in the presence or absence of insulin for only one hour
To determine if the L6 cells display variations in GLUT1 and GLUT4 protein levels
under acute treatment conditions, the cells were treated with 1 M each RA, LG268, and TTNPB
with and without insulin (10 nM) for one hour following differentiation. GLUT4 protein
expression was significantly increased in all conditions in which insulin was used (Figure 3.9AC). However, GLUT1 protein expression was significantly reduced in all conditions in which
insulin was used (Figure 3.9A and 3.9B). The addition of the ligands did not affect GLUT1
protein expression, however, TTNPB led to significant reductions in GLUT4 protein expression
compared to control and TTNPB + insulin led to significant reductions compared to insulin
(Figure 3.9).

3.10 Changes in GLUT1, GLUT3, GLUT4 and GLUT6 levels in L6 cells
treated with RA, LG268, or TTNPB in the presence or absence of insulin for 6
days
A major role of insulin in muscle glucose metabolism is to induce GLUT4 translocation,
therefore, we measured whether there was any change of GLUT1 and GLUT4 expression levels
in L6 cells treated with RA, LG268, and TTNPB in the absence or presence of insulin for 6 days.

146

Figure 3.8. Abundance levels of key proteins in glucose uptake and usage pathway in
gastrocnemius muscle in VAD and VAS STZ-induced diabetic rats treated with saline or
insulin. A. Protein levels of GLUT1, GLUT4, GAPDH, lactate dehydrogenase (LDH), pyruvate
dehydrogenase (PDH), pyruvate kinase mutase (PKM ½), and -actin in VAD or VAS STZdiabetic ZL rats treated with saline or insulin. B-G. Quantification analysis of GLUT1, GLUT4,
GAPDH, PKM ½, LDH, and PDH, respectively. Male ZL rats at weaning were fed a VAS diet or
an isocaloric VAD diet. Rats were fasted for 24 hours, and received a single injection of STZ via
the tail vein and allowed to have their respective diet ad libitum. Then the VAS or VAD rats with
STZ-induced diabetes were were treated with saline (control, 100 μL, intramuscular injection,
VAS-C or VAD-C) or insulin (0.5 IU/100 g BM, intramuscular injection, VAS-INS or VADINS). Rats were fed ad libitum for 3-4 hours and then euthanized for tissue sample collection.
Muscle tissue protein isolation and western blotting procedure was performed as described in
Materials and Methods. Blots were visually detected using ECL Western Blotting Substrate on
ChemiDoc Software System. The ratio of the densities of specified proteins to -Actin in the
same treatment group was calculated and used for statistical analysis by averaging each group
with the VAD-C group arbitrarily set as 1 for control. All p-values ≤ 0.05; * indicates statistical
significance. One-way ANOVA statistical analysis was performed using SPSS software. Data are
presented as means ± S.E.M (n=3).
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Figure 3.9. GLUT1 and GLUT4 protein levels in L6 cells following one-hour treatment of
RA, LG268, or TTNPB in the presence or absence of insulin. A. A representative blot of
protein levels of GLUT1, GLUT4, and -actin in L6 cells treated with 2% HS (control), insulin
(10 nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin, TTNPB (1 M), TTNPB +
insulin for one hour. B-C. Quantification analysis of GLUT1 and GLUT4, respectively. Cells
were maintained in 60 mm dishes and were subjected to differentiation with 2% HS for 6 days.
Following differentiation, L6 cells were treated with 2% HS (control), insulin (10 nM), RA (1
M), RA + insulin, LG268 (1 M), LG268 + insulin, TTNPB (1 M), TTNPB + insulin for 1
hour. Following treatment, whole cell lysate was collected as described in Materials & Methods.
Blots were visually detected using ECL Western Blotting Substrate on ChemiDoc Software
System. The ratio of the densities of specified proteins to -Actin in the same treatment group
was calculated and used for statistical analysis with control group set as 1. All p-values ≤ 0.05;
for (B) a>b; for (C) a>b>c>d, a/b>c/d. One-way ANOVA statistical analysis was performed
using SPSS software. Data are presented as means ± S.E.M (n=3).
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To our surprise and similar to the results shown in Chapter II, the protein expression levels of
GLUT1 and GLUT4 were significantly decreased in L6 cells treated with insulin in comparison
with the control group (Figure 3.10A-C). None of the ligands alone led to changes in GLUT1
and GLUT4 expression levels. Interestingly, RA + insulin and TTNPB + insulin caused further
reduction of GLUT1 and GLUT4 expressions compared to control, insulin, RA, and TTNPB
(Figure 3.10A-C), demonstrating the synergistic effect of RA and insulin as well as the possible
signaling pathway mediating RA’s effects. We also measure the expression levels of GLUT2, 3,
5, 6 and 8 in the same cell samples. GLUT3 protein expression was markedly increased in L6
cells treated with TTNPB + insulin (Figure 3.10A and 3.10D). Insulin alone, RA + insulin and
LG268 + insulin significantly increased GLUT3 protein expression compared to control, RA,
LG268, and TTNPB (Figure 3.10A and 3.10D). Interestingly, L6 cells treated with RA alone
displayed significant reductions in GLUT3 protein levels compared to all treatment conditions
(Figure 3.10A and 3.10D). GLUT6 protein expression levels were markedly enhanced with the
treatment of L6 cells with RA and TTNPB (Figure 3.10A and 3.10E). RA + insulin, LG268 +
insulin, and TTNPB + insulin all significantly increased GLUT6 protein expression compared to
control (Figure 3.10A and 3.10E). We could not detect the protein levels of GLUT2, 5 and 8 in
the samples.

4. Discussion
Due to skeletal muscle glucose metabolism playing a pivotal role in whole body glucose
homeostasis, the aim of our study was to investigate possible mechanisms in which skeletal
muscle cells respond to nutritional and hormonal stimuli. It has been thought for a while that the
postprandial rise of plasma insulin stimulates glucose uptake in skeletal muscle via GLUT4
translocation, which has been a topic researched extensively as well as the beneficial effects of
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Figure 3.10. Changes in glucose transporter protein levels in L6 cells treated with RA,
LG268, or TTNPB in the presence or absence of insulin. A. A representative blot of protein
levels of GLUT1, GLUT3, GLUT4, GLUT6 and -actin in L6 cells treated with 2% HS
(control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M), LG268 + insulin, TTNPB
(1 M), TTNPB + insulin for 6 days. B-E. Quantification analysis of GLUT1, GLUT4, GLUT3,
and GLUT6, respectively. Cells were maintained in 60 mm dishes and were subjected to
differentiation with 2% HS (control), insulin (10 nM), RA (1 M), RA + insulin, LG268 (1 M),
LG268 + insulin, TTNPB (1 M), TTNPB + insulin. The medium was replaced every 2 days
with its respective treatment condition. On day 6 of treatment, whole cell lysate was collected as
described in Materials & Methods. Blots were visually detected using ECL Western Blotting
Substrate on ChemiDoc Software System. The ratio of the densities of specified proteins to Actin in the same treatment group was calculated and used for statistical analysis with control
group set as 1. All p-values ≤ 0.05; for (B) a>b; for (C) a>b>c; for (D) a>b>c>d; for (E)
a>b>c>d>e, c/d>d/e. One-way ANOVA statistical analysis was performed using SPSS software.
Data are presented as means ± S.E.M (n=3).
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physical exercise on skeletal muscle glucose regulation224,487,488,507. There are a multitude of
factors that can influence skeletal muscle glucose metabolism such as skeletal muscle fiber type,
level of physical exercise, nutrient availability, and hormonal factors, all of which can positively
or negatively regulate glucose uptake and utilization in skeletal muscle489,508,509. Within skeletal
muscle, studies investigating the effects of VA and its derivatives on glucose regulation have
been limited376,482. Due to the obesogenic/high-fat diet society, it is important to have a greater
understanding of the mechanisms in which a fat-soluble vitamin such as VA and its derivatives
have on skeletal muscle glucose regulation.
The anabolic hormone insulin initiates its action after binding to the insulin receptor, a
process that starts an intracellular signaling cascade362. The binding of insulin and its receptor
will lead to the phosphorylation and activation of IRS proteins, with IRS-1 often viewed as the
primary IRS in skeletal muscle401. However, we show in Figure 3.1 that RA and TTNPB can
actually increase IRS-1 protein levels following 6 days of treatment whereas the addition of
insulin to RA led to significant decreases in IRS-1 (Figure 3.1). This could be due to a
homeostatic mechanisms initiated by the L6 muscle cells in response to insulin treatment for 6
days. The same effect was not reciprocated in the animal experiment in which STZ-induced
diabetic VAD-C and VAS-INS rats had significantly higher levels of IRS-1 compared to the
other groups (Figure 3.6). However, the phosphorylation of Akt at Thr308 was increased
significantly by the ligands + insulin in L6 cells and in the VAS-C and VAS-INS experiment
(Figures 3.1 and 3.6). No significant changes were seen in the phosphorylation Akt at Ser473 in
L6 cells. However, phosphorylation at this site was significantly increased in VAS-C, VAD-INS,
and VAS-INS rats compared to VAD-C (Figures 3.1 and 3.6). One reason is the different length
of treatment time, 6 days for L6 cells and 3-4 hours for diabetic rats. Nevertheless, the results
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shown in this study suggest that the presence of VA and its derivatives within skeletal muscle
can assist in the activation of Akt upon insulin stimulation.
Within skeletal muscle cells, the insulin-stimulated activation of Akt will lead to
inactivation glycogen synthase kinase-3 (GSK-3) by phosphorylating specific sites on the
enzyme such as site Ser21 on GSK-3 and Ser9 on GSK-3182,183. Through this inhibition of
GSK-3, GS can be activated181,404. In L6 cells we find that RA + insulin, TTNPB alone, and
TTNPB + insulin are capable of increasing the phosphorylation of GSK-3 (Ser21) compared to
the control group (Figure 3.2A-B). A similar effect was seen with the phosphorylation of GSK3 (Ser9) in L6 cells with the addition of RA alone capable of significantly increasing
phosphorylation (Figure 3.2A and 3.2D). In the VAD diabetic rats, those receiving insulin had
significantly higher levels of GSK-3 phosphorylation compared to those receiving saline
(Figure 3.7A-B). Interestingly, the insulin-treated VAD and VAS diabetic rats also displayed
significantly lower levels of total GSK-3 than the saline-treated rats (Figure 3.7A and 3.7C).
This suggests that insulin may not only promote the inactivation of GSK-3, but also decreases
total GSK-3 levels. We also found that only the VAS-INS group displayed significantly higher
levels of GSK-3 phosphorylation with concomitant decreases in total GSK-3 protein levels
compared to VAD-INS (Figure 3.7A, 3.7D-E), suggesting the critical role of VA status in the
GSK-3β protein expression.
In L6 cells, the phosphorylation of GS at Ser641 was significantly reduced in all
conditions in which insulin was used and of the ligands, only RA alone was also capable of
significantly reducing GS phosphorylation (Figure 3.2A and 3.2F). The reduced phosphorylation
of GS correlated with increases in total GS protein levels with the L6 cells treated with RA +
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insulin and TTNPB + insulin having a synergistic effect (Figure 3.2A and 3.2F-G). However,
Gys1 gene expression in L6 cells seems to be driven primarily by the effects of insulin (Figure
3.4A). Interestingly, the L6 cells receiving both LG268 and insulin displayed total GS levels
similar to that seen with control (Figure 3.2A and 3.2G). The VAD-C rats displayed significantly
higher phosphorylation of GS than the other groups while the VAS-INS displayed even lower
levels of phosphorylation than the VAD-INS and VAS-C rats (Figure 3.7A and 3.7F). Again, this
significant reduction in GS phosphorylation correlated with significant increases in total GS
protein levels in the VAS-INS rats (Figure 3.7A and 3.7F-G). Due to the variations in both the
total proteins and their phosphorylated forms under the treatment conditions, the ratio of
phosphorylated protein to the respective total protein was not chosen as the presentation
formation. We decided to use the ratios of those proteins to -actin as the presentation format as
the protein abundance levels of -actin appeared to be unchanged by the treatment conditions.
These results suggest that in the presence of VA and insulin, the activity of GSK-3 is reduced,
thus promoting GS protein abundance. Another study using the soleus muscle of 24-month old
rats found that an increase in the phosphorylation of GS corresponded with decreases in total GS
protein levels454. Therefore, it is possible that the phosphorylation state of GS might have altered
its stability and in turn impact total GS protein levels. The in-vitro GS data was confirmed in
measurement of glycogen content as glucose release measures. RA + insulin and TTNPB +
insulin both led to significant increases in the amount of glucose released in the L6 cells
following six days of treatment (Figure 3.5). These results indicate that under these conditions
that there is an increase in glucose storage in the form of glycogen.
Besides being used for glycogen formation, glucose that enters skeletal muscle can be
used for energy production and can also be converted to lactate510,511. In the L6 cells we show
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that the protein levels GAPDH, PDH, LDH, and pyruvate kinase remain unchanged by all
treatment conditions (Figure 3.3). Only the L6 cells treated with RA displayed significantly
lower Ldha gene expression levels compared to those treated with insulin alone (Figure 3.4B).
The VAD and VAS diabetic rats did not display any significant differences in GAPDH or PDH
(Figure 3.8A-B and 3.8E). However, the VAD-C group displayed significantly higher levels of
pyruvate kinase and LDH compared to the VAS groups, thus further indicating that presence of
VA promotes the shuttling of glucose towards the formation of glycogen (Figure 3.8A and 3.8CD).
The peroxisome proliferator-activated receptor gamma (PPAR) coactivator-1alpha
(PGC-1) and PGC-1 are nuclear encoded transcriptional coactivators that have been shown to
play a role in skeletal muscle metabolism and function512-514. We show in L6 cells, that the
expression levels of the gene encoding PGC-1 (Ppargc1a) are only induced by TTNPB +
insulin after 6 days of treatment (Figure 3.4D). However, the expression levels of the gene
encoding PGC-1 (Ppargc1b) are increased by insulin, RA + insulin, and TTNPB + insulin,
suggesting that insulin is driving the expression of PGC-1β in L6 muscle cells (Figure 3.4E).
GLUT4 is the glucose transporter commonly referred to as the insulin-stimulated glucose
transporter in skeletal muscle whereas GLUT1 is thought to regulate skeletal muscle glucose
uptake during basal conditions199,498. Both GLUT1 and GLUT4 protein levels have been shown
to be decreased in the skeletal muscle of individuals with T2DM200,515. Even though GLUT4 is
the insulin-responsive glucose transporter, its gene expression levels in the L6 cells also did not
display any significant changes by any of the long-term (6 days) treatment conditions (Figure
3.4C). It was interesting to find that following 6 days of treatment, RA + insulin and TTNPB +
insulin promoted significant reductions in both GLUT4 and GLUT1 protein levels compared to
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all other treatment conditions (Figure 3.10). Insulin alone and LG268 + insulin also produced
significant reductions compared to control, RA, LG268, and TTNPB (Figure 3.10). This could
imply that L6 cells respond to pro-longed insulin and RA treatment with a homeostatic
mechanism to decrease glucose uptake by decreasing GLUT4 and GLUT1 protein levels. We
demonstrated here that the expression levels of IR-β in L6 cells were not different among
treatment groups. These results indicated that our total cell lysate included membrane fraction. It
is not possible that the decreases in GLUT1 and GLUT4 protein levels could be the loss of the
plasma membrane fraction during whole-cell lysate collection. We found that GLUT3 and
GLUT6 protein levels can also be regulated by RA and insulin within the L6 cells. GLUT3
protein expression levels were significantly increased with all conditions in which insulin was
used, but showed the greatest increase with TTNPB + insulin (Figure 3.10). GLUT6, on the other
hand, was found to be markedly increased by RA and TTNPB (Figure 3.10). As far as we know,
this is the first time that this phenomenon is reported. While limited research has been conducted
on the kinetics and potential stimuli of GLUT6, it has been shown previously in L6 cells that
GLUT3 protein expression can be increased using triiodothyronine as well as by insulin-like
growth factor-1 (IGF-1)217,516,517. The underlying mechanism regulating the glucose transport
under these conditions deserves to be investigated in more detail. Short-term treatment of L6
cells with insulin for one hour produced significant increases in GLUT4 protein levels (Figure
3.9). This indicates that the L6 cells are indeed responsive to insulin and that the regulation of
GLUT4 may be time dependent.
With the significant changes seen in the protein expression levels of key enzymes in the
glycogen synthesis pathway in both in-vitro and in-vivo coupled with no changes seen in the
protein expression levels of GAPDH, LDH, PDH, or pyruvate kinase in the L6 cells while the
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VAD-C rats displayed significant increases in LDH and pyruvate kinase protein levels, our
results demonstrate that when skeletal muscle is exposed to both VA and insulin, they work
cooperatively to regulate glucose metabolism through increase of GS expression, which may
have enhanced the glucose utilization via further metabolism to storage. This can be of
importance in diverting glucose from lactic acid production to glycogen formation in individuals
that suffer from complications associated with diabetes such as myopathy and/or neuropathy.
Furthermore, we demonstrate that the RAR signaling pathway is in part how RA-mediates its
effects on L6 cells glucose utilization and GS regulation (Figure 3.11). We propose that through
the binding of RA with RARs, it will work synergistically with insulin signaling to favor the
formation of glycogen by inhibiting the activity of GSKs via their phosphorylation, thus
enhancing glycogen synthase to promote glycogen formation. In a study that utilized mice with
muscle-specific knockout of GLUT4, the mice displayed significant decreases in IRS-1/Akt
signaling while having increases in GS activity and glycogen content under basal (non-insulin
dependent) conditions231. The results shown here indicate that the mechanisms in which VA and
insulin elicit their effects are complicated and require more study.

5. Conclusion
Due to the regulation of skeletal muscle glucose metabolism being able to have an effect
on whole body glucose homeostasis, it is important to understand the mechanisms in which
hormonal and nutritional stimuli interact within skeletal muscle. Here, we demonstrate that VA
and RA can interact with insulin to promote GS protein abundance within skeletal muscle in-vivo
and in-vitro. These findings could lead to the development of new and improved therapies for
diseases with altered glucose metabolism.
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Figure 3.11. Schematic representation of proposed mechanisms involved in the long-term
presence of RA and insulin effecting glucose utilization in L6 muscle cells. Upon insulin
binding to the insulin receptor there is activation of IRS proteins leading to a signaling cascade.
Insulin signaling is involved in the formation of glycogen by inhibiting GSK and by stimulating
the activity of GS. We propose that through the binding of RA with RAR, it will work
synergistically with insulin signaling to favor the formation of glycogen by inhibiting GSK, thus
enhancing glycogen synthase. Abbreviations: G-6-P, glucose-6-phosphate; GS, glycogen
synthase; GSK, glycogen synthase kinase; IR, insulin receptor; IRS, insulin receptor substrate;
RAR, retinoic acid receptor; RXR, retinoid-X-receptor; UDP, uridine diphosphate.
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CHAPTER IV. CONCLUSIONS AND FUTURE
DIRECTIONS
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1. Conclusion
In this dissertation, we have shown that vitamin A (VA) derivative, retinoic acid (RA),
can synergize with insulin to induce the expression of glycogen synthase (GS) in skeletal muscle
in both in-vitro and in-vivo models systems. Specifically, we used rat L6 skeletal muscle cells
and skeletal muscle from VA deficient (VAD) and VA sufficient (VAS) STZ-induced diabetic
rats that received either saline (VAD-C and VAS-C) or insulin (VAD-INS and VAS-INS)
injections. The research results shown in this dissertation probe the mechanisms underlying two
study questions: (1) How does RA alone and in conjunction with insulin affect glucose
metabolism in L6 skeletal muscle cells? (2) What are the glucose-derived end product(s)
associated with the combination of VA and insulin in skeletal muscle cells? The answers to these
two questions are delineated in Chapters II and III, which can provide insights into the
mechanisms for the development of skeletal muscle insulin resistance and metabolic diseases as
well as possible therapeutic interventions.
In Chapter II, we investigated the effects of retinoids including RA, retinal (RAL), and
retinol (ROL) on rat L6 skeletal muscle cell glucose usage, and obtained the following results.
First, the changes in medium pH and glucose levels with the retinoids mimicked what you may
expect with the accelerated or enhanced glucose metabolism. ROL did not produce any
significant changes in medium pH and glucose levels. However, RAL led to significant
reductions in medium pH and glucose levels after 10 days after treatment began, suggesting
possible conversion of RAL to RA. The RA treated L6 cells display significant reductions in
medium pH and glucose levels as early as 4 days after treatment began. This indicates that RA
exerts the biological activity within skeletal muscle. Secondly, when used in combination, RA
and insulin had a synergistic effect in reducing medium pH and glucose levels. Third, the
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retinoic acid receptor (RAR) specific agonist TTNPB mimicked the responses seen with RA
alone and with insulin, suggesting that the RA-mediated effect is by activation of the RAR
nuclear receptor. Fourth, L6 cells incubated in media with increasing concentrations of glucose
(15 and 25 mM vs. 5 mM glucose) started displaying reductions in medium pH and glucose
levels after 2 days of treatment and this trend continued through day 6. These results suggest that
the reductions in medium pH and glucose levels are due to the muscle cells taking in the
extracellular glucose for either storage or further metabolism. Fifth, following 6 days of
treatment, insulin alone and RA + insulin promoted reductions in both GLUT1 and GLUT4
protein levels. These results could be due to a homeostatic mechanism within these cells in
response to pro-longed insulin treatment. It seems that the presence of RA decreased the insulinmediated reduction of GLUT4 even further to almost disappearance. Collectively, these results
demonstrate that there is an elevation of glucose utilization in rat L6 skeletal muscle cells when
treated with both RA and insulin, with the RA-mediated effect being due to the activation of the
RAR signaling pathway.
In Chapter III, we investigated the potential mechanism of the RA and insulin-mediated
enhancement of glucose usage through investigation of the effects of VA and insulin on key
proteins involved in insulin signaling, glucose usage, and glycogen metabolism in both L6
skeletal muscle cells and in the gastrocnemius muscle of VAS and VAD STZ-induced diabetic
rats. First, the phosphorylation of Akt at Thr308 was increased significantly by the ligands +
insulin in L6 cells and in the gastrocnemius muscle of VAS-diabetic rats treated with and
without insulin. The levels of Akt phosphorylation at Ser473 were significantly increased in
VAS-C, VAD-INS, and VAS-INS rats compared to VAD-C. However, no change of Akt
phosphorylation at Ser 473 was observed in L6 cells with any of the treatment conditions. This
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discrepancy may be due to the different length of treatment time, 6 days for L6 cells versus 3-4
hours for rats. Secondly, we found that the presence of VA and insulin can have a profound
effect on the regulation of key proteins involved in glycogen signaling. Specifically, L6 cells
treated with RA + insulin, TTNPB alone, and TTNPB + insulin displayed significant increases in
the phosphorylation of GSK-3 (Ser21) compared to the control group with a similar effect seen
in the phosphorylation of GSK-3 (Ser9) with the addition of RA alone capable of significantly
increasing phosphorylation. Both, the VAD-INS and VAS-INS diabetic rats displayed
significantly higher levels of glycogen synthase kinase-3 (GSK-3) phosphorylation
concomitantly with significantly lower levels of total GSK-3 compared to the saline-treated
rats. These results suggest that insulin may promote both the inactivation of GSK-3 as well as
in decreases total GSK-3 protein levels. The VAS-INS group displayed significantly higher
levels of GSK-3 phosphorylation with concomitant decreases in total GSK-3 protein levels
compared to that of VAD-INS, which suggests that VA status is of importance in order for
insulin to mediate the same effects seen in GSK-3β protein expression as with GSK-3. In L6
cells, the treatment of RA + insulin and TTNPB + insulin had a synergistic effect leading to
significant increases in total glycogen synthase (GS) protein levels that correlated with
significant reductions in the phosphorylation of GS at Ser641. Similarly, rats in the VAS-INS
group displayed significantly lower levels of GS phosphorylation compared to the VAD-C,
VAD-INS, and VAS-C groups which correlated with significant increases in total GS protein
levels.
We also show in Chapter III that proteins in the glucose usage pathway, including lactate
dehydrogenase (LDH) and pyruvate kinase, remain unchanged by all treatment conditions in L6
cells. However, the VAD-C group displayed significantly higher levels of pyruvate kinase and
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LDH compared to the VAS groups, further suggesting that presence of VA promotes the
shuttling of glucose towards the formation of glycogen. Finally, RA + insulin and TTNPB +
insulin had a synergistic effect in enhancing glycogen content in L6 skeletal muscle cells
compared to all other treatment conditions. These results further support the western blot data
indicating that in skeletal muscle VA and insulin work cooperatively to regulate glucose
metabolism through the regulation of proteins involved in glycogen synthesis to promote glucose
storage in the form of glycogen. Furthermore, we demonstrate that the RAR signaling pathway is
in part how RA-mediates its effects on L6 cells glucose utilization and GS regulation. We also
have shown that this effect is not dependent upon the enhanced protein expression of GLUT4
with GLUT4 protein levels being decreased by the treatments of RA + insulin and TTNPB +
insulin in L6 cells. However, GLUT3 protein levels were significantly increased by insulin, RA
+ insulin, LG268 + insulin, and TTNPB + insulin with TTNPB + insulin having the greatest
effect. GLUT6 protein levels were significantly higher in L6 cells treated with RA, LG268, and
TTNPB with TTNPB having the greatest effect. Therefore, these results suggest that multiple
glucose transport systems could be working cooperatively for glucose uptake under these
treatment conditions.

2. Future Directions
Even though the results presented in this dissertation have provided ample evidence that
VA and insulin work cooperatively in skeletal muscle to enhance glucose utilization, future
research questions (see Figure 4.1) can be extracted from the findings to help extend our
understandings of the development of muscle-related insulin resistance, myopathies, and various
metabolic diseases.
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Figure 4.1 Proposed future experiments to be performed. See Ch.4 section 2 for description.
Abbreviations: GS, glycogen synthase; IRS, insulin receptor substrate; RA, retinoic acid; RXR,
retinoid-X-receptor; T2DM, type 2 diabetes mellitus; VA, vitamin A;, VAD, vitamin A deficient;
VAS, vitamin A sufficient.
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2.1 Do RA and insulin work cooperatively to enhance GS protein stability in
rat L6 skeletal muscle cells?
In this dissertation, we show that GS is regulated at the protein level by RA and insulin in
L6 cells, however, Gys1 gene expression is driven primarily by the actions of insulin. This
increased expression level of protein could be due to an increase in protein stability due to the
treatment with RA and insulin. Therefore, it would be worth performing protein stability
experiments such as a cycloheximide chase assay and western blotting to determine if the
combination of RA and insulin enhance GS protein stability through increasing translation rates.
If an increase in translation is not the case, then RA and insulin could be mediating their effects
through lowering degradation rates, therefore, experiments could be performed that focused on
measuring protein degradation.

2.2 What role does retinoid-X-receptor (RXR) play in rat L6 skeletal muscle
cell glucose utilization?
In Chapters II, we have shown that the RXR agonist LG268 alone and in combination
with insulin had no effect on glucose utilization in the L6 cells in regards to changes in medium
pH and glucose levels compared to control and insulin alone. In Chapter III we show that LG268
actually abrogates the effects of insulin on total GS protein levels in L6 cells and this effect was
also seen in the glycogen measurements. These results suggest that treatment of L6 cells with
LG268 does not favor glycogen formation, therefore, other pathways that could use glucose such
as fatty acid synthesis for example, should be investigated in more detail.
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2.3 How does insulin mediate its effect on rat L6 skeletal muscle cell glucose
utilization if the expression level of insulin receptor substrate-1 (IRS-1) is
decreased?
One interesting finding in Chapter III was that IRS-1 protein levels were significantly
reduced in L6 cells treated with RA + insulin, whereas RA alone and TTNPB alone led to
significant increases in IRS-1 protein levels. We believe that this could be a homeostatic
mechanism to pro-longed insulin treatment in which the cell starts limiting its typical response to
insulin by decreasing IRS-1 protein levels. However, as shown in Chapter two, insulin in part is
mediating the utilization of glucose within the L6 cells. In Chapter three, we also show no
change in IRS-2 protein levels with insulin treatment alone in the L6 cells, however, RA and RA
+ insulin led to significant increases in IRS-2 protein levels. Therefore, it is worth investigating
if other IRS’s or membrane associated signaling proteins are contributing to the insulin-mediated
effect. Since RA is capable of increasing IRS-1 and IRS-2 protein levels, it would also be
interesting to determine the mechanism of this induction. Therefore, protein stability assay and
reporter gene assay may be used to explore the potential mechanisms. It remains to be
determined whether there are RARE sequences located within the promoters of IRS-1 and IRS-2
genes, and if so, which sequences are required for this RA-mediated effect.

2.4 How is glucose transported into the L6 muscle cell with pro-longed
treatment of insulin and RA?
Similar to what was seen with IRS-1, GLUT1 and GLUT4 protein levels were
significantly reduced in response to RA + insulin as well as insulin alone following six days of
treatment in the L6 cells. Again, we believe that this is a homeostatic mechanism initiated by the
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L6 cells to limit glucose uptake. It has been shown in mice that muscle-specific knockout of
GLUT4 led to significant increases in skeletal muscle GS activity and glycogen content while
significantly decreasing muscle glucose uptake231. These results agree with those presented in
this dissertation, therefore, there may be another glucose transporting system that also plays a
role in skeletal muscle glucose uptake. We show in this dissertation that both GLUT3 and
GLUT6 can possibly play a role in the glucose uptake and usage in L6 cells when RA and insulin
are used for pro-longed periods, however, we could not detect GLUT2, GLUT5, or GLUT8.
Western blot assays can be performed on more of the known glucose transporters (GLUTs) to
determine if any has higher protein expression with the treatment conditions used in this
dissertation. Also, it has been shown that vitamin C can be transported into cells by a sodium
vitamin C dependent (SVCT) transporter as well as GLUTs such as GLUT1, GLUT3, and
GLUT4, therefore, it is possible that glucose is using a nontraditional GLUT under these
treatment conditions220.

2.5 Does VA status and insulin promote glycogen storage in the skeletal
muscle of rats with type 2 diabetes mellitus (T2DM)?
The prolonged insulin treatment in the in-vitro model system in this dissertation
resembled that more of a T2DM state, while the in-vivo model system was the type 1 diabetes
mellitus (T1DM) state. Therefore, further studies in our lab can be performed using VAD and
VAS rats still receiving saline or insulin injections, but with diabetes induced to resemble that of
T2DM to determine if these animals display similar results in regards to GS phosphorylation and
total GS protein levels. Furthermore, glycogen content within the animals can also be directly
measured. It would also be interesting to use both lean and obese animal model systems to
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determine if adiposity influences the effects seen with VA status and insulin on skeletal muscle
glucose utilization and metabolism.

3. Summary
The work presented in this dissertation lays the foundation and provides evidence that
there are possible benefits in studying the role of VA in skeletal muscle glucose metabolism.
There is much still being discovered regarding glucose metabolism in skeletal muscle. More indepth studies performed both in-vitro and in-vivo are needed to grasp a full understanding of the
regulation of skeletal muscle glucose metabolism and glycogen homeostasis. With a greater
understanding, possible therapeutic benefits and intervention points could arise for individuals
suffering from a variety of metabolic diseases.
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Table 3.1 List of real-time PCR primers used in this dissertation
Protein

Gene Symbol

Direction

Sequence

Glycogen Synthase (GS)

Gys1

Lactate Dehydrogenase
(LDH)
Glucose Transporter Type
4 (GLUT4)
Peroxisome ProliferatorActivated Receptor
Gamma, Coactivator-1
Alpha (PGC-1)
Peroxisome ProliferatorActivated Receptor
Gamma, Coactivator-1
Beta (PGC-1)

Ldha

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5’ TTTTCCTTGGTCCAGTGTCC 3’
3’ CGGTGGGCTCACTTTTGTAT 5’
5’ CCGTTACCTGATGGGAGAAA 3’
3’ ACGTTCACACCACTCCACAC 5’
5’ TCAGGCATCAATGCTGTTTTCTAC 3’
3’ TCTACTAAGAGCACCGAGACCAAC 5’
5’ CGCAACATGCTCAAGCCA 3’
3’ TTAGGCCTGCAGTTCCAGAGAG 5’

Forward
Reverse

5’ AGAAGCTCCTCCTGGCCACATC 3’
3’ TGTACAAGGCCGGCTCTGAGAC 5’

Slc2a4
Ppargc1a

Ppargc1b
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